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Abstract
Objectives
The objectives of these studies were to assess the role of potential modifying
factors in determining the degree of LV hypertrophy in patients with HCM and to
identify targets for intervention and to assess the ability of ACE inhibition and/or
AG-II receptor blockade to cause regression of LV hypertrophy in patients with
HCM.
Methods
Patients referred to the National Heart, Lung and Blood Institute, Bethesda,
Maryland, for evaluation of HCM, were screened using standard echocardiographic
techniques. Family members of patients with familial HCM were also screened by
echocardiography and for the presence of the disease causing mutation. This allowed
inclusion of patients in studies who were known to have disease causing mutations
but who had no evidence of LV hypertrophy. All patients subsequently underwent
cardiac MRI studies to evaluate LV mass and maximal wall thickness. LV indices
were then compared with potential modifying factors to assess their role in
determining phenotypic expression. Disease regression was also examined using
enalapril and losartan in a randomized double-blind placebo controlled study.
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Results
The gender differences in the pattern of LV hypertrophy observed in patients
with HCM is similar to other forms of pressure overload hypertrophy. Women have
smaller volumes and a relatively thicker myocardium compared to men. This pattern
should reduce wall stress and may slow the progression to heart failure. In addition,
this highlights a number of limitations including the difficulty in establishing the
diagnosis in borderline cases when a single unified definition of HCM is applied to
both genders.
The ability of insulin-like growth factor-1 and its binding protein (1GFBP3)
to modulate cardiac hypertrophy in familial hypertrophic cardiomyopathy was
examined in 150 subjects with determined genetic status. Plasma 1GF-1
concentrations were lower in HCM patients. A significant inverse correlation existed
between IGF-1 concentrations and maximum LV wall thickness assessed by MR1.
No association was found between 1GFBP3 concentrations and cardiac hypertrophy.
As IGF-1 improves cardiomyocyte function, we postulate that increased IGF-1
activity causes a milder cardiac phenotype because it counteracts the myocyte
contractile dysfunction induced by sarcomeric mutation, thereby attenuating the
compensatory myocardial hypertrophic response.
BNP has recently emerged as a screening tool for patients with heart failure.
Although it has poor positive predictive value it is a good negative predictor (97%)
and therefore can be used to exclude significant heart disease in patients presenting
with breathlessness. We hypothesized that levels of BNP would correlate with the
severity of LV hypertrophy in HCM. This proved incorrect with no correlation
observed. However, sarcomeric mutations that are likely to have a worse prognosis
19
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(higher incidence of SCD and more frequent progression to heart failure) were
associated with significantly higher BNP levels compared to mutations that followed
a more benign course, independent of LV systolic function or current symptoms.
Genetic factors have been proposed as modifiers of LV hypertrophy in
several disease states including HCM. We reassessed the role of two genetic
polymorphisms that have previously been reported to influence the extent of LV
hypertrophy in HCM. The ACE gene polymorphism consisting of the presence or
absence of a long intronic section of DNA is associated with measured serum levels
of ACE. HCM patients who are homozygous for the deletion have a greater degree of
LV hypertrophy. However we could find no correlation between the i98Lys"Asn gy.j
missense mutation and LV hypertrophy in HCM that has also been reported.
We hypothesized that ACE inhibition and/or AG-II receptor blockade would
result in regression of LV hypertrophy in HCM. Non-obstructed HCM patients were
randomized to receive enalapril alone, losartan alone, a combination of both drugs, or
placebo for a period of six months. LV mass was determined before and after the
study period. Enalapril, alone or in combination with losartan, but not losartan alone
significantly reduced LV mass compared to placebo.
Conclusions
Identification of modifying factors in the phenotypic expression of HCM
helps in our understanding of the mechanisms which explain the marked variation
observed. This may provide avenues for therapeutic intervention either in the
regression or prevention of development of LV hypertrophy in HCM with potentially
subsequent improvement in symptoms and prognosis.
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Short Abstract
The objectives of this study were to assess the role of potential modifying
factors in the phenotypic expression of hypertrophic cardiomyopathy (HCM) and to
assess therapeutic options that might cause regression of left ventricular (LV) mass
in HCM.
A total of 269 patients were carefully phenotyped and LV mass was
determined by cardiac MRI. The role of gender, insulin-like growth factor-I (IGF-I)
and genetic polymorphism in the angiotensin converting enzyme (ACE) and
endothelin-1 (ET-1) genes in determining LV mass in HCM was assessed. The
relationship between brain natriuretic peptide (BNP) and HCM caused by known
sarcomeric mutations was also assessed. The role of ACE inhibition and/or blockade
was also assessed in regression of LV hypertrophy in non-obstructive HCM patients.
Female patients were found to have relatively thicker hearts with smaller
cavities than male patients as in LV hypertrophy caused by pressure overload. Higher
physiological levels of IGF-I were associated with lesser degrees of LVH which may
be due to increased muscular efficiency. BNP levels were associated with the disease
causing mutation but not to the degree of LVH. Mutations associated with an adverse
prognosis had significantly higher BNP levels. The insertion/deletion (I/D) ACE
gene but not ET-1 gene polymorphism was associated with LV mass in HCM.
Treatment with enalapril alone or in combination with losartan resulted in a 7% and
8.5% reduction in LV mass respectively over 6 months.
HCM is a complex disease with many potential phenotypic modifiers. These
studies suggest that identifying modifying factors is important to explore therapeutic
21
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options in the management of these patients. In addition further studies exploring the
long term impact of such therapies on disease progression are indicated and their role
in disease prevention in pre-clinical states.
22
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1. Introduction
HCM is a relatively common autosomal dominant inherited cardiac condition
characterized by LV hypertrophy that is inappropriate for the degree of afterload.
(Maron 2002) The disease was first reported by a pathologist, Donald Teare, in 1958,
when he described asymmetrical hypertrophy of the left ventricle in a number of
young adults. (Teare 1958)
The prevalence of echocardiographically detectable disease in an adult
population is about 1:500. (Maron et al. 1994; Maron et al. 1995) Clinical diagnosis
is usually established by the presence of LV hypertrophy on 2-dimensional
echocardiography in the absence of other cardiac or systemic disease (e.g.
hypertension or aortic stenosis) that may be capable of producing the degree of
Figure 1-1: Cross section through heart of patient with HCM.
Although there is marked global hypertrophy, there is
disproportionate thickening of the ventricular septum.
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hypertrophy identified. (Klues et al. 1995) In addition to the LV hypertrophy, HCM
is also characterized by diastolic dysfunction, myocardial ischaemia and,
supraventricular and ventricular arrhythmias. The extent of LV hypertrophy, diastolic
dysfunction and myocardial ischemia is an important determinant of clinical course.
(Frank and Braunwald 1968; Wigle et al. 1995)
Clinical course is extremely variable. The majority of subjects remain
asymptomatic and therefore, presentation can be at any age. However, subjects may
complain of breathlessness, chest pain, palpitations, fatigue, and symptoms of
impaired consciousness (pre-syncope and syncope), resulting in impaired exercise
tolerance and significant functional limitation. (Cannan et al. 1995; Cecchi et al.
1995; Fay et al. 1990; Frank and Braunwald 1968; Maron et al. 1999b; Maron et al.
2003a) One of the most catastrophic associations with HCM is the risk of SCD,
which can occur in otherwise healthy, asymptomatic and young individuals. (Maron
et al. 1982) Although early reports suggested mortality rates of 3-6%, (Shah et al.
1974) based on tertiary centre experience, more recent reports suggest a much lower
rate of about 1%. (Cannan et al. 1995; Cecchi et al. 1995; Kofflard et al. 1993;
Shapiro and Zezulka 1983; Spirito et al. 1989)
Approximately 5-10% of patients may progress to advanced end-stage heart
failure with ventricular dilatation and wall thinning, and LV systolic dysfunction
resembling dilated cardiomyopathy. (Spirito et al. 1987)
HCM is caused by mutations in genes that encode components of the
sarcomere which has led it to be termed a disease of the sarcomere. (Thierfelder et al.
1994) To date, mutations in at least ten genes have been reported to cause the
disease. (Bonne et al. 1995; Geisterfer-Lowrance et al. 1990; Gollob et al. 2001;
25
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Hoffmann et al. 2001; Kimura et al. 1997; Olson et al. 2000; Poetter et al. 1996;
Satoh et al. 1999; Thierfelder et al. 1994) An additional locus has been identified
recently on chromosome 7 although the causative gene has not been determined.
(Song et al. 2006)
Not all patients who carry a disease causing mutation will express LV
hypertrophy. (Fananapazir and Epstein 1995; Marian et al. 2001; Maron et al. 1998)
It is common to find no evidence of LV hypertrophy in a pre-adolescent child.
However, during periods of rapid growth, development of LV hypertrophy occurs
with the completed phenotype usually present by the time of physical maturity.
(Maron et al. 1986a; Spirito and Maron 1987) However, with the advance of
molecular techniques, genotype-phenotype studies have demonstrated that complete
disease expression can be delayed until much later in life. This is most commonly
seen in patients with mutations in troponin T or myosin-binding protein C. (Charron
et al. 1998; Maron et al. 2001; Niimura et al. 1998; Elliott et al. 1999a)
In addition some patients with disease causing mutations may still have fibre
disarray and diastolic dysfunction but never develop LV hypertrophy. This has been
seen especially in patients with troponin T and a-tropomyosin mutations and these
patients have been shown to be still at risk of SCD.
1.1. Left Ventricular Hypertrophy
LV hypertrophy is a major independent risk factor for morbidity and
mortality from cardiovascular disease. (Frohlich 1991; Levy 1988) Patients with
HCM have also been reported to be at increased risk for sudden cardiac death.
(Maron et al. 1982; McKenna and Deanfield 1984) As in other disease states, cardiac
26
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hypertrophy in FICM is due to hypertrophy of myocytes and hyperplasia of several
other cell types, namely, fibroblasts, smooth muscle cells and endothelial cells.
Indeed, the non-myocyte cellular hyperplasia may account for more than half of the
LV mass. (Davies and McKenna 1995; Ferrans et al. 1972) Although cardiac
myocytes are normally terminally differentiated cells, there is evidence that in adult
life, myocyte hyperplasia may occur in massive LV hypertrophy. (Ferrans and
Rodriguez 1987)
In the classical form of the disease as described by Teare, (Teare 1958)
hypertrophy is isolated to the anterior septum. However, there is considerable
heterogeneity. Localized segments of hypertrophy can occur anywhere including the
apex which was original described in Japanese patients (Sakamoto et al. 1976) but is
known to occur, all be it, less frequently in other populations. (Kitaoka et al. 2003)
Hypertrophy can also be symmetrical or affect the mid-cavity at the level of the
papillary muscles. (Poetter et al. 1996)
The degree of LV hypertrophy is also variable and can range from mild (13-
15mm) to severe (>30mm) [Normal <13mm]. Extreme athletes can develop mild
localised wall thickness creating diagnostic difficulty that can often only be resolved
by a period of de-training and exclusion of abnormal relaxation.
LV hypertrophy is a physiologic response to increased afterload, volume
overload, or acute or chronic ventricular injury in a variety of cardiac disease states.
The increased LV wall thickness reduces ventricular wall tension (Laplace law:
Tension = Pressure x LV radius h- 2LV wall thickness) and augments LV systolic
function in the short and medium term. If hypertrophy continues to adequately
compensate for increased wall stress then systolic function remains preserved.
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However if hypertrophy fails to keep pace with wall stress then as the result of
myocyte necrosis, fibrosis, and myocellular energy depletion, systolic dysfunction
results and congestive cardiac failure ensues.
There is increasing evidence that the LV hypertrophy in HCM is also
secondary, and may be an attempt to compensate for intrinsically impaired LV
contraction. The primary abnormality in many instances may be malfunctioning of a
sarcomeric protein. (Marian 2000) There is, for example, evidence that in HCM
caused by missense mutations of the P-myosin heavy chain gene, mutant P-myosin
translocates fluorescently-labelled actin at increased velocity in an in-vitro motility
assay. (Cuda et al. 1997) In addition, single skinned slow skeletal (soleus muscle)
myofibers, demonstrated to contain mutant P-myosin, generate reduced isometric
force, unloaded shortening velocity and power. (Malinchik et al. 1997)
Thus, in contrast to cardiac conditions associated with increased afterload,
such as hypertension, in HCM, normal systemic pressures are perceived as excessive
load by a diseased myocardium with impaired contractile properties. Furthermore, as
the hypertrophy and impairment of contraction are not uniform throughout the LV,
regional differences in LV contractility may act as a stimulus for maintenance of the
LV hypertrophy.
An important clinical feature of HCM is the presence or absence of
obstruction to left ventricular outflow. Although it is only present in about 25-30% of
patients (Maron et al. 2003c) it has lead to a confusing array of terms used to
describe the condition, including idiopathic subaortic stenosis (Braunwald et al.
1964) and hypertrophic obstructive cardiomyopathy. However, HCM is preferred as
it covers the whole spectrum of disease. Subaortic obstruction occurs as a result of
28
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systolic anterior motion (SAM) of the mitral valve leaflets with mid-systolic contact
of the leaflets with the ventricular septum. This results in physical obstruction to
outflow with a higher proportion of forward flow being ejected in early systole.
(Wilson et al. 1967) The exact cause of SAM is uncertain but maybe due to a drag
effect created by the high velocity ejection jet (Sherrid et al. 1993; Sherrid et al.
2000) and/or the Venturi phenomenon. (Cape et al. 1989; Wigle et al. 1985)
Figure 1-2: M-mode echocardiogram from patient with obstructive HCM demonstrating SAM of the
mitral valve leaflets (arrow) with brief contact of the leaflets with the ventricular septum
The outflow tract obstruction results in a harsh crescendo-decrescendo
murmur at the apex radiating to the base. In addition, a pansystolic murmur radiating
to the axilla may be heard, as a result of the concomitant mitral regurgitation. There
is often a bifid (not bisferiens) pulse and a double apex beat with the first impulse
arising from early systole before the dynamic obstruction develops and a second
impulse after.
Obstruction can also occur in the mid-cavity at the level of the papillary
muscles, in which instance there is no SAM. (Wigle et al. 1985) This can be
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associated with a distal LV aneurysm with VT arising from a substrate in the apical
aneurysmal segment. In this case there is an hourglass configuration of the LV on
echocardiographic four chamber views and LV ventriculography. Figure 1-3.
Figure 1-3: LV angiogram from patient with mid-cavity obstruction demonstrating a large apical
aneurysm
Although there is a poor correlation between the magnitude of LV
hypertrophy and reported symptoms in HCM, LV hypertrophy does have a direct
relationship with prognosis. There is an increased risk of sudden death in patients
with severe LV hypertrophy. (Elliott et al. 2000; Elliott et al. 2001; Spirito et al.
2000; Wigle et al. 1985) However, a small number of families with rare mutations in
either troponin T or a-tropomyosin are also at increased risk of sudden death despite
only mild LV hypertrophy. (Karibe et al. 2001; Varnava et al. 2001)
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1.2. Diastolic Dysfunction
Diastolic dysfunction, even in the presence of normal systolic function, is
believed to be responsible for functional limitation in a variety of cardiac disease
states, although it is a difficult concept to define and the mechanisms by which this
occurs is unclear. Diastole is traditionally defined as the period between the end of
aortic ejection and the beginning of ventricular contraction of the succeeding beat. It
is determined by both passive and active events. There is assumed to be passive
relaxation of the myocardium from stored potential energy as well as active
relaxation (inactivation) following re-uptake of cytosolic calcium by the
sarcoplasmic reticulum.
A common haemodynamic abnormality in HCM is an elevated LV end-
diastolic pressure (LV EDP) in the presence of normal or reduced LV diastolic
volume. Hence, it is probably related to an alteration in the LV diastolic properties
with a direct shift of the diastolic pressure-volume relation and impaired LV
relaxation. The increased LV stiffness and impaired relaxation both result in
elevated filling pressures and symptoms associated with cardiac failure.
The causes of impairment of passive relaxation in HCM include the degree of
LV hypertrophy, fibrosis (accumulation of fibrillar Type I collagen, and an increase
of the collagen hill ratio) (Boerrigter et al. 1998; Lombardi et al. 2003; Mundhenke
et al. 2002) and cellular disarray which are pathogonomic of the disease. (Davies and
McKenna 1995; Hughes 2004)
Relaxation in HCM, as in coronary artery disease, is governed by
inactivation-dependent mechanisms. Myocardial inactivation is an energy requiring
process during which calcium (Ca2+) is sequestered by the sarcoplasmic reticulum
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(SR). In HCM, as in other forms of heart failure, there is down regulation of the SR
Ca2+-ATPase pump, resulting in persistent elevation of intracellular calcium
concentration and prolonged interaction of contractile elements. (Gwathmey et al.
1991; Somura et al. 2001)
Exercise tolerance is dependent on an increase in cardiac output which in turn
is dependent on heart rate and stroke volume augmentation by increased LV end-
diastolic diameter and contractility. In HCM stroke volume augmentation is limited
by the diastolic filling characteristics of the abnormal left ventricle and consequently
exercise capacity is impaired. (Leie et al. 1995; Nihoyannopoulos et al. 1992)
Numerous studies have suggested the benefit of pharmacologic agents in the
treatment of diastolic dysfunction in HCM. Improvement has been demonstrated
with P-blockers, calcium antagonists (verapamil, diltiazem, and dihydropyridines),
class 1A anti-arrhythmics (disopyramide, cibenzoline) and nicorandil. (Betocchi et
al. 1996; Bonow et al. 1985; Bourmayan et al. 1985; Hamada et al. 2001; Izawa et
al. 2003; Matsubara et al. 1995) Improved filling may also lead to enhanced exercise
tolerance. However, these agents are vasodilatory and therefore will reduce afterload
which may provoke or worsen outflow tract obstruction.
1.3. Myocardial Ischaemia
Myocardial ischaemia is common in patients with HCM despite
angiographically normal coronary arteries, and consequently angina is a common
symptom. (Lazzeroni et al. 1997) Regional myocardial perfusion abnormalities are
demonstrated by exercise thallium scintigraphy and are often associated with
apparent cavity dilatation indicative of sub-endocardial ischemia. (Cannon, III et al.
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1991) In young patients, the myocardial ischemia is often not associated with chest
pain, but is an important cause of symptoms of exercise-induced impaired
consciousness. (Dilsizian et al. 1993)
a <1 A A "A 1 Stress
0 a A A A A * Reperfusion
•





















ft A A Stress
* *




Figure 1-4: Thallium perfusion scan from patient with HCM. The top row from each slice is
following stress. In addition to regional perfusion defects, there is apparent cavity dilatation indicative
of sub-endocardial ischemia
Treatment of angina in HCM can be difficult as symptoms are often atypical
and may not be related to exertion. P-blocker therapy and calcium antagonist are the
mainstay of treatment for patients with HCM although no consensus exists about
which drug to use first. (Braunwald et al. 2002; Cohen and Braunwald 1967;
Goodwin 1973; McKenna and Behr 2002) Verapamil is the most commonly used
calcium antagonist and is often effective in patients who fail to respond to p-blocker
therapy. It also has been shown to cause reversal of the myocardial perfusion defects.
(Petkow et al. 2000)
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Ischaemia in HCM is multifactorial and is due to mechanisms which cause an
imbalance between myocardial oxygen demand and myocardial perfusion. Increased
demand occurs as a result of an increased muscle mass and an increase in both
systolic and diastolic wall stress. The presence of outflow tract obstruction will
further increase these wall stresses and exacerbate myocardial ischaemia. (Cannon,
111 et al. 1987) Relief of outflow tract obstruction reduces wall stress, improves
haemodynamics and reduces the burden of myocardial ischaemia. (Cannon. Ill et al.
1991; Cannon, 111 et al. 1992)
Endothelial and smooth muscle intimal proliferation may result in luminal
narrowing of the intra-myocardial small vessels and therefore decrease myocardial
perfusion and is regarded as a form of 'small vessel' disease. (Maron et al. 1986b;
Tanaka et al. 1987) These microvasculature abnormalities, together with the supply:
demand mismatch may explain the impaired coronary vasodilator reserve that is
observed in patients with HCM. (Cannon, III et al. 1985; Krams et al. 1998)
Bridging of an epicardial coronary artery by the myocardium is characterized
by systolic compression and remains clinically silent in the vast majority of cases,
but has been associated with myocardial ischaemia. Its reported prevalence is highly
variable and is found, not surprisingly, more commonly at post-mortem than on
angiography. (Mohlenkamp et al. 2002) It is thought to be more common in patients
with HCM (Achrafi 1992) and is also associated with an increased risk of sudden
cardiac death in children. (Yetman et al. 1998) This retrospective study included a
highly select group of children undergoing coronary angiography and the association
has been disputed. (Mohiddin et al. 1999; Mohiddin et al. 2000)
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1.4. Arrhythmias
Supraventricular and ventricular arrhythmias occur commonly in patients
with HCM. (Cecchi et al. 1995; Maron et al. 1999b) Atrial fibrillation is the most
common sustained arrhythmia and occurs at some point in about 20-25% of patients
(Olivotto et al. 2001; Robinson et al. 1990) and. as in the general population, has an
increasing incidence with advanced age. Although AF can be associated with
significant morbidity and mortality due to functional disability, heart failure and
heart failure-related death, and embolic cerebrovascular disease, it is well tolerated in
about one third of patients. (Olivotto et al. 2001) Heart failure is particularly
associated with AF when onset occurs before age 50 years and is associated with
outflow tract obstruction. (Olivotto et al. 2001) Embolic stroke has an incidence of
about 1% and prevalence of 6% which is markedly increased compared to HCM
patients without AF. (Furlan et al. 1984; Higashikawa et al. 1997; Maron et al. 2002;
Robinson et al. 1990) Older age, heart failure, and left atrial size are significantly
associated with an increased risk of thrombo-embolic events. (Maron et al. 2002)
The sudden onset of AF, resulting in loss of the atrial transport mechanism
and irregular filling and emptying of the left ventricle, can cause devastating
haemodynamic deterioration, and precipitate syncope or even SCD due to worsening
of myocardial ischemia or precipitation of ventricular arrhythmias. (Boriani et al.
2002; Doi and Kitaoka 2001; Favale et al. 2003; Lopez et al. 2000; Olivotto et al.
2001)
One alternative therapeutic approach if anti-arrhythmic drugs are poorly
tolerated is to perform AV nodal radio-frequency ablation with insertion of a
permanent pacemaker. If the AF is paroxysmal, a dual chamber device with mode
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switching capability can be implanted allowing the patient to take advantage of
periods of sinus rhythm, while reverting to ventricular pacing mode during AF.
In addition to AF, patients can also be affected by other SVTs which are
common in the general population, such as AV nodal and AV re-entry tachycardia.
The latter has been described in association with HCM with families identified with
the clinical syndrome of cardiac hypertrophy, AV conduction block and, accessory
AV conduction. (Boriani et al. 2002; Gulotta et al. 1977) This familial condition was
linked to a locus on chromosome 7q3 (7q34-q36) (MacRae et al. 1995) and was
eventually identified to be a mutation in the gene for the y2 regulatory subunit of
AMP-activated protein kinase (PRKAG2). (Gollob et al. 2001) AMP-activated
protein kinase acts as a metabolic sensor in cells. Disruption of the regulatory subunit
PRKAG2 may affect the normal regression of muscle fibres during AV septation.
However, subsequent studies have shown that the cardiac hypertrophy differs
significantly to that observed in HCM. There is certainly myocyte hypertrophy and a
slight increase in interstitial fibrosis but there is no myofibrillar disarray which is the
hall mark of HCM. In addition there is vacuole formation within the myocytes and
evidence suggests these are filled with glycogen-associated particles. (Arad et al.
2002) Therefore the cardiac hypertrophy in these patients should really be considered
a separate entity to HCM as it is more akin to a glycogen storage disease.
VT is also commonly observed in patients with HCM and recordings from
ICDs at times of appropriate device therapy would suggest that ventricular
arrhythmias are the commonest cause of SCD in HCM. Non-sustained VT is
frequently seen on Holter monitoring and has been associated with an increased risk
of SCD. (Maron et al. 1981; McKenna et al. 1981; Monserrat et al. 2003; Spirito et
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al. 1994) Similarly VT induced during programmed ventricular stimulation at EP
studies has been associated with an increased risk of SCD and has been used as an
indication for implantation of an ICD. (Fananapazir et al. 1992) However, this has
been strongly debated as the frequent occurrence of non-specific endpoints, such as
polymorphic VT or VF has meant that invasive EP studies are thought to add little to
the risk stratification of patients with HCM. (Behr et al. 2002) Some refinement of
the EP protocol demonstrated an association between VF and increased fractionation
of paced right ventricular electrograms in patients with HCM. (Saumarez et al. 1992)
EP studies do still have a role in the assessment and treatment of other abnormalities
such as the presence of accessory AV conduction pathways, atrial flutter or AF and
occasionally monomorphic ventricular tachycardia which is often associated with
mid-cavity obstructive HCM and a distal LV aneurysm. (Alfonso et al. 1989)
1.4.1. Sudden Cardiac Death
Although ventricular arrhythmias are likely to be the commonest cause of
SCD in HCM, the mechanisms leading to this catastrophic event take account of a
combination of factors. (Elliott et al. 2000) A large number of clinical features have
been associated with an increased risk of SCD but they are all limited by poor
positive predicative value. (Maki et al. 1998; Maron et al. 1981; McKenna et al.
1981; McKenna et al. 2002; Olivotto et al. 1999; Sadoul et al. 1997; Spirito and
Maron 1990)
An abnormal blood pressure response to exercise, defined as a failure to
augment blood pressure by >20 mm Hg during a maximum symptom-limited
exercise test, gives a sensitivity of 75%, specificity of 66%, negative predictive value
of 97% and positive predictive value of 15% in predicting SCD. (Sadoul et al. 1997)
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This allows identification of patients who are at low risk of SCD but an abnormal
blood pressure response has limited applicability in determining high risk patients
without further risk stratification. Elliott et al further defined the criteria for an
abnormal blood pressure response to exercise as failure to augment blood pressure by
>25 mm Hg. In this study, there was a significant association between an abnormal
blood pressure response and SCD in patients <40 years old but not in older patients.
(Elliott et al. 2000)
The degree of hypertrophy in HCM has also been identified as a risk factor. A
maximum wall thickness >30 mm has been associated with increased risk of SCD.
(Elliott et al. 2000; Spirito and Maron 1990; Spirito et al. 2000) However this has
also been contested as most SCDs in HCM occur in patients with maximum wall
thicknesses less than 30 mm. (Elliott et al. 2001) In other studies no relationship
between extent of LV hypertrophy and SCD could be found at all. (Olivotto et al.
2003)
The presence of non-sustained VT on Holter monitoring has probably
received the most attention of all risk factors associated with HCM. (McKenna et al.
1981; Fananapazir et al. 1992; Maron et al. 1981; Monserrat et al. 2003; Spirito et al.
1994) However, the presence of non-sustained VT on ambulatory monitoring in
HCM is extremely common. On routine monitoring, 90% of adults demonstrated
ventricular arrhythmias. (Maron et al. 2003a) Non-sustained VT may only be
important when associated with symptoms or when it occurs frequently. (Spirito et
al. 1994)
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A family history of SCD when combined with a history of syncope does have
a significant positive predictive value for SCD. (Elliott et al. 2000; McKenna et al.
1981; McKenna and Behr 2002)
SCD occurs most frequently in children and young adults although can occur
at any age. (Maron et al. 2000a) HCM is, in fact the most common cause of SCD in
the young.
Much has been made of so called "malignant mutations'. Since the discovery
of the first gene mutation responsible for HCM, there has been hope that phenotype-
genotype correlations would allow accurate prediction risk of SCD. However, as
with most aspects of this heterogeneous disease, this too has proved difficult but
genotyping may be included as part of a risk profile. (Firoozi et al. 2003; McKenna
et al. 2002) It is certainly true that some gene mutations are associated with a higher
incidence of SCD. (Epstein et al. 1992; Marian et al. 1995; Yamauchi-Takihara et al.
1996) Some mutations are associated with a high incidence of SCD but only mild
hypertrophy. (Karibe et al. 2001; Watkins et al. 1995) For instance troponin T
mutations have a high incidence of SCD with minimal or no hypertrophy but do have
other hall marks of HCM such as myocyte disarray. (Varnava et al. 2001)
Perhaps one of the most controversial and difficult aspects of risk
stratification in HCM is the risk attributable to exercise. Although SCD occurs most
commonly during fairly mild exertion and occasionally even at rest, it is associated
with more vigorous activities. (Maron et al. 1982; Maron et al. 2000a) This has lead
to recommendations that athletes diagnosed with HCM should not continue
participation often with significant psychological and even financial impact. Recent
recommendations suggest that patients should not participate in competitive activities
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at all, unless of particularly low intensity. However, an exception is made for older
subjects provided they have no other significant risk factors for sudden death.
(Firoozi et al. 2003) The American Heart Association defines various sporting
activities depending on the perceived intensity. Recommendations are then made for
different cardiovascular diseases as to which activities are discouraged and which
should be permitted. The proviso, however, is that other clinical information is taken
into account before a final decision is made. (Maron et al. 2003b)
The natural history of HCM and the incidence of SCD have been altered little
by the use of anti-arrhythmic medications. Verapamil and P-blockers are largely
ineffective in reducing the burden of ventricular arrhythmias and reducing the
incidence of SCD. Amiodarone has been shown to reduce the frequency of
ventricular arrhythmias in patients with HCM. (McKenna et al. 1984; McKenna et
al. 1985) However, the ability to translate this reduction in ventricular arrhythmias
into increased survival has been disputed. (Fananapazir et al. 1991; Gilligan et al.
1991) Amiodarone can be used successfully in the treatment of supraventricular
arrhythmias, (Robinson et al. 1990) in particular AF. (Maron et al. 2002)
Improvement in ICD technology in recent years has led to an alternative
treatment to anti-arrhythmic drugs for patients at high risk for SCD. ICDs have
proved very effective in the prevention of SCD in a variety of cardiovascular disease
states including HCM. (Maron et al. 2000b) Patients who have survived a cardiac
arrest or sustained ventricular tachycardia are at particular risk of recurrent events
and should therefore be considered for implantation of an ICD. (Elliott et al. 1999b)
Retrospective studies of patients with ICDs have also shown clear benefit in patients
who have them implanted for a secondary indication (previous cardiac arrest or
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sustained ventricular tachycardia). (Begley et al. 2003) ICD implantation for primary
prevention of SCD in HCM is less well defined. There are still significant device
related complications and inappropriate shocks that limit their utility. Current
guidelines for implantation of ICDs in HCM for primary prevention are classified as
a class lib indication (situations for which ICDs are frequently used but there is a
divergence of opinion with respect to the necessity of implantation -
usefulness/efficacy is less well established by evidence and opinion), and for
secondary prevention as a class I indication (situations for which there is evidence
and/or general agreement in favour of implantation).
1.5. Genetics
HCM has marked allelic variability with at least ten genes already identified
as causing the disease. These ten genes are:
• P-myosin heavy chain - MYH7, 14q 12 (Geisterfer-Lowrance et al. 1990)
• a-tropomyosin - TPM1, 15q22.1 (Thierfelder et al. 1994)
• troponin T - TNNT2, lq32 (Thierfelder et al. 1994)
• myosin binding protein-C - MYBPC3, 11 p 1 1.2 (Bonne et al. 1995)
• essential and regulatory light chains of myosin - MYL3, 3p21.3-p21.2 and
MYL2, 12q23-q24.3 (Poetter et al. 1996)
• troponin I - TNNI3, 19q 13.4 (Kimura et al. 1997)
• titin - TTN, 2q24.3 (Satoh et al. 1999)
• cardiac actin - ACTC, 15q 11 -q 14 (Olson et al. 2000)
• troponin C - TNNC1 (Hoffmann et al. 2001)
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HCM has also been associated with the Wolf-Parkinson-White syndrome and
located to a further locus at 7q3 (MacRae et al. 1995). However, as already
discussed, identification of the responsible gene (y2 regulatory subunit of AMP-
activated protein kinase PRKAG2) (Gollob et al. 2001), and additional histological
evidence (Arad et al. 2002) has allowed reclassification of the hypertrophic
component of this association as a glycogen storage disease distinct from other forms
of HCM. (Arad et al. 2005) A further locus on chromosome 7 has also recently been
identified. (Song et al. 2006) In addition considerable non-allelic heterogeneity exists
with over one hundred mutations reported in MYH7 alone.
These ten genes, however, barely account for 50% of patients with HCM. The
remainder must have, as yet, undefined mutations in one of these genes or very likely
in entirely different genes which may include the possibility of involving non-
sarcomeric genes. Genetic screening of known genes in unrelated patients often
yields previously unreported mutations and even, on occasion, more than one
mutation in the same individual. These patients can be double heterozygotes or even
homozygotes. (Mohiddin et al. 2003) Since the discovery of p-MHC mutations as a
cause for HCM, HCM has been considered to be a 'disease of the sarcomere'.
(Thierfelder et al. 1994) PRKAG2 was therefore, initially thought to be the first non-
sarcomeric gene mutation causing HCM. However, as indicated, recent evidence
would suggest it is classified as a separate disease.
The mechanism by which sarcomeric gene mutations cause HCM, in
particular the non-uniform pattern of hypertrophy is unfortunately unclear. It is
incorrect to say that mutations result in weaker contractile sarcomeric units resulting
in compensatory hypertrophy. Comparison of mutant and normal myosin
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demonstrates enhanced kinetics of the cross-bridge cycle without affecting either the
motion developed or the force generated. (Palmiter et al. 2000; Thierfelder et al.
1994) It must therefore be the random combination of mutant and normal protein that
results in abnormal sarcomeric function. Increased stress perceived by the
cytoskeleton will trigger compensatory mechanisms with local production of
mitogens leading to hypertrophy.
Although as a general rule mutations in genes encoding proteins involved in
force generation were associated with HCM and those involved in force transmission
were associated with dilated cardiomyopathy, subsequent mutations have been found
in genes that can be responsible for both HCM and dilated cardiomyopathy, such as
ACTC, TNNT and even MYH7. (Kamisago et al. 2000; Olson et al. 1998; Stefanelli
et al. 2004) This includes mutations that are found in the same functional domain of
the subsequent protein.
1.5.1. Penetrance
To further complicate the situation, in addition to this marked genetic
heterogeneity, extensive screening of families with known disease causing mutations
have demonstrated that LV hypertrophy varies markedly even between family
members with identical disease causing mutations (i.e. same genetic background). In
some instances the degree of hypertrophy is undetectable and therefore the mutation
is incompletely penetrant and patients are considered skips. The 908Val"Leu and 256Gly"
Glu mutations in the MYH7 gene are associated with -60% penetrance, whereas, in
contrast, the 403ArgGln mutation in the MYH7 gene is almost 100% penetrant.
(Epstein et al. 1992; Fananapazir and Epstein 1994) Figure 1-5
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Figure 1-5: Variation in LVWTmax between different mutations
Although the majority of HCM patients will have developed their full
phenotype by the time of adulthood, delayed expression can occur. This is most
evident in patients with mutations in the gene MYBPC3. (Niimura et al. 1998) This
adds to the difficulty in screening family members as it is not possible to exclude the
subsequent development of disease in adults without LV hypertrophy.
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1.5.2. Phenotypic Variability
Some of the phenotypic variation observed is also mutation specific. The
most important feature that is often attributed to specific mutations is prognosis. This
has lead to certain mutations being considered 'malignant' while others are deemed
'benign' depending on the perception of risk of SCD. The MYH7 mutation 403Ar8_Gln
is almost universally accepted as malignant with high penetrance and incidence of
SCD. (Epstein et al. 1992; Epstein et al. 1992; Watkins et al. 1992) Conversely there
is not only low penetrance in the MYH7 mutations 908Val"Leu and 256Gly"Glu but there
is also a very low incidence of SCD. (Fananapazir and Epstein 1994) Still further
mutations have a mild cardiac phenotype but a high incidence of SCD. (Karibe et al.
2001; Varnava et al. 2001) Other features have also been attributed to certain genes
or mutations. Mutations in the essential and regulatory light chains are associated
with a rare form of the cardiomyopathy where the hypertrophy is localised to the
mid-cavity at the level of the papillary muscles resulting in a mid-cavity gradient
rather than an outflow tract gradient. (Poetter et al. 1996) This form of HCM may be
associated with a distal LV aneurysm and patients may be prone to monomorphic VT
arising from the apical aneurysm.
Although much has been made of phenotype-genotype correlations there is,
of course, a certain amount of disagreement. For instance the MYH7 mutation
606Leu"Val has variably been described as both malignant and benign. (Fananapazir
and Epstein 1994; Watkins et al. 1992) Thus, distinct phenotypes in different
families with the same underlying mutation highlight the influence of modifying
factors, which may be genetic or non-genetic, in the phenotypic expression of HCM.
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2. Methods
In Section II of thesis I have explored the role of four potential modifying
factors in the phenotypic expression of HCM.
Gender has such an important impact on all cardiovascular disease it must be
considered in addition when assessing any other modifying factors. I have therefore
first considered the impact of gender on morphological development in HCM by
comparing data from all HCM patients referred to National Heart, Lung, and Blood
Institute (NHLBI), National Institutes of Health, Bethesda, Maryland, who had
undergone cardiac MRI.
I also studied the role of IGF-I, a potent mitogen of cardiomyocytes, and its
major plasma binding protein, IGFBP3, in influencing the development of LV
hypertrophy in HCM. A small subset of these patients had levels of BNP measured to
determine its relationship to disease severity and heart failure symptoms in HCM.
Finally common genetic polymorphisms in two genes (ACE and ET-1) that
theoretically were felt likely to influence LV hypertrophy genesis in HCM were
explored.
In Section III, following on from the observations from our genetic studies on
the involvement of the renin-angiotensin system on LV hypertrophy in HCM, a
randomised, double-blind placebo-controlled study was conducted to investigate the
possibility of LV hypertrophy regression using ACE inhibitors and/or ARB drugs.
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2.1. Patient Population
A total of 269 patients were included in all studies (235 adults, >20 years; 34
children, <20 years). To evaluate gender differences. 208 adult patients with
morphologic evidence of HCM were compared. The influence of IGF-I and its major
binding protein IGFBP3 on the development of LV hypertrophy in patients with
known sarcomeric mutations was assessed in 100 patients (50 patients with
morphologic evidence of HCM and 50 patients with a disease causing mutation but
without LV hypertrophy) and 50 family members without disease causing mutation
(controls). BNP levels were measured in 37 of these patients with a disease causing
mutation and 19 controls. HCM genotyping had already been established in a number
of large kindred in our own laboratory under separate genetic protocols. DNA from
229 patients was tested for genetic modifiers of HCM. Figure 2-1.
Population (269 patients)
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Figure 2-1: Distribution of patients included in studies
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Eighty-nine patients were enrolled in the prospective randomised, double-
blind, placebo controlled study examining LV hypertrophy regression in HCM.
Patients were referred to the NHLB1 from centres mainly within the USA
either having had the diagnosis of HCM established or for the purposes of screening.
Patients could also self-refer and as a result some patients from other countries were
included. In addition family screening was undertaken in patients with sufficiently
large pedigrees, if requested, or were the disease causing mutation was known.
All HCM patients seen at NHLB1 were consented with a screening protocol
which permitted basic investigations to allow initial phenotyping. Patients and family
members who participated in family screening studies signed a separate consent. In
addition a separate consent for genetic studies was signed by anyone from whom
DNA was collected. This permitted the analysis of DNA for mutations suspected of
causing HCM as well as specific mutations suspected of being potential modifiers of
the disease. Specific protocols and consents were obtained from patients enrolled in
the studies looking at IGF-I in HCM and regression of LV hypertrophy with ACE
inhibitors and ARB drugs. All protocols and consents were approved by the
Institutional Review Board of the NHLBI.
HCM in adults was defined as a diastolic LV wall thickness of >13 mm by
echocardiography (in children >2 standard deviations of published normal values) in
the absence of another cause for the increased cardiac hypertrophy. Diastolic LV
wall thickness of >16 mm by MRI was also considered to indicate hypertrophy This
higher value was determined from our own studies on normal controls and is likely
due to the greater spatial resolution of the MRI images. Other causes of the LV
hypertrophy were excluded.
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2.2. Investigations
2.2.1. Echocardiography
All patients underwent initial assessment by echocardiography. Standard
transducer positions were used to obtain two-dimensional images. The distribution of
LV hypertrophy was assessed in the parasternal long axis, short axis, and apical two
and four chamber views. Continuous wave Doppler was used initially to determine
the presence of outflow tract or intra-cavitary gradients. If a gradient was established,
pulsed wave Doppler was used to determine the level of obstruction and to assist
exclusion of coexistent aortic valve disease. A gradient of >30 mm Hg was
considered significant obstruction.
2.2.2. Cardiac Magnetic Resonance Imaging
MRI was used to assess LV mass and volumes. Scanning was performed in a
1.5 T clinical scanner (GE, Waukesha, Wl) using a cardiac phased array coil. The
studies were gated to the ECG and acquired during a single breath hold. Contiguous
multi-slice short axis images (8 mm thickness) were obtained to define the site of
maximal LV wall thickness at end diastole (LVWTmax). Measurement of LV
volumes, mass and ejection fraction were made offline on a dedicated workstation.
The epicardial and endocardial borders of each short axis image at both end-diastole
and end-systole were then traced by hand providing an end-diastolic (ED) and end-
systolic (ES) area for each slice. As the slices were of known thickness, it was then
possible to calculate ED and ES volumes for the LV cavity and myocardium for each
slice. The summation of these volumes provided ED and ES LV volumes (EDV and
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ESV) as well as the ED volume of LV myocardium. The volume ofmyocardium was
then multiplied by an assumed specific gravity of cardiac muscle (1.05g/ml) to
provide the ED LV mass. Stroke volume (SV) was calculated as the difference
between EDV and ESV volume. The heart rate was recorded at the time of the study
which allowed calculation of cardiac output (CO) from the derived SV (HR x SV).
Ejection fraction (EF) was also calculated from the EDV and ESV (SV/EDV x 100).
The LA dimension was measured from the four chamber view.
Validation of MRI Measurements: The ability of MRI to accurately
determine volumes was first validated with the aid of water filled phantoms of
varying sizes (range 7.5-465 ml). There proved to be excellent correlation between
the volume of 15 water-filled phantoms and their absolute volume: Volume phantom =
1.00 x Volume absolute - 1.5 ml, R2 = 0.9998. In addition the inter-observer variability
was determined for cardiac indices (normal subjects, and patients with coronary
artery disease, HCM and valvular heart disease). Table 2-1 and Figure 2-2.
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Cardiac Parameter n Linear Relation R2 Co-efficient of Inter-
observer Error
LV Volumes (ml) 20 y-1.01x+3.8 0.987 6.1%
LV end-diastolic mass (g) 9 y=0.996x+3.9 0.973 4.7%
LV end-systolic mass (g) 9 y=l .09x4-21.3 0.989 4.1%
LV ejection fraction (%) 10 y=1.002x+0.42 0.916 5.9%
LV stroke volume (ml) 10 y=0.957x+5.7 0.992 3.7%
x and y, observer 1 and 2
Table 2-1: Inter-observer variability of cardiac indices by MR1
Observer 1
LV Diastolic Volume (ml)
Figure 2-2: Correlation of LV diastolic volume between 2 observers
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LV mass should not change throughout the cardiac cycle. Although the LV
thickens during systole, the length of the ventricle shortens. Therefore the volume of
LV myocardium and hence LV mass should be the same in systole and diastole.
These values were therefore compared as an additional internal measure of validity.
Figure 2-3.
Diastolic LV Mass (g)
Figure 2-3: Correlation between systolic and diastolic LV mass
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LV ejection fraction (EF) measured by MRI was compared to LV EF
measured by radionuclide angiography (RNA) in 46 subjects. The relation was best
described by the following quadratic equation: EFmri = -0.0058x(EFrna) +
1 .391x(EFrna), R2 - 0.8856. The deviations from the quadratic fit and actual MRI
measurements were relatively small but became larger in the range of 55 to 75%. In
subjects with EF <70% (n=31) the relation was described by the following linear
regression equation: EFmri = I.OIx(EFrna) + 3.49, R2 = 0.8535. Figure 2-4.
Radionuclide EF (%)
Figure 2-4: Correlation between EF measured by MRI and radionuclide angiography
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SECTION II: MODIFYING FACTORS
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3. Gender Differences in the Phenotypic Expression of Hypertrophic
Cardiomyopathy
3.1. Introduction
Gender-specific cardiovascular differences have been described in normal
humans and animals. Functional parameters, such CO and EF, are gender
independent; whereas morphological parameters, LV volumes and mass, are gender
dependent even after correction for body surface area. (Lorenz et al. 1999) Similar
differences are observed for right ventricular parameters.(Forman et al. 1997; Lorenz
et al. 1999; Marcus et al. 1999; Sandstede et al. 2000; de Simone G. et al. 1995)
In addition, the cardiac response to several cardiovascular disease states also
demonstrates gender-specific differences. A greater degree of LV hypertrophy,
smaller chamber volumes and consequently lower wall stress is observed in women
with aortic stenosis compared to men. (Aurigemma and Gaasch 1995; Kostkiewicz et
al. 1999; Marcus et al. 1999; Rohde et al. 1997) A similar pattern of gender
difference is also observed in hypertension with a much stronger correlation between
indices of LV hypertrophy and blood pressure observed in women. (Savage et al.
1998; Vriz et al. 1997; Zabalgoitia et al. 1996) In addition, experimental models of
pressure overload hypertrophy not only demonstrate similar morphologic differences
but suggest there is an earlier transition to heart failure in male animals. (Douglas et
al. 1998; Weinberg et al. 1999)
Although a similar degree of LV hypertrophy is seen between male and
female rats during chronic volume overload due to an aorto-caval fistula, LV
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volumes are better preserved in the female rats, again limiting the increase in wall
stress. (Gardner et al. 2002)
SCD is much more common in men compared to women, however, women
have longer corrected QT intervals and a higher incidence of Torsades de Pointes.
This apparent paradox is likely to be explained by the greater prevalence of coronary
artery disease in men, although a higher proportion of SCD in women occurs in the
absence of prior overt coronary artery disease. (Dahlberg 1990; Larsen and Kadish
1998)
The role of gender in determining cardiac phenotypic expression and clinical
presentation in HCM has been uncertain, in part due to lack of a reliable method for
measuring LV mass in F1CM. Cardiac MRI provides a powerful tool to define
potential differences in LV dimensions and function that are independent of
geometry. Understanding the impact of gender on phenotypic expression is an
important consideration before assessing the contribution of other potential
modifiers.
3.2. Methods
Adult patients, who had been assessed as part of other studies, and who had
morphological evidence of HCM, were included in this comparison. Two hundred
and eight adult patients met the criteria for the diagnosis of HCM as detailed
previously (Mean age 41 ±0.9 years, range 19-76 years). There were 116 male
patients and 92 female patients. All patients had previously undergone a screening
echocardiogram and cardiac MRI. Cardiac MRI parameters were compared to assess
gender differences. Sixty-one patients (27 male and 34 female) had significant
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outflow tract obstruction. Therefore the cardiac MRI parameters of the remaining
non-obstructed patients were also compared separately to exclude the influence of
obstruction on these parameters. All parameters were also compared after correction
for BSA, calculated using the Dubois formula (BSA = 0.20247 x height (m) 0 723 x
weight (kg) 0425). (DuBois and Dubois 1916) The blood pressure documented on
initial assessment was recorded and used for the purposes of analysis. The ratio of
LVWTmax to EDV is proportional to wall stress and was calculated for all patients
and compared between groups.
3.2.1. Statistics
Comparisons between male and female patients were made with an unpaired
student t-test. Analysis of co-variance was also performed to include other
confounders. All results are expressed as mean ± SEM. A p-value < 0.05 was
considered significant.
3.3. Results
Male and female patients (all patients and non-obstructed patients) were well
matched for age. However, women had a significantly lower systolic and diastolic
blood pressure in addition to lower height, weight and BSA. Table 3-1.
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*p<0.001, **p<0.0005, p<0.0001, male vs. female (all patients); tp<0.005, ftp<0.0002, +ttp<0.0001,
male vs. female (non-obstructed)
Table 3-1: Comparison of blood pressure, height, weight and BSA by gender
SV, EDV, ESV and LV mass were all lower in women compared to men.
However there was no difference in EF or LVWTmax. The ratio LVWTmax : EDV was
significantly higher in women compared to men. Table 3-2.
All Patients NormalA
Male Female Male Female
SV (ml) 91±2.6** 75±2.2
EF (%) 69±0.9 72±1.0 67±0.7 67±0.9
EDV (ml) 123±3.1 ** 99±2.4 136±4.4 96±4.3
ESV (ml) 32±1.3** 25±1.1 45±2.0 32±1.7
LV mass (g) 241±8.9** 192±7.4 1 78±4.5 125±4.9
LVWTmax (mm) 24±0.6 24±0.6
LVWTmax/EDV (mm/ml) 0.21±0.01 ** 0.26±0.01
*p<0.05, **p<0.0001, male vs. female; A Selected normal values derived from Lorenz et al, 1999
Table 3-2: Comparison ofMRI parameters between male and female patients
58
Modifying Factors in HCM Gender
Non-obstructed NormalA



















+p<0.0005, "i"tp<0.0002, p<0.0001, male vs. female; A Selected normal values derived from Lorenz et
al, 1999
Table 3-3: Comparison ofMRI parameters between non-obstructed male and female patients
After correction for BSA, differences still existed in EDV and ESV (not non-
obstructed patients). However, there was no longer any significant difference in SV
or LV mass. LVWTmax when corrected for BSA was actually significantly greater in
women compared to men. Table 3-4 and Table 3-5.
All Patients NormalA











69±1.6 61 ± 1.9
91 ± 1.6 79±1.5
-I, indexed to BSA; *p<0.05, **p<0.001, male vs. female; A Selected normal values derived from
Lorenz et al, 1999
Table 3-4: Comparison ofMRI parameters correct for BSA between male and female patients
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Non-obstructed NormalA













tp<0.05, male vs. female; A Selected normal values derived from Lorenz et al, 1999
Table 3-5: Comparison of MRI parameters corrected for BSA between non-obstructed male and
female patients
To assess whether gender was independently predictive of LV mass and
volumes in HCM, analysis of co-variance was performed on all patients including
age and systolic BP as potential confounders. The percent of variance in LVWTmax-I
explained by these variables was 16.1% (p<0.0001) and gender was an independent
predictor (p<0.005). Gender was also an independent predictor of LVWTmax/EDV
(p<0.0005). The percent of variance explained by the whole model was 10.0%
(p<0.0001). There was no significant co-variance between the variables and SV-I, EF
or LV mass-1 but there was some co-variance between the variables and EDV-1 and
ESV-I (R2=5.2%, p<0.02 and R2=3.8%, p<0.05 respectively) with gender being an
independent predictor in both instances (p<0.005 and p<0.01 respectively).
The same analyses were performed on the non-obstructed subset of patients.
The percent of variance in LVWTmax-I was 17.5% (p<0.0001) and gender was an
independent predictor (p<0.05). The percent of variance in LVWTmax/EDV was
11.36% (p<0.001) and again gender was an independent predictor (p<0.005). There
was no significant co-variance between these variables and SV-I, EF, EDV-I, ESV-1
or LV mass-I.
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3.4. Discussion
Gender differences in LV hypertrophy have been reported in a variety of
disease states. (Douglas et al. 1998; Kostkiewicz et al. 1999; Rohde et al. 1997;
Savage et al. 1998; Vriz et al. 1997; Weinberg et al. 1999; Zabalgoitia et al. 1996) In
animal studies, normal female rats had smaller indexed LV masses and smaller LV
volumes but had thicker indexed walls. (Forman et al. 1997) This relationship was
maintained in rats subjected to pressure overload by aortic banding. However,
although the LV mass of female rats continued to rise with age, that of male rats fell
with advancing age suggesting an early transition to dilatation and heart failure.
(Douglas et al. 1998)
MR1 studies of normal human volunteers showed greater LVM-I, EDV-I,
ESV-I, and LVWT-I in men compared to women and this relationship did not alter
with increasing age. (Sandstede et al. 2000) Rohde et al studied the gender
differences in left ventricular geometry in relation to aortic valve disease and the
effect of particular valve lesions. Female patients with pure aortic stenosis had
smaller LV mass and volumes but greater wall thickness. Female patients with pure
aortic regurgitation, however, had similar wall thickness but still had smaller LV
mass and volumes. (Rohde et al. 1997) Similar observations have been made in adult
patients with hypertension. (Vriz et al. 1997) Our results, suggest that the
hypertrophic response in women and men with HCM is similar to that observed in
adult patients with other forms of pressure overload.
Attempts to explore the impact of gender on phenotypic expression in
patients with HCM have concluded that no difference exists in LV wall thickness,
although women did have smaller LV mass and volumes compared to men.
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(Dimitrow et al. 1998; Maron et al. 1999a) However in these studies men were
compared directly to women with no attempt made to correct for the smaller body
size of women and this may have concealed important differences in measured
parameters.
These studies also used cardiac ultrasound to evaluate the gender differences.
LV mass was derived indirectly from equations that make assumptions of LV
morphology. These calculations probably do not apply to HCM as in HCM the
cardiac hypertrophy is often asymmetric and regionally distributed resulting in
distortion of the LV cavity. Further, the cardiac morphology varies markedly from
one HCM patient to another. We therefore used MRI to study the cardiac effects of
gender in HCM as it provides a more direct assessment of LV structure (mass and
volumes) and function.
Although women in our study have smaller LVM-I, they have greater
LVWT-I, which may represent favourable adaptation, as this combination of small,
thick walled hearts will result in significantly reduced wall stress. Indeed, relative
wall thickness (LVWT/EDV) was significantly greater in women compared to men.
These results may therefore partially explain the survival advantage for women with
HCM that has been reported previously. (Koga et al. 1984)
3.4.2. Limitations
A single definition of HCM is applied to both male and female patients. As
body size clearly has an impact on cardiac dimensions, borderline cases may be
reported as normal. Therefore a greater number of female patients may be diagnosed
as normal or mistakenly considered phenotypically negative in the presence of a
disease causing mutation. However, LVWTmax/EDV is internally controlled and
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should largely be independent of overall body size. Although, BSA has a better
correlation with cardiac dimensions than height or weight (Lorenz et al. 1999), it is
uncertain whether this is the optimum method to correct these values for body size
and as such, spurious differences may exist in indexed values. Information on
medication use in these patients was not available.
3.5. Conclusions
Distinct gender-specific differences in cardiac morphology exist in patients
with HCM. Women have smaller, thicker walled hearts compared to men. The
pattern of gender differences is similar to that observed in patients with pressure
overload but not other forms of hypertrophy indicating that the hypertrophic response
in HCM may be due to a perceived pressure overload by abnormal sarcomeres.
Although women have relatively thicker hearts, cavity size is smaller, which will
reduce wall stress, and may provide a distinct survival advantage. These results have
important implications for the design of studies that examine genes and therapies that
may modify phenotypic expression in HCM.
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4. Influence of Insulin-like Growth Factor-I and IGFBP3 on
Phenotypic Expression in Hypertrophic Cardiomyopathy
4.1. Introduction
In this study we explore the ability of IGF-1 and IGFBP3 to modulate LV
hypertrophy of HCM in a genetically-defined population. IGF -1 is an attractive
candidate in this respect for several reasons. It mediates most of the actions of
growth hormone. Receptors for IGF-1 are expressed in cardiac myocyte, and signal
cell growth, differentiation and survival through endocrine, paracrine or autocrine
mechanisms. (Fuller et al. 1991; Ito et al. 1993) They stimulate cardiomyocyte
hypertrophy by increasing protein synthesis and accumulation (Decker et al. 1995;
Fuller et al. 1991), retard apoptotic signalling (Chen et al. 2000; Morales et al. 2000;
Sun et al. 2000), and improve cardiomyocyte function. (Kinugawa et al. 1999; Li et
al. 1997a) Due to their inotropic effects, IGF-1 or GH have been used with variable
success in the treatment of chronic heart failure. (King et al. 2001; Perrot et al. 2001;
Welch et al. 2002) Further, high IGF-1 states such as acromegaly are associated with
LV hypertrophy, and GH/IGF-1 suppression in affected patients is followed by
regression of the LV hypertrophy and improved cardiac function. (Colao et al. 2001)
Cardiac excitation-contraction coupling has been shown to be impaired in ventricular
myocytes of transgenic animals with IGF-1 deficiency (Ren and Brown-Borg 2002),
and in humans, low IGF-1 in GH deficiency syndrome is associated with reduced LV
mass and impaired LV function, and GH replacement therapy normalizes these
cardiac indices. (Colao et al. 2002) IGF-I gene expression is up-regulated in
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hypertrophied myocardium, including HCM. (Li et al. 1998; Li et al. 1997b; Pauliks
etal. 1999)
These findings have led to attempts to reverse the cardiac hypertrophy in
HCM using specific inhibitors of GH/IGF-1 system. (Demirtas et al. 1998; Gunal et
al. 1996) However, despite the significant advances in our understanding of IGF-1,
its role in HCM remains uncertain. This study therefore examines whether
differences in LV hypertrophy in HCM may be influenced by differences in
circulating concentrations of 1GF-I and IGFBP3.
4.2. Methods
The study was performed after informed consent and consisted of 150
subjects from 33 unrelated families (5±6 subjects per family) who were genotyped.
(Fananapazir and Epstein 1994) One hundred subjects from several unrelated
families had one or more of 26 disease mutations in one of six sarcomeric genes.
Table 4-1.
Subjects with positive genetic diagnosis were separated into two groups
based on magnetic resonance estimations of LVWTmax: Group 1 were adult patients
and young HCM patients (<20 years) with a LVWTmax of >16 mm or >2 SD above
published normal values, respectively; and Group 2 were subjects with LVWTmax
within the range of normal controls. The control group consisted of 50 family
members without a disease causing mutation. Subjects also underwent
echocardiography, treadmill and bicycle exercise tests, and ambulatory
electrocardiographic (ECG) Holter monitoring.
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Gene Mutation Group 1 Group 2 Total
MYH7 R143Q 0 1 1
Ml 49V 2 0 2
Y162C 1 0 1
N187K 3 3 6
G256E 0 1 1
G389E 3 3 6
R403Q 5 1 6
D479N 1 0 1
V606W 0 1 1
R663H 3 4 7
R719W 3 0 3
R723C 3 0 3
E743D 1 0 1
G768R 1 0 1
R847H 3 3 6
R870H 2 1 3
D906G 0 5 5
L908V 8 14 22
TPM1 V95A 5 5 10
ACTC V9L 0 1 1
G99K 3 0 3
MYL2 K111X 1 1 2
P95R 1 0 1
MYL3 R154H 0 1 1
MYBP3 T842X 2 0 2
E258K 3 1 4
Total 54 46 100
Table 4-1: Molecular defects causal for HCM
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4.2.1. Plasma IGF-I and IGFBP3 Concentrations
Only a small amount of 1GF-1 circulates in the free form. Most of the plasma
IGF-1 is bound to specific carrier proteins, insulin-like growth factor binding
proteins (IGFBPs). These have an important role in the regulation of IGF-1. IGFBP3
accounts for more than 90% of all circulating IGFBPs, although all six identified
carrier proteins probably have distinct physiologic roles. (Kelley et al. 1996) Blood
was obtained in the non-fasting state after one hour of supine rest. Serum or EDTA
plasma sample was prepared for determination of IGF-I and IGFBP3 concentrations
within one hour of blood collection and shipped frozen in a plastic vial to Endocrine
Sciences, Calabasas Hills, CA 91301. The hormone concentrations are measured
using radio-immunoassay (RIA) using a monoclonal antibody directed against a
synthetic segment of the IGF-I peptide and a high affinity polyclonal antibody
specific for the binding subunit, IGFBP-3P, of IGFBP3.
4.2.2. Statistics
Data are presented as mean ± 1 SEM. Differences between mean values were
compared by one-way ANOVA. Bonferroni multiple comparisons test was used to
test differences between individual groups. Spearman's correlation was used to
examine the relation between two variables. A two-tailed p<0.05 was considered
significant. To evaluate the relationship between IGF-1 and LVWT, we used
covariance techniques that account for the familial relationships among the members
of the study. A variance component analysis approach (Hopper and Mathews 1982)
being implemented in the genetic software, SOLAR (Almasy and Blangero 1998)
was used for the data analysis. This approach is able to deal with families of different
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sizes and structures. It takes full account of the different types of relationship within
a family in performing association studies on two quantitative traits.
4.3. Results
4.3.1. Magnetic Resonance Criteria ofLV hypertrophy and HCM
Family members without genetic mutation (Controls): By MR1, LVWTmax
was <16 mm and LV mass was <170 g in all of the 23 normal adult subjects.
Similarly, LVWTmax was <14 mm and LV mass was <165 g in all of the 27 young
control subjects.
Subjects with sarcomeric gene mutations: LVWTmax varied markedly from 9
mm to 44 mm, and LV mass from 57 g to 670 g in the 68 adult subjects with positive
genetic diagnosis. LVWTmax also varied markedly from 9 mm to 28 mm, and LV
mass from 37 g to 208 g in the young subjects with disease mutation. Although there
was a significant correlation between LVWTmax and LV mass, the same LV mass
was associated with up to 20 mm difference in LV wall thickness. Figure 4-1.
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Figure 4-1: Relation between maximum LV wall thickness (LVWT) and LV mass in 68 adult
subjects with disease mutation.
In this selected population, LVWTmax was >16 mm (HCM present) in 44 of
the 68 adult subjects with positive genetic diagnosis, a disease penetrance of 65%.
By comparison, an LV mass criterion of >180 gm identified HCM in only 14 of the
68 adult subjects, a disease penetrance of only 21%, p<0.0001.
4.3.2. Relation ofIGF-I Levels to Age
Age-related IGF-1 concentrations were highly variable in the 150 subjects.
However, IGF-1 concentrations, as reported previously, (Juul, 2001; Lannsen et al,
2001; Strasburger et al, 2001, Stratakis et al, 1996) increase with age reaching a
maximum at 10 to 15 years, and then decline after 20 years of age. Figure 4-2.
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Age (years)
Figure 4-2: Relation of IGF-I levels to age
4.3.2. Clinical Findings
As IGF-I levels decline beyond the age of 20, the groups were further divided
by age into adults and young patients and comparisons made between these groups.
There were no significant differences between the groups with regards to age,
gender, and body surface area. Young patients without sarcomeric mutation had
slightly higher blood pressure compared to patients with sarcomeric mutations.
Table 4-2.
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Adults (>20 years)
Group 1 Group 2 Controls
n=44 n=25 n=23
Young Patients (<20 years)




















Bonferroni multiple comparisons test; - *p<0.05 compared to group 1 and 2; **p<0.01 compared to
group 1
Table 4-2: Clinical characteristics of patients and controls in IGF-I study
Indices of cardiac hypertrophy by echocardiography and MRI were
significantly greater in group 1 (Mutation +ve, phenotype +ve) compared to group 2
(mutation +ve, phenotype -ve) and controls (mutation -ve) in both adults and young
patients. Table 4-3 ancl Table 4-4. In addition the QTc of adult patients was longer in
group 1 compared to group 2 and controls. Young patients with sarcomeric mutations
with and without LV hypertrophy had smaller LV internal dimensions by
echocardiography compared to controls and young patients without sarcomeric
mutations (controls) had greater peak systolic and diastolic blood pressure with
exercise despite similar exercise tolerance.
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Adults (>20 years)
Group 1 Group 2 Controls ANOVA
12 lead ECG
heart rate (bpm) 69±2 67±3 67±2 ns
PR interval (ms) 169±5 155±4 160±4 ns
QRS width (ms) 91 ±2 86±2 86±2 ns
QT interval (ms) 398±6 377±6 381±5 p<0.05
QTc 423±4 399±6* 400±5* p<0.0005
Echocardiogram
septum (mm) 20±0.9 10±0.4** 10±0.2** p<0.0001
posterior wall (mm) 10±0.2 9±0.2 9±0.2 ns
LVIDd (mm) 44±1 45±1 44±1 ns
LVIDs (mm) 26±1 28±1 28±1 ns
left atrium (mm) 42±1 35±1** 34±1** p<0.0001
FS (%) 42±1 38±2 41±1 ns
MRI
LVWTmax (mm) 24±0.9 13±0.6** 12±0.4** p<0.000!
LV mass (g) 176±15 108±6** 112±6* p<0.0001
EDV (ml) 111±6 101±4 111±5 ns
ESV (ml) 29±2 29±2 34±2 ns
EF (%) 74±1 72±2 69±1 ns
SV (ml) 82±5 73±4 76±4 ns
Ambulatory ECG
heart rate (bpm) 70±1 75±3 72±3 ns
SVT 11±4 3±2 3±3 ns
non-sustained VT 7±2 0 1±1 ns
Exercise test
duration (s) 549±29 503±35 620±42 ns
peak sBP (mm Hg) 153±3 149±5 163±4 ns
peak dBP (mm Hg) 75±2 78±4 79±3 ns
02 consumption (ml/kg/min) 19±1 22±2 22±2 ns
Bonferroni multiple comparisons test; *p<0.01, **p<0.0001 versus group 1; Group 1, mutation
+ve, phenotype +ve; Group 2, mutation +ve, phenotype -ve; controls, mutation -ve.
Table 4-3: Clinical findings of adult patients and controls in IGF-I study
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Young Patients (<20 years)
Group 1 Group 2 Controls ANOVA
12 lead ECG
heart rate (bpm) 74±4 77±3 78±4 ns
PR interval (ms) 142±7 140±3 138±3 ns
QRS width (ms) 95±7 80±2 81±2 ns
QT interval (ms) 382±10 359±7 362±6 ns
QTc 422±11 401 ±5 408±3 ns
Echocardiogram
septum (mm) 16±2.5 8±0.7** 7±0.2** p<0.0001
posterior wall (mm) 9±0.3 7±0.2** 7±0.2** p<0.0001
LVIDd (mm) 40±3 38±lt 43±1 p<0.05
LVIDs (mm) 21±2tt 22±lft 27±1 p<0.000l
left atrium (mm) 38±3 29±1** 29±1** p<0.000l
FS (%) 45±2 41±1 38±1** p<0.005
MRI
LVWTmax (mm) 19±1.3 1 ]±0.4*** 11±0.6*** p<0.0001
LV mass (g) 115±14 64±5** y^±6*** p<0.0002
EDV (ml) 99±9 76±5 85±5 ns
ESV (ml) 27±4| 18±1 25±2:j: p<0.005
EF (%) 73±2 76±1 72±1 ns
SV (ml) 60±6 58±4 61±3 ns
Ambulatory ECG
heart rate (bpm) 83±4 82±2 80±2 ns
SVT 0 0 0 ns
non-sustained VT 1±3 1±1 0 ns
Exercise test
duration (s) 653±82 605±41 674±37 ns
peak sBP (mm Hg) 137±8 146±5 159±5* p<0.05
peak dBP (mm Hg) 58±3 67±3 77±4** p<0.005
02 consumption (ml/kg/min) 26±3 29±2 31±2 ns
Bonferroni multiple comparisons test; * p<0.05, **p<0.01, ***p<0.001 versus group 1; Jp<0.05
compared to group 2; +p<0.05, ttpO.OOOl versus group 3; Group 1, mutation +ve, phenotype +ve;
Group 2, mutation +ve, phenotype -ve; controls, mutation -ve.
Table 4-4: Clinical findings of young patients and controls in IGF-I study
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Young subjects aged 5 to 19 years: The regression lines describing the
relation between age and IGF-1 concentrations in groups 1 and 2 subjects, and
normal controls (group 3) were similar. (The number of subjects was too small to test








• Groups 1 & 2: r=0.43, p<0.05







Figure 4-3: Relation of IGF-I levels to age in young patients
Adult subjects aged 20 to 67years: There were no differences among the
slopes of the regression lines describing the relation between age and IGF-1 in adults
with HCM, adults with disease mutation without HCM and normal controls (p=0.54)
but there were significant differences among the intercepts (p<0.05). This indicates
that IGF-1 concentrations were lower in the subjects with LV hypertrophy (HCM).
Figure 4-4.
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Age
Figure 4-4: Relation ofIGF-I levels to age in older patients
4.3.4. Relation ofIGF-I Levels to Cardiac Indices in HCM
There was no correlation between IGFBP-3 concentrations and severity of
cardiac hypertrophy or indices of cardiac function. However, there was a highly
significant negative correlation between IGF-1 concentrations and maximum LVWT
following correction for potentially confounding factors (age, gender, body surface
area, IGFBP3, and family relationships). Notably, there was no correlation between
IGF-I concentrations and LV mass, presence or absence of LV outflow obstruction,
or heart failure as demonstrated by level of exercise performance. Table 4-5.
Variable Mean Pa Pb
LV mass (g) 129±8 0.48 0.16
LVWTmax (mm) 18±0.7 <0.02 <0.01
LVWTmax:EDV (mm/ml) 0.19±0.01 <0.0005 <0.0005
pa After adjustment for familial relationship; p1'After adjustment for familial relationship, age,
gender, BSA, BP, and IGFBP3
Table 4-5: Relation of IGF-I levels to cardiac indices in HCM
75
Modifying Factors in FICM Insulin-like Growth Factor-I
IGF-1 concentrations andLVfunction: LV wall stress is inversely related to
LVWT, and directly to LV volume. Notably, in the present study LVWTmax:EDV
ratio was independent of age and was highly significant and independent correlate of
IGF-1 concentrations.
HCM subjects tended to have higher LV ejection fractions and
circumferential shortening. However, there was no direct correlation between IGF-1
concentrations and LV systolic function.
4.4. Discussion
Cardiac hypertrophy is a major independent risk factor for morbidity and
mortality from cardiovascular disease. (Levy et al. 1990) Severe LV hypertrophy in
HCM has also been reported to be associated with a poor prognosis. (Spirito et al.
2000) In this study of the role of circulating IGF-1 in determining magnitude of LV
hypertrophy in HCM, we found that the plasma concentrations of the hormone were
lower in HCM patients and correlated negatively with LVWTmax. There was,
however, no correlation between its binding protein, 1GFBP3 concentrations, and
cardiac hypertrophy. These findings are at variance with previous reports.
These conclusions depended on certain experimental considerations that
apply critically to all evaluations of potential modifiers of phenotypic expression in
HCM. First, we required a sensitive method to quantify and compare cardiac
structure and function. Previously, echocardiography has been used to estimate LV
mass and volumes. However, the calculations rely on assumptions of LV
morphology that may not be valid as the LV in HCM is often distorted and the
distribution of the LV hypertrophy varies markedly. (Wigle et al. 1985) Notably, the
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hypertrophy affects primarily the anterior inter-ventricular septum in the common
asymmetrical septal hypertrophy variety. The hypertrophy affects the distal half of
the LV in apical HCM, and prominently the LV at the level of the papillary muscles
in mid-cavity HCM. In contrast, only a relatively small part of the LV is thickened
and the rest of the heart is relatively normal in focal HCM. MRI estimates of LV
mass, LVWTmax and LV volumes are based on direct examination ofmultiple slices
of the LV from base to apex with clear presentations of regional LV wall thickness.
Second, the relatively large number of subjects with a genetic diagnosis, and the
diversity of families and mutations causal for HCM, reduced the bias due to undue
influence of a certain mutation or inherited modifying factor on phenotypic
expression. We further corrected for the position of members in families as family
relationships may also affect inheritance of modifying factors. Third, as the
concentrations of hormones such as IGF-1 differ in the young compared to adult
patients, we analysed the data separately for the two age groups. Finally, we
corrected for other potentially confounding factors such as body surface area, gender,
and concentrations of the carrier protein IGFBP3.
Our initial hypothesis was that given the trophic actions of the hormone
(Fazio et al. 2000), high IGF-1 concentrations would correlate with more severe
cardiac hypertrophy in HCM, but unexpectedly, found the converse to be the case.
The explanation for this finding may lie in the proposed aetiology of the cardiac
hypertrophy in HCM, and the ability of IGF-1 to improve myocyte function.
Genetic causes of HCM consist mostly of single substitutions of a conserved
amino acid that are incorporated into the sarcomere where they presumably act as
'poison peptides'. Alternatively, in some instances HCM is associated with deletion
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mutations, and hence, presumably the disease may also be caused by haplo-
insufficiency. The primary abnormality therefore in both cases is malfunctioning
sarcomeres and the LV hypertrophy is compensatory and mediated by 'modifying'
factors. This view is supported by several observations:
• in HCM caused by missense mutations of several genes result in abnormal
function of the acto-myosin molecular motor (Cuda et al. 1997; Palmiter et
al. 2000)
• single skinned slow skeletal myofiber expressing mutant cardiac myosin alter
isometric force, power, and unloaded shortening velocity (Lankford et al.
1995)
• tagging MRI studies have shown impaired regional LV wall contraction in
HCM (Kramer et al. 1994)
• highly variable phenotypic expression in family members with the identical
disease mutation (Fananapazir and Epstein 1994)
• the cardiac hypertrophy often develops and progresses during puberty with
rapid body growth (Maron et al. 1986a)
• cardiac hypertrophy involves proliferation of several cell types that do not
express the mutant gene. (Ferrans 1998)
As the hypertrophy and impairment of contraction are not uniform throughout
the ventricle, regional differences in LV contractility may act as a stimulus for
maintenance of the LV hypertrophy. Increased cytosolic Ca2+ and sensitivity of the
acto-myosin molecular motor to Ca2+, may further aggravate sarcomeric dysfunction.
(Karibe et al. 2001; Marian 2000) Abnormal myocyte stretch and stress may be the
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stimulus for local release of hormones that, in addition to circulating hormones, are
responsible for hypertrophy and proliferation of several cell types, characteristic of
the compensatory LV hypertrophy. Myocardial ischemia caused by excessive oxygen
demand and abnormal intra-myocardial blood vessels may contribute to the cardiac
remodelling. (Fananapazir 1999)
Thus, in contrast to conditions associated with increased afterload, such as
hypertension, normal systemic pressures in HCM are perceived as an excessive load
by a myocardium with impaired contractile properties. This leads to similar
compensatory LV hypertrophy through perhaps the action of myocardial trophic
factors or circulating growth factors. The cardiac hypertrophy is, however,
maladaptive. It reduces LV wall tension and augments systolic function in the short
and medium term, but in the long term, myocyte necrosis, fibrosis, and myocellular
energy depletion, lead to cardiac failure.
Our findings therefore lead us to postulate that high concentrations of
circulating IGF-1 improve failing myocytes, by helping to compensate for
sarcomeric dysfunction and reduce the stimulus for development of the maladaptive
cardiac hypertrophy by improving muscle efficiency. A notable observation was that
the IGF-1 concentrations correlated better with maximum LV wall thickness than LV
mass. This may be explained by the fact that expression ofmutant contractile protein
and IGF-1 in the myocardium, are not uniform, and further, the LV walls are subject
to different stresses and strains. (Cuda et al. 1997; Li et al. 2002)
Our findings are at variance with reports of a direct association between IGF-
1 and IGFBP3 concentrations and LV hypertrophy in HCM (Demirtas et al. 1998;
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Saeki et al. 2002), and provide evidence that the use of antagonists of GH and IGF-1
in HCM may have deleterious long-term results.
As IGF-1 prevents myocyte apoptosis, the role of declining IGF-1
concentrations with advancing age in the pathogenesis of heart failure caused by
myocyte death and replacement by fibrous tissue observed in some patients requires
further evaluation.
4.4.1. Limitations
We did not quantify IGF-1 receptors or autocrine/paracrine activities of IGF-
1 by measuring myocardial tissue concentrations of the hormone. These data are,
however, difficult to obtain or to interpret as IGF-1 concentrations may well vary
significantly in different regions of the myocardium.
4.5. Conclusions
HCM is appears to be less severe when associated with high physiological
concentrations of circulating IGF-1. Identification of this important modifier of
phenotypic expression will improve our risk stratification and permit development of
novel therapeutic strategies to treat the HCM.
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5. Brain Natriuretic Peptide and Disease Severity in HCM
5.1. Introduction
Brain natriuretic peptide was originally isolated from porcine brain, (Sudoh et
al. 1988) hence the name and subsequently from porcine heart. (Hasegawa et al.
1991; Saito et al. 1989) It shares considerable homology with atrial natriuretic
peptide (ANP) but there are significant differences. BNP is synthesized as a large
molecular weight pro-hormone (N-terminal pro-BNP), however, there is little storage
of pro-BNP and therefore any augmentation of production of BNP will require a
prolonged stimulus. Although, like ANP, BNP is synthesized in atrial tissue, it is
predominantly produced in ventricular tissue. (Mukoyama et al. 1991; Yasue et al.
1994) Post-translational processing of pro-BNP occurs in cardiomyocytes; however,
both high molecular weight pro-BNP and BNP appear in the circulation. (Yandle et
al. 1993) Most radio-immunoassays of BNP actually measure both forms, however
as there is such a strong correlation between these two levels, (Yandle et al. 1993)
the total level is still a good measure of augmented production.
BNP levels are elevated in a number of pathological states involving either
cardiovascular or renal disease. Table 5-1 The mechanisms by which these diseases
cause augmentation of BNP levels include:
• intravascular volume overload
• increased central venous pressure
• tachycardia
• impaired renal function.
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Cardiovascular conditions causing elevated levels of BNP are summarised in
the table below. (Sagnella 1998)
Disease BNP Reference
Essential hypertension T (Buckley et al. 1993)
Tachycardias T (Kohno et al. 1992)
Heart failure Ttt (Yandle et al. 1993)
Isolated diastolic dysfunction Tt (Lang et al. 1994)
Mitral stenosis Tt (Matsumoto et al. 1995)
Aortic stenosis TTT (Ikeda et al. 1997)
Dilated cardiomyopathy TTTT (Matsumoto et al. 1995)
Hypertrophic cardiomyopathy
non-obstructive TTT (Hasegawa et al. 1993)
obstructive TTTT (Hasegawa et al. 1993)
Myocardial infarction
on admission TTT (Morita et al. 1993)
during recovery TTTT (Morita et al. 1993)
Chronic renal failure
dialysis-independent TT (Buckley et al. 1992)
dialysis-dependent TTT (Lang et al. 1992)
Approximate relative increase compared to controls: "f, up to 3 fold; j"T, -3-10 fold; t1"f, - 10-30
fold; TttT, >30 fold
Table 5-1: Relative increase in BNP in different pathological states
BNP causes vasodilatation and natriuresis and counteracts the effects of the
adrenergic, renin-angiotensin-aldosterone and anti-diuretic hormone systems and
therefore, have a beneficial effect in heart failure. (Saito et al. 1987; Yoshimura et al.
1991) Infusion of BNP decreases arterial and venous pressure, increase cardiac
output and suppresses neuro-hormonal activation.
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BNP levels are elevated in patients with HCM and this increased level of
BNP is further enhanced by the presence of LV outflow tract obstruction. (Hasegawa
et al. 1993) In patients with HCM, BNP levels have also been shown to be
independently associated with NYHA functional class and LVWTmax. Unfortunately,
there is considerable overlap between levels and functional class, with significantly
elevated levels occurring in patients who were otherwise asymptomatic or minimally
symptomatic, limiting its clinical utility. (Maron et al. 2004)
Although there have been studies exploring the prognostic significance of
BNP levels in heart failure this has not been applied to patients with HCM. In this
study we investigated the relationship between BNP levels and hypertrophic
cardiomyopathy in group of patients with defined mutational status.
5.2. Methods
Thirty-seven subjects, in whom the disease causing mutation was known,
participated in this study allowing inclusion of subjects without significant LV
hypertrophy despite a disease causing mutation. Individuals with LV outflow tract
obstruction were excluded from the study because of the affect of augmented LV
pressure on BNP levels. An additional 19 related subjects without HCM mutation
were included as controls. The 56 patients and controls were recruited sequentially
from subjects participating in the previous study. All patients were in sinus rhythm.
All subjects underwent mutational analysis, clinical examination, ergometric
upright bicycle exercise testing with breath-by-breath gas analysis and MRI. All
studies were performed at least 48 hours off all medications.
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Blood for plasma BNP estimation was withdrawn after at least 30 minutes
rest and measured by Cardiorenal Lab, Mayo Clinic using previously published
methods.
5.2.1. Mutational Subgroups
Seven sarcomeric gene mutations (7 families) were identified in the 37 HCM
subjects. These mutations were absent in 19 normal family members included as
controls. Group 1 consisted of 22 of the 37 patients in whom the sarcomeric mutation
was associated with a benign prognosis. They belonged to 4 relatively large families
in which only 2 premature deaths (< 55 years of age) have occurred in 116 (1.7%)
affected family members. In contrast, group 2, consisted of 15 patients in whom the
sarcomeric mutations have been associated with a high incidence of SCD. Twenty-










MYH7 14q3 Asn187Lys 5 0/8 (0%) 0
Lys847Glu 6 0/51(0%) 1
Leu908Val 8 2/46 (4%) 10
ACTC 15q11-q14 Glu"Lys 3 0/11 (0%) 0
Group 2
MYH7 14q3 Glu389Gln 5 8/14(57%) 0
Arg403Gln 2 6/15 (40%) 1
TPM1 15q22 Val95Ala 8 11/26 (42%) 7
Table 5-2: Mutational subgroups of patients included in BNP study
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5.2.2. Statistics
Data are expressed as mean ± SEM. Two-sample continuous variables were
compared using Student's t-test. Multiple groups were compared using one-way
analysis of variance and differences between individual groups were compared using
Bonferroni multiple comparisons test. Spearman's correlation was used to test
association between two continuous variables and analysis of co-variance was
performed to examine the relation of BNP to other variables. A p-value <0.05 was
considered significant.
5.3. Results
The two groups and controls did not differ significantly with regards to age,
gender, BSA, systolic blood pressure, or functional class, although the diastolic BP









Age (years) 28±3 25±3 25±4
Gender (males) 9 (41%) 7 (47%) 5 (26%)
BSA (m2) 1,69±0.07 E68±0.10 1.58±0.10
systolic BP (mm Hg) 113±3 111±3 112±3
diastolic BP (mm Hg) 71±3* 63±2 65±2
NYHA functional class 1.3±0.1 1,4±0.2 N/A
Bonferroni multiple comparisons test;- *p<0.01 compared to group 2
Table 5-3: Clinical characteristics of patients and controls in BNP study
HCM patients had significantly greater LV mass, LVWTmax, higher EF and
larger left atrium (LA). When indexed to body surface area, HCM patients had
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greater LVWTmax-I and LV mass-I. LA-I of patients in group 2 was greater than that
of patients in group I and controls. There were no differences between the groups
with regards to exercise duration or MVCL. However, group 2 had a significantly
lower peak systolic BP compared to controls (p<0.05).
All HCM Group 1 Group 2 Controls
BNP level (pg/ml) 131±37* 50±18 251i80*t 28i5
MRI
LVWTmax (mm) 18±]*** 17±2* 19il** 12il
LV mass (g) 114±9* 112±13 119±13 85i8
LA (mm) 51±1*** 47±1 * 56±2**ff 41il
EDV (ml) 100±4 100±6 99i7 96i8
ESV (ml) 27±2 25±2 29i3 29±3
EF (%) 74±1 * 76±1 * 71±2 70il
SV (ml) 73±3 75±5 70i5 67i6
MRI (Indexed to BSA)
LVWTmax-I (mm/m2) 10.7±0.5*** 10.0±0.7* 11.7i0.8** 7.8±0.3
LV mass-I (g/m ) 66±4* 64±5 69±5 52i3
LA-I (mm/m2) 31 ± 1 28±1 36±3*f 27i2
EDV-I (ml/m2) 59±2 59±3 59±2 61i2
ESV-I (ml/m2) 15±1 * Mil* 16±1 18il
SV-I (ml/m2) 44±2 45i2 43i2 42i2
Exercise test
duration (s) 427±31 446i39 403±52 361i39
peak sBP (mm Hg) 146±4 154i4 135i6* 160±6






Bonferroni multiple comparisons test;- *p<0.05, *'
fp<0.05, +tp<0.001 compared to group 1; Group
mutations
^<0.005, ***p<0.0005 compared to controls;
, benign mutations; Group 2, malignant
Table 5-4: Clinical findings in patients and controls in BNP study
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Plasma BNP levels varied markedly but were on average 5 times higher in the
HCM patients compared to controls (131 ±37 pg/ml versus 28±5 pg/ml, p<0.01). In
addition, plasma BNP levels were significantly greater in group 2 (malignant
mutations), compared to both group 1 (benign mutations) and controls. Figure 5-1.
















Figure 5-1: BNP levels in the three groups
Group 2
There was no correlation between cardiac indices by MRI and BNP.
However, after indexing to BSA, LA-I, LV mass-I and LVWTmax-I significantly
correlated with BNP. Figure 5-2. There was no correlation between BNP, and age,
gender, blood pressure, cardiac index, ejection fraction, and LV volumes indexed to
BSA.
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Figure 5-2: Scatter plots of correlation between BNP and cardiac indices
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As the distribution of BNP levels in HCM patients was positively skewed
(3.02±0.39), the data was transformed by taking the log normal (Ln) value of BNP
which normalised the distribution (-0.24±0.39). Stepwise regression including BNP
(dependent variable), age, gender, mutational group, blood pressure, LA-I, LVM-1,
and LVWT-I demonstrated mutational group as the only independent predictor of Ln
BNP levels (p<0.05).
5.4. Discussion
HCM is characterized by marked genetic and phenotypic heterogeneity.
Although several prognostic factors have been identified, including the nature of the
molecular defect causing the disease, (Epstein et al. 1992; Marian et al. 1995;
Yamauchi-Takihara et al. 1996) risk evaluation of affected patients remains difficult.
Some patients with a sarcomeric mutation, but with mild or no LV hypertrophy may
still be at risk for sudden death which further complicates the problem of risk
stratification. (Karibe et al. 2001; Varnava et al. 2001; Watkins et al. 1995) In
addition, knowledge of why certain sarcomeric mutations are associated with a
higher incidence of sudden death and the exact mechanism of sudden death is
limited.
BNP is related to atrial natriuretic peptide but is secreted predominantly by
LV myocytes. (Yasue et al. 1994) Human BNP levels are increased in conditions
associated with volume over- and after-load, LV hypertrophy, and LV systolic and
diastolic dysfunction, such as hypertension, mitral regurgitation, aortic stenosis and
regurgitation, dilated cardiomyopathy, and myocardial ischemia. HCM is associated
with LV hypertrophy, myocardial ischemia and diastolic dysfunction. In keeping
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with this, Hasegawa et al, have reported that myocardial tissue expression of BNP is
several times higher in patients with HCM, particularly those with LV outflow tract
obstruction.
We report on the clinical associations of plasma BNP levels in patients in
whom the molecular cause of HCM has been determined, and who had detailed MRI
evaluation of LA and LV dimensions. No patient had outflow tract obstruction or
depressed LV function. Knowing the genetic status also allowed participation of
family members with the same genetic background as the HCM patients in whom the
disease mutation was known to be absent who could act as controls.
Utilization of MRI to quantify LV structure and function also provided
distinct advantages. The LV is significantly distorted in HCM and hence, LV mass
derived from echocardiographic indices is likely to be inaccurate due to several
assumptions that are included in the calculation. In addition, the site of maximum LV
wall thickness may not be the proximal inter-ventricular septum but in an area that is
difficult to assess through standard echocardiographic windows. As would be
expected, LV mass and LV wall thickness indices varied markedly in our patients,
even in those with identical mutation.
Patients with mutations associated with a high incidence of sudden death had
significantly higher BNP levels than those patients with mutation associated with a
benign prognosis despite similar LVM-I, LVWT-I and symptoms. However, LA-I
was significantly greater in those patients with malignant mutations compared to
both those with benign mutations and controls suggesting that these individuals may
be more likely to have had factors associated with elevated BNP levels such as
systolic or diastolic dysfunction. However, 3 asymptomatic individuals in this group
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with minimal or no LV hypertrophy and normal systolic function had markedly
elevated plasma BNP levels. Therefore, mutations associated with a poor outcome
may have effects on myocardial properties (myocardial ischemia, diastolic function
etc), even in the absence of appreciable LV hypertrophy.
5.4.1. Limitations
Rest and exercise haemodynamic findings were not available in our patients.
The HCM subjects with a malignant mutation were more likely to have abnormal
blood pressure responses to exercise. Hence, we cannot be certain that diastolic
dysfunction and elevated filling pressures are not also important determinants of
BNP levels. This is more likely given that there was a significant difference in LA
dimension. However, only a signal linear measure of LA dimension was available. It
is clear, however, that patients with malignant mutations may have elevated BNP
levels despite absence of congestive symptoms or LV hypertrophy. It may be that
exercise BNP levels correlate better than resting BNP values with clinical findings
and prognosis in HCM, particularly, as myocardial ischemia detected by exercise
thallium scintigraphy is present in about two-thirds of HCM patients and may be an
important cause of sudden death in patients in whom HCM is caused by malignant
mutations. A further important study may be to relate resting and exercise BNP
levels prospectively to subsequent cardiac events.
5.5. Conclusions
Plasma BNP levels are markedly elevated in patients with HCM, and this is
in part determined by the sarcomeric mutation responsible for the disease
91
Modifying Factors in HCM Brain Natriuretic Peptide
independent of the degree of LV hypertrophy present. Plasma BNP levels vary
markedly in our patients with HCM, ranging from 1.6 - 1062 pg ml"', limiting its
utility as a marker of severity of disease. However elevated plasma BNP levels in the
absence of significant LV hypertrophy may indicate abnormalities of LV function
that could influence outcome. Members of families with a malignant history of HCM
and no LV hypertrophy should be considered at risk of sudden death if a disease
causing mutation cannot be excluded.
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6. Genetic Modifiers of Phenotypic Expression in HCM
6.1. Introduction
In contrast to genetic mutations, polymorphisms are variations in individual
DNA sequences found in individuals, groups or populations that may give rise to
certain characteristics. The least frequent allele or genetic marker occurs more
frequently that can be accounted for by mutation alone. These polymorphisms may
either alter the expression or function of the final product without in isolation causing
disease. However, as a result of their modification of the final product, they may
influence the course of other disease processes. A number of genetic polymorphisms
have been implicated in the modification of a variety of cardiovascular diseases
including coronary artery disease (Nakai et al. 1994) and HCM. (Brugada et al.
1997; Marian et al. 1993; Osterop et al. 1998)
Angiotensin-I converting enzyme is a zinc metallo-peptidase whose main
function is to convert angiotensin-I (AG-I) into angiotensin-II (AG-II) and inactivate
bradykinin. AG-II is a potent vasoconstrictor, stimulates the production of
aldosterone and may stimulate the development of cardiac hypertrophy. There is
wide inter-patient variation in ACE levels but they remain fairly consistent within
individuals. Familial aggregation of ACE levels suggested that its production is
under genetic control. A polymorphism in the ACE gene influences its expression.
(Rigat et al. 1990) The polymorphism consists of the presence or absence of a 250
base pair (bp) insertion in a non-coding section (intron 16) of the gene. Subjects
homozygous for the deletion (DD) have higher levels of ACE than heterozygous
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subjects (ID) and subjects homozygous for the insertion (II). The DD genotype has
been associated with hypertension and the development of LV hypertrophy in
cardiomyopathy (Marian et al. 1993) and aortic stenosis. (Wong et al. 1996) It has
also been related to the risk of SCD in HCM. (Marian et al. 1993)
Endothelin-1 (ET-1) is a 21 amino acid peptide and is a potent
vasoconstrictor produced by endothelial and smooth muscle cells. In addition to
being vasoactive, it has been implicated in mediating the hypertrophic response of a
number of cell types and stimulates the production of other hormones. (Ito et al.
1991; Shubeita et al. 1990) It was originally isolated from porcine endothelial cells
and has since been cloned and sequenced. A G/A polymorphism at position 8002 in
intron 4 of the ET-1 gene has previously been identified. Although it is unlikely to
directly influence the expression or function of ET-1 it may be in linkage
disequilibrium with other functional polymorphisms that could influence the
development of LV hypertrophy in HCM.
The ACE gene polymorphism has previously been shown to influence the
development of LV hypertrophy in patients with HCM. The ET-1 gene
polymorphism has also been demonstrated to influence LV hypertrophy, in
conjunction with gender, in HCM (Brugada et al. 1997) and may influence the
propensity to malignant cardiac arrhythmias in patients with coronary artery disease.
(Kozak et al. 2002)
In this study we re-examined the relationship between these two
polymorphisms in a larger cohort of patients with HCM.
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6.2. Methods
This study was performed after informed consent in 229 patients with HCM
in whom DNA had been extracted for analysis. The genetic cause of HCM was
known in 109/229 (48%) patients which allowed inclusion of family members with
an HCM causing mutation but with little or no LV hypertrophy. All patients
underwent screening echocardiography and cardiac MRI. Indices of cardiac
hypertrophy were correlated with ACE and ET-1 genotype.
6.2.1. GeneticAnalysis
DNA from patients with HCM was extracted from whole blood using
standard techniques and stored in 100ng/pL concentrations. This was subsequently
diluted to 20ng/pL concentrations for further analysis.
ACE gene polymorphism: Polymerase chain reaction (PCR) was used to
detect the insertion (I)/deletion (D) polymorphism of the ACE gene. 5pL of
20ng/pL DNA, lpL of 12.5ng/pL sense primer
(5'CTGGAGACCACTCCCATCCTTCT3'), IpL of 12.5ng/pL antisense primer
(5'GATGTGGCCATCACATTCGTCAGAT3') and 18pL of water was added to
Ready-To-Go RT-PCR beads (Amersham Pharmacia Biotech). The total reaction of
25pL was run on a GeneAmp PCR System 9700 for 30 cycles of 94°C for 1 min
denaturation, 58°C for 1 min annealing, and 72°C for 1 min extension. The PCR




490bp 190bp Figure6-1:EthidiumbromidelshowingrpatternsfPCRoductdemonst a inA Ee otypes(490inse iohomozyg t'II', 190bpdeletionhomozygote'DD\and4p/190inserti n/deletioneterozI ').B kchannelsi dicatfa lePCRs m l sw r-run.
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Endothelin gene polymorphism: A PCR was also performed on DNA to
detect the ET-1 gene polymorphism. 5pL of 20ng/pL DNA, lpL of 12.5ng/pL sense
primer (5'AGTAGCAGAGAGATCTATGCATCC3'), lpL of 12.5ng/pL antisense
primer (5'CAGCATGTTCTAAATTCTACCAACCC3') and 18pL of water was
added to Ready-To-Go RT-PCR beads (Amersham Pharmacia Biotech). The total
reaction of 25pL run on a GeneAmp PCR System 9700 for 30 cycles of 94°C for 1
min denaturation, 65°C for 1 min annealing, and 72°C for 40 sec extension. The G
allele has a Taql digestion site which results in 2 products of 230 bp and 144 bp. The
presence of the G8002A polymorphism removes this digestion site and results in a
single product of 374 bp. Therefore the PCR product was digested with Taql and run
on agarose gel with ethidium bromide staining. To digest 15pL of PCR product was
added to lpL of the Taql, lpL of NE Taq buffer, lpL of BSA and 32pL of water.




374bp 230bp 144bp Figure6-2:Ethidiumbromidelshowingrpatt nsfPCRroductfollowingTaqldigestemonst at gtG800 AET-1poly orphism.Homoz gfth Galleleh d2productsof144bpnd30.hom zygotef rthAal elsinr t37heterozygotespr ductsf144b ,230an 374bp.
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6.2.2. Statistics
Results are expressed as mean ± SEM. Differences between groups were
analysed using a one-way analysis of variance. To evaluate the relationship between
ACE genotypes (II, ID, and DD) and left ventricular wall thickness, we used
covariance techniques, which account for the familial relationships among the
members of the study. A measured genotype approach of variance component
analysis (Hopper and Mathews 1982) being implemented in the genetic software,
SOLAR (Almasy and Blangero 1998) was used for the data analysis. This approach
is able to deal with unrelated individuals as well as pedigrees of different sizes and
structures. It fully accounts for the different types of relationship within a pedigree in
performing association studies on the measured genotypes and quantitative traits. To
eliminate the effect of potential confounders, for the analyses we adjusted for age,
sex, and blood pressure.
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6.3. Results
The 229 patients came from 148 families. Of the 109 patients with a known
genetic defect, there were 28 mutations in 6 genes. Table 6-1.
Gene Locus No. of Mutations No. of Families No. of Patients
MYH7 14q3 19 24 79
TPM1 15q22 1 1 12
ACTC 15q11-q14 3 3 11
MYL2 12q23 2 2 2
MYL3 3p21 1 1 1
MYBP3 llpl 1 2 2 4
Total 28 33 109
Table 6-1: Families and mutations of patients in genetic modifier study
6.3.1. ACE Gene Polymorphism
There were 43 patients homozygous for the insertion allele, 129 who were
heterozygous and 57 homozygous for the deletion allele. There was no difference
between the three groups with regards to age, gender, blood pressure or BSA.
II ID DD
n=43 n=129 r^IIc
Age (years) 36±3 36±1 35±2
Gender (males) 22 (51%) 68 (53%) 27 (47%)
BSA (m2) 1.78±0.05 1.81±0.03 1.89±0.04
Systolic BP (mm Hg) 119±2 119±1 119±2
diastolic BP (mm Hg) 70±2 70±1 70±2
Table 6-2: Clinical characteristics of patients by ACE genotype
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On echocardiography there was a gradual increase in LA size between (II)
patients and (DD) patients. The same was true of septal thickness. There was no
significant difference between the groups with regards to LV internal dimension,
posterior wall thickness, or outflow tract obstruction. Table 6-3.
II ID DD ANOVA
Septum (mm) 16±1 18±1 20±1* p<0.05
Posterior wall (mm) 9±0.2 10±0.2 10±0.3 ns
LVIDd (mm) 43±1 43±1 44±1 ns
LVIDs (mm) 26±1 26±1 25±1 ns
LA (mm) 37±1 39±1 42±1** p<0.01
OT gradient (mm Hg) 11±4 14±2 10±3 ns
OT, outflow tract; Bonferroni multiple comparisons test, *p<0.05, **p<0.01 compared to II
Table 6-3: Echo findings of patients by ACE genotype
MRI indices of cardiac hypertrophy were also compared. There was no
difference in LV volumes between patients. Although patients who were either
heterozygous or homozygous for the D allele had lower EF and greater LV mass,
neither reached statistical significance. However, LVWTmax was significantly greater
in patients with the D allele. After indexing the cardiac MRI values to BSA, patients
with the D allele had greater LVWTmax-I compared to patients homozygous for the I
allele. Table 6-4.
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II ID DD ANOVA
LVWTmax (mm) 19±1 22±1 * 23±1** p<0.01
LV mass (g) 167±16 189±9 198±12 ns
EDV (ml) 109±6 104±3 108±4 ns
ESV (ml) 27±3 27±1 28±2 ns
EF (%) 73±2 70±1 70±1 ns
SV (ml) 81 ±5 78±2 80±3 ns
LVWTmax-I (mm/m2) 10.4±0.6 12.3±0.3* 12.3±0.4* p<0.02
LV mass-1 (g/m2) 89±6 102±4 104±6 ns
EDV-I (ml/m2) 60±2 58±1 57±2 ns
ESV-I (ml/m2) 15±1 15±1 15±1 ns
SV (ml/m2) 45±2 43±1 42±1 ns
Tukey-Kramer multiple comparisons test, *p<0.05, **p<0.01 compared to II
Table 6-4: Cardiac MRI findings of patients by ACE genotype
Multivariable analysis using a measured genotype approach to account for the
familial relationships was performed with age, gender and blood pressure included as
possible confounders. LVWTmax-I was found to be independently significantly
associated with ACE genotype.
6.3.2. Endothelin-1 Gene Polymorphism
There were 138 patients homozygous for the G allele, 84 patients
heterozygous and 7 patients homozygous for the A allele. There were no differences
in basic clinical characteristics, echocardiographic findings or cardiac MRI
parameters between the different genotypes. Table 6-5.
There was no association between ET-1 genotype and any variable by
multivariable analysis.
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GG GA AA
n=138 n=84 n=7
Age (years) 35±1 38±2 34±5
Gender (males) 67 (49%) 46 (55%) 4 (57%)
BSA (m2) 1.81±0.03 1.85±0.03 1.83±0.08
systolic BP (mm Hg) 119±2 119±2 119±3
diastolic BP (mm Hg) 71±1 70±1 66±4
Septum (mm) 19±1 18±1 23±3
Posterior wall (mm) 10.0±0.2 10.0±0.2 9.9±0.1
LVIDd (mm) 43±1 45±1 45±2
LVlDs (mm) 25±1 26±1 26±2
LA (mm) 39±1 40±1 40±2
OT gradient (mm Hg) 14±2 9±2 19±13
LVWTmax (mm) 22±1 21±1 24±3
LV mass (g) 188±9 186±10 198±41
EDV (ml) 104±3 110±3 98±7
ESV (ml) 27±1 28±1 25±3
EF (%) 71±1 70±1 67±3
SV (ml) 77±2 82±3 73±6
LVWTmax-1 (mm/m2) 12.0±0.3 11.7±0.4 13.1±1.6
LV mass-I (g/m2) 100±4 99±5 105±19
EDV-I (ml/m2) 57±1 59±1 54±4
ESV-I (ml/m2) 15±1 15±1 14±2
SV-1 (ml/m2) 43±1 44±1 40±3
Table 6-5: Clinical characteristics of patients by ET-1 genotype
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6.4. Discussion
The association of genetic polymorphisms with cardiovascular disease has
been well established. The combination of these polymorphisms with genetically
determined cardiovascular diseases such as HCM has also been explored and
provides an attractive explanation for the wide phenotypic variability observed in
HCM. Some investigators have reported that as much as 60% of the variation in LV
mass in individuals is due to genetic factors. (Verhaaren et al. 1991) The association
between particular genetic factors and HCM is further enhanced when there is a
plausible theory as to the mechanism by which the polymorphism affects phenotypic
expression.
The I/D polymorphism of the ACE gene is an excellent candidate modifier
gene because of its known affects on the expression ofACE itself. Higher levels of a
circulating ACE and hence AG II should have significant affects on the development
of LV hypertrophy in HCM due to its direct trophic action on cardiomyocytes
independent of its impact on vasomotor function. Our results confirm that the DD
polymorphism is associated with a greater degree of LV hypertrophy in HCM. This
has important ramifications. Assuming from this that development of LV
hypertrophy in HCM is in part dependent on circulating ACE levels, then blockade
of the conversion of AG 1 to AG II or the blockade of the action of AG II at its
receptor should abrogate the development of hypertrophy. As there is continuous
turnover of cardiac muscle there must be a continuous stimulus to maintain the
cardiac hypertrophy and therefore blocking of ACE/AG II should also effect a
reduction in LV mass over time.
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Flowever, contrary to previous reports we could find no correlation between
the G8002A ET-1 genotype and degree of LV hypertrophy in our cohort of HCM
patients.
6.4.1. Limitations
ACE and ET-1 levels were not available for correlation with indices of
cardiac hypertrophy. However, the I/D polymorphism in the ACE gene has
previously been associated with variation in ACE levels. Although there have been
reports of an association between both of these polymorphisms and malignant
arrhythmias in different clinical settings (Kozak et al. 2002; Marian et al. 1993), we
did not have arrhythmia monitoring available for comparison in these patients.
6.5. Conclusion
These results suggest that the renin-angiotensin system is implicitly linked
with the development of LV hypertrophy in HCM and thereby offers a target for
therapeutic intervention. Although these results do not exclude the role of endothelin
in the development of LV hypertrophy they do suggest that the G8002A ET-1
polymorphism is not an important factor in the phenotypic expression of HCM.
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SECTION III: DISEASE MODIFICATION
Modifying Factors in FICM RAS System Modification in HCM
7. Modification of the Renin-Angiotensin System in HCM
7.1. Introduction
The renin-angiotensin system (RAS) plays an important role in the
development of LV hypertrophy in hypertension and may also contribute to the
increased cardiac mass in HCM. (Lechin et al. 1995; Yoneya et al. 1995) In addition
to the classical or endocrine RAS a local or paracrine/autocrine RAS may respond to
localized stimuli and tissue requirements. (Bader et al. 2001; Varagic and Frohlich
2002) Mechanical stretch and autonomic activity activate cardiac RAS cascades, and
many or all RAS components, including aldosterone, are produced in situ. (Bader et
al. 2001; Balcells et al. 1997; Delcayre et al. 2000; Varagic and Frohlich 2002)
Several adverse cardiovascular effects of the RAS are attributed to
angiotensin-II (AG-II) activity at the angiotensin receptor-1 (ATi). Activation ofAT]
receptors on fibroblasts, cardiomyocytes, smooth muscle cells and endothelial cells
promotes mitogenesis, myocyte hypertrophy, myocardial fibrosis, vasoconstriction
and arrhythmogenesis. (Berry et al. 2001; Paradis et al. 2000) In contrast, AG-II)
activity at angiotensin receptor-2 (AT2) receptors is reported to oppose some or all
the effects of ATi activity. (Brede and Hein 2001; Kurisu et al. 2003) AT] receptor
antagonists do not inhibit AT2 receptors, and may actually augment their activity by
increasing AG-II availability. (Berry et al. 2001) This, along with findings
suggesting that local RAS production of AG-II may occur independently of renin and
ACE activity, suggests that the optimal inhibition of local cardiac RAS requires
combination therapy. (Balcells et al. 1997)
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Animal models and clinical studies of hypertensive cardiomyopathy have
demonstrated that ACE, ATi and aldosterone inhibition ameliorate myocardial
fibrosis myocyte hypertrophy, perfusion abnormalities, and electrocardiographic LV
hypertrophy. (Brilla et al. 2000; Frohlich 2001; Linz et al. 1995; Mathew et al. 2001;
Pitt 1998; Sato et al. 2002; Varagic et al. 2001) Observations that these effects did
not correlate with the activity of circulating RAS components or with the magnitude
of blood pressure reduction suggested a role for local RAS or aldosterone in the
pathogenesis of the cardiomyopathy. (Pitt et al. 2003)
LV hypertrophy in HCM develops primarily as a maladaptive consequence of
mutant gene expression of sarcomeric proteins rather than to pressure or volume
overload. (Thierfelder et al. 1994) HCM is similarly characterized by myocyte
hypertrophy and disarray, and hyperplasia of several other cell types including
fibroblasts, endothelial cells and smooth muscle cells. (Ferrans 1998) Myocardial
fibrosis is common, and is often more pronounced than in hypertensive cardiac
hypertrophy. (Tanaka et al. 1987)
Evidence that renin-angiotensin-system activity contributes to the severity of
HCM has been suggested by observations that in comparison to the ACE gene
intronic polymorphism, the intronic deletion polymorphism is associated with
increased plasma ACE concentrations and occurs at an increased frequency in HCM
patients than in unaffected family members or in unrelated controls, and may also
influence the severity of LV hypertrophy. (Lechin et al. 1995; Marian et al. 1993;
Pfeufer et al. 1996; Tesson et al. 1997) Common polymorphisms in both ATi and
AT2 receptors may also influence the magnitude of hypertrophy. (Deinum et al.
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2001; Osterop et al. 1998) Finally, in a mouse model of human sarcomeric gene
HCM, AG1I blockade reduces the degree of myocardial fibrosis. (Lim et al. 2001)
The clinical utility of RAS system manipulation in HCM remains clinically
untested despite its gradual introduction as an empiric therapeutic modality. The
primary hypothesis of this study is that the RAS is involved in the genesis and
maintenance of LV hypertrophy in HCM, and ACE inhibitors and/or ATI receptor
antagonism will cause regression of the increased LV mass, leading to improved
symptoms and functional indices.
7.2. Methods
This double-blind, placebo-controlled study was performed after informed
consent according to a protocol approved by the Intramural Research Board of
National Heart, Lung, and Blood Institute, National Institutes of Health. The primary
goal of this study was to determine whether six months of ACE inhibition and/or
ATi receptor blockade therapy reduces cardiac hypertrophy compared to placebo in
patients with HCM.
One hundred and thirty-one consecutive unrelated patients were evaluated.
Forty-two subjects did not meet entry criteria. Table 7-1 and 7-2.
109
Modifying Factors in HCM RAS System Modification in HCM
Inclusion Criteria:
age 20-55 years
LV wall thickness >16 mm by MRI
LV outflow tract gradient of <30 mm Hg at rest, and <55 mm Hg following
isoprenaline infusion to a heart rate of 120 bpm at cardiac catheterization
NYHA functional class 1 -11.
Table 7-1: Inclusion criteria in enalapril/losartan study
Exclusion Criteria:
significant other cardiovascular disease
chronic atrial fibrillation
bleeding disorder or anaemia
renal impairment (urea > 22 mg/dl and creatinine >1.4 mg/dl); K+ <3.3 mmol/1
or >5.1 mmol/1
hypertension: >160 mm Hg systolic or >95 mm Hg diastolic
hypotension: systolic arterial pressure <100 mm Hg confirmed 30 minutes later
pregnancy and lactation
LV ejection fraction <50% (radionuclide angiography)
dependence on diuretics, verapamil, P-blockers, or anti-arrhythmic drugs
sensitivity to ACE inhibitor e.g. angio-oedema
ACE inhibitor or losartan treatment within 6 months of the study
Table 7-2: Exclusion criteria in enalapril/losartan study
The remaining 89 patients were randomized to receive placebo, 10 mg
enalapril, 50 mg losartan, or 10 mg enalapril plus 50 mg losartan. Block
randomization was performed separately for men and women. Investigators were
blinded to treatment assignment.
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Patients underwent echocardiography, cardiac MRI, treadmill exercise test,
ergometric upright bicycle exercise testing with breath-by-breath gas analysis,
ambulatory ECG Holter monitoring, radionuclide angiography, and cardiac
catheterisation. All studies were performed at baseline and at 6 month follow-up.
Patients in the 4 arms of the study were well matched with regards to clinical
findings and severity of HCM. In addition components of the RAS were also
assessed including ACE genotype. Table 7-3.
Placebo Losartan Enalapril Combination
<N(NIIC n=21 n=23 n=23
Age (years) 34±9 34±9 38±8 37±11
Gender (males) 14(64%) 14(67%) 16 (70%) 14(61%)
NYHA 1.7±0.1 1.6±0.5 1.7±0.1 1.8±0.4
Symptoms
nil 2 (9%) 2(10%) 5 (22%) 4(17%)
angina 9(41%) 5 (24%) 8 (35%) 9 (39%)
dyspnoea 14(63%) 14(67%) 12 (52%) 15 (65%)
pre-syncope 7 (32%) 8 (38%) 7 (30%) 11 (48%)
syncope 1 (5%) 3(14%) 5 (22%) 4(17%)
palpitations 14(64%) 8 (38%) 12(52%) 12(52%)
fatigue 3 (14%) 3 (14%) 2 (9%) 7 (30%)
Echocardiogram
septum (mm) 17±1 17±1 17±1 17±1
posterior wall (mm) 10±1 9±0.2 9±0.4 9±0.2
LVIDd (mm) 44±1 45±1 48±1 44±1
LVIDs (mm) 25±1 26±1 27±1 25±1
LA (mm) 37±1 44±1 44±1 41 ±2
Table 7-3: Baseline characteristics of patients in enalapril/losartan study
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7.2.1. Radionuclide Ventriculography
LV systolic function was determined by estimating rest and exercise LV
ejection fractions. Diastolic function was determined by measurements of peak
filling rate (PFR), time to peak filling rate (TPFR), and atrial contribution to LV
stroke volume. (Bonow 1990)
7.2.2. Cardiac Catheterisation
Cardiac catheterisation was performed via the right femoral artery and vein.
Selective coronary angiography was performed at baseline to exclude existing
significant coronary artery disease. This was not repeated at follow-up. The presence
of LV outflow tract obstruction was excluded by recording simultaneous LV and
femoral artery pressures. To ensure there was no provocable LV outflow tract
obstruction, patients received an isoprenaline infusion to a heart rate of
approximately 120 bpm while recording from LV and femoral artery.
7.2.3. Renin-Angiotensin System
ACE genotype was determined by previously described methods (section
6.2.1.). Blood for renin, ACE, and AG-II levels was collected after >15 minutes lying
supine and after an overnight fast. Blood was spun down immediately, and serum
was taken on wet ice directly to the Clinical Pathology Lab for analysis.
7.2.4. Safety Considerations
As enalapril and losartan are vasodilators and may therefore increase LV
systolic load by aggravating LV outflow obstruction, only patients with non¬
obstructive HCM were included in the study. Following randomization, heart rate
112
Modifying Factors in HCM RAS System Modification in HCM
and blood pressure were monitored for 3 days on drug therapy, in the absence of an
adverse event, the patient received the drug for six months. Haemoglobin, platelets,
coagulation, electrolytes, renal function and liver function were checked at baseline
and at 1,3, and 6-month follow-up. Urinary pregnancy test was performed monthly
in women of child-bearing age.
7.2.5. Statistics
Data are expressed as mean ± 1 SEM. Data were compared using Student t
test. Pearson's test was used to examine the correlation between variables. A two-
sided p<0.05 was considered significant. Statistical significance was tested following
Bonferroni correction for multiple comparisons.
7.3. Results
7.3.1. Regression ofLVMass and Symptoms
LV mass decreased significantly in the enalapril and enalapril plus losartan
arms of the study compared to the placebo arm. There was a smaller insignificant
decrease in LV mass compared to placebo in the losartan arm of the study. LV
diastolic, systolic and stroke volumes were unaffected in any of the treatment groups.
Table 7-4.
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Placebo Losartan Enalapril Combination
Baseline LV mass (g) 235±19 237±21 241±14 214±21
Follow-up LV mass (g) 234±16 230±22 225±14 196±19
A LV mass (g) -1.3±6 -6.7±4 -16.5±4* -18.2±5*
A EDV (ml) -5.3±3 2.5±5 6.4±4 -2.0±3
A ESV (ml) -0.6±2 0.5±4 -0.8±2 -0.7±2
A SV (ml) -4.7±3 2.3±3 -5.6±3 -1.3±3
*p<0.05 compared to controls
Table 7-4: Change in MRI indices
Proximal septal thickness by echocardiography was reduced significantly in
the enalapril arm of the study. Left atrial dimension was also significantly diminished
in patients on enalapril plus losartan. Other LV indices were unaffected by ACE
inhibition or ATi antagonism. Table 7-5.
Placebo Losartan Enalapril Combination
A septum (mm) 0.2±0.2 -0.1±0.3 -0.5±0.2* -0.3±0.2
A posterior wall (mm) -0.1±0.1 -0.2±0.2 0.1 ±0.2 0±0.1
A LVIDd (mm) -0.4±0.3 1.0±0.8 -0.6±0.5 -0.7±0.3
A LVIDs (mm) 0.4±0.3 0.7±0.5 0.7±0.3 -0.3±0.4
A left atrium -0.4±0.5 0.3±0.5 -0.7±0.4 -1.3±0.4**
*p<0.01, **p<0.001 compared to placebo
Table 7-5: Change in echocardiographic indices
The New York Heart Association functional class improved significantly in
the enalapril plus losartan arm of the study (from 1.8±0.4 to 1.5±0.5, p<0.02) but not
in the other arms of the study. There was no significant change in individual cardiac
symptoms.
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7.3.2. Clinical Parameters
Exercise Testing: Treadmill exercise testing was not associated with any
complication. No significant changes in heart rate and systolic and diastolic blood
pressures were noted at rest or with exercise in any of the study-arms. Similarly,
exercise durations were not changed significantly. Table 7-6.
Placebo Losartan Enalapril Combination
Maximum HR (bpm) 0±2 12±8 7±9 7±9
Peak sBP (mm Hg) -2±6 10±11 13±9 7±9
Peak dBP (mm Hg) 5±5 10±6 4±4 6±6
Duration (sec) -21 ±35 40±39 15±47 -9±30
Table 7-6: Changes in exercise parameters
Cardiac Catheterization: Most of the haemodynamic changes occurred in the
enalapril plus losartan arm of the study and were limited to modest changes in
systolic and mean arterial pressures and LV end-diastolic pressure. Notably, the
absence of significant LV mass reduction in patients receiving losartan occurred
despite significant reduction in systolic aortic pressures (15 ± 12 mm Hg, p<0.01), a
change that was greater than that observed in patients receiving enalapril (7 ± 14 mm
Hg). LV outflow tract pressure gradient did not increase significantly in any
therapeutic arm of the study. Cardiac output and pulmonary arterial capillary wedge
pressure were unchanged in the placebo group over the 6-months period, and did not
change significantly in the three treatment groups compared to placebo. Table 7-7.
There was no significant correlation between changes in arterial pressures
and LV mass regression.
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Placebo Enalapril Losartan Combination
Heart rate (bpm) -1±3 li3 li3 -2i2
RA mean (mm Hg) 0±1 Oil Oil lil
RV EDP (mm Hg) 0±1 Oil Oil Oil
PA mean (mm Hg) 0±1 Oil -lil 2il
PACW mean (mm Hg) Oil Oil -lil lil
Cardiac Index (L/min/m2) -O.liO.l O.liO.l -0.3i0.1 OiO.l
Ao systolic (mm Hg) 2i3 7i3 15i3** 17i4**
Ao diastolic (mm Hg) -li2 5i2 4i2 8i2***
Ao mean (mm Hg) -li2 4i3 4i2* ]
LV systolic (mm Hg) li3 10i2* 9i3 I
LV EDP (mm Hg) 0i2 li2 0i2 5il
LV OT gradient (mm Hg) -2i2 li2 -3i2 3i4
Data represent mean ± SEM change from baseline to follow-up; EDP, end-diastolic pressure;
PACW, pulmonary artery capillary wedge, Ao, aorta; *p<0.05, **p<0.01, ***p<0.001 compared to
placebo
Table 7-7: Changes in haemodynamic parameter
Radionuclide Ventriculography: There was no significant change in the
indices of LV systolic and diastolic function at rest or with exercise during the 6-
months of follow-up in any of the therapeutic arms of the study. Table 7-8.
Placebo Enalapril Losartan Combination
Resting EF (%) -li2 2i2 -li2 -li2
Exercise EF (%) -6il 4i2 li2 2i2
TPFR (ms) 3i9 4il0 15i8 3il3
Atrial contribution
to SV (%)
8il -li2 0i2 -li2
Table 7-8: Changes in radionuclide angiography parameters
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7.3.3. ACE Genotype and Circulating RAS Hormones
The frequencies of the ACE D and I alleles were 0.64 and 0.36 respectively.
These frequencies were not significantly different than those reported in large non-
HCM populations. (Lindpaintner et al. 1996)
Plasma ACE levels varied markedly in the HCM population (2-85 U/L). DD
genotype was associated with significantly higher serum ACE levels compared to
both ID and II genotypes (plasma renin, AG-1, and AG-II levels were unaffected).
Figure 7-1.
One-way analysis of variance, p<0.0001




Figure 7-1: ACE levels by genotype
However, in this relatively small group of patients, neither LV mass nor
LVWTmax was affected by ACE genotype. In addition, there was no correlation
between circulating RAS hormone concentrations (ACE, plasma renin, and AG-II)
and LV mass or LVWTmax. Figure 7-2 and 7-3.
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Figure 7-2: Affect of ACE genotype on LV mass
not significant
Genotype




Changes in LV mass were unaffected by ACE genotype, as demonstrated by
similar LV mass reduction in the enalapril plus losartan arm of the study in patients
with the DD genotype and patients with ID or II genotype (19±8 gram and I8±8
gram respectively, p=0.89)
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Changes following inhibition of the renin-angiotensin system: Enalapril,
alone or in combination with losartan, significantly reduced plasma ACE and
increased plasma renin concentrations. No significant changes in ACE levels were
observed with losartan or placebo. Figure 7-4.
The changes in the levels of circulating ACE and other hormones of the RAS
did not correlate with changes in LV mass and other cardiac indices.
Placebo Losartan Enalapril Combination
Figure 7-4: Change in plasma ACE concentration and plasma renin activity following RAS inhibition
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7.3.4. Influence ofGender and RAS on Cardiac Indices
The frequencies of the ACE D and I alleles in men (0.62 and 0.38) and
women (0.68 and 0.32) were similar. Women had lower LV mass and volumes
before and after correcting for BSA.
In patients receiving enalapril or enalapril plus losartan, LV mass reduction
was less in women compared to men but the difference was not significant (13±4
gram versus 21 ±5 gram, p=0.2).
7.3.5. Adverse Events and Long Term Outcome
Therapy was terminated after 1.3-4.2 months in 7 patients due to adverse
events detailed below. (More than one adverse event per patient) Table 7-9.
All patients Placebo Enalapril Losartan Combination
Hypotension 5 0 1 1 3
Light-headedness 5 0 1 1 3
Fatigue 3 0 1 0 2
Cough 1 0 1 0 0
Tachycardia 1 0 0 0 1
Hearing Loss 1 1 0 0 0
Total 16 1 4 2 9
Table 7-9: Adverse events during enalapril/losartan study period
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Patients have been followed-up for a mean period of 4.1+1.5 years, maximum
8 years. Following participation in the study 34 patients did not receive long term
medical therapy. The remaining patients were treated with P-blockers (12), verapamil
(5), disopyramide (1), and/or enalapril or losartan (42). One patient in the placebo
arm of the study died suddenly during strenuous exercise 7 years after completing the
study.
7.4. Discussion
This is the first randomized placebo-controlled study of the effects of
inhibition of the RAS in human HCM. Magnetic resonance imaging was used to
determine LV mass to overcome a common problem associated with assessment of
LV hypertrophy in HCM. Enalapril was tolerated well in most patients with non¬
obstructive HCM, and therapy for 6 months resulted in 16.5 grams of LV mass
regression. Combination therapy with enalapril and losartan resulted in a similar
reduction (18.2 grams) of LV mass, but was associated with a higher incidence of
adverse events. Losartan reduced LV mass insignificantly (6.7 gm, p>0.05) despite
larger mean changes in blood pressure than seen with enalapril. These effects of RAS
inhibition in HCM are supported by similar findings in animal models of HCM. (Lim
et al. 2001)
Our findings support the hypothesis that RAS activity contributes
significantly to expression of phenotype in HCM. Many studies examining the role
of RAS inhibition in patients with LV hypertrophy resulting from essential
hypertension have demonstrated the effectiveness of ACE-inhibitors, AT| receptor
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blockers and aldosterone inhibitors at reducing LV mass independently of blood
pressure reduction. (Mathew et al. 2001)
As reported by others, we observed an increase in plasma ACE hormone
levels associated with the ACE D allele. However, the changes in LV mass were not
associated with circulating renin-angiotensin hormones, blood pressure response, or
genotype. This unexpected finding may be attributed to the varied genetic causes of
HCM in subjects in our study compared to studies examining for ACE
polymorphism effects in single large pedigrees (Mathew et al. 2001; Tesson et al.
1997) and the relatively small number of patients included in the study.
As ATi receptors are believed to mediate many of the adverse effects of RAS
and receptor blockade reduces cardiac mass in hypertensive LV hypertrophy and in
various animal models, the absence of a significant effect of losartan on LV mass,
was an unexpected finding. Several explanations could account for this. An effect on
LV hypertrophy smaller than that of enalapril may be detectable by a larger study.
Similarly, the use of larger doses of losartan may have improved efficacy. However,
the losartan dose used here is comparable to those used in similar studies of
hypertensive LV hypertrophy, and the hypotensive effects of losartan were similar to
those of enalapril in this study. The differences in LV mass regression may therefore
represent a divergence of the anti-hypertensive and anti-hypertrophic effects of the
two drugs. As ACE inhibition interrupts the RAS cascade more proximally, the
effects of enalapril on downstream RAS targets, other that the AT) receptor, may
have been responsible for these differences. ACE inhibition also inhibits the
enzymatic breakdown of bradykinin, increasing the activity of this anti-hypertrophic
species. (Pitt 1998) Also, AT] receptor blockade does not inhibit angiotensin-II
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binding at the AT2 receptor, which may even be potentiated by increased AG-II and
the resultant increased AT2 receptor activity may actually antagonize AT] receptor
activity and promote the development of LV hypertrophy. (Inagami 1999; Pitt 1998;
Senbonmatsu et al. 2003) The findings of our study are consistent with a report that
losartan (25 mg/day) failed to influence exercise-induced LV hypertrophy that is
considered to be dependent on the RAS. (Myerson et al. 2001)
The reductions in cardiac mass were modest and significant cardiac
hypertrophy remained. Optimizing ACE inhibition with more prolonged therapy
and/or combinations with aldosterone antagonists (Tsybouleva et al. 2004) may
improve LV mass reduction. The doses used in this study were relatively small to
minimise side effects. In addition tissue bound ACE inhibitors are now available
which may have greater efficacy. However it is likely that trophic signals other than
those generated through RAS activity are also important. Indeed, our study suggests
that female gender, and hence oestrogen, may also play an important independent
role in modifying the cardiac phenotype in HCM as indicated also by other
investigators. (Deinum et al. 2001)
7.4.1. Clinical implicationsfor the management ofHCM
Therapy reducing LV mass is only of benefit if it is also associated with an
improvement in symptoms and/or prognosis. In this respect, several clinically
important issues are not resolved by our study. Considerations for patient safety
included the selection of relatively asymptomatic study subjects in whom a treatment
effect on functional status will be minimal. Similarly, the short duration of therapy
and the low event rate do not allow assessment of prognostic impact.
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Our results also cannot be extended to obstructive HCM as patients with
resting or provocable LV outflow obstruction were excluded because the
vasodilatory effects of enalapril and losartan may worsen obstruction and associated
symptoms.
Patients with hypertensive LV hypertrophy have been shown to gain
significantly clinically and prognostically from renin-angiotensin system antagonism,
more so than with other anti-hypertensive agents despite the same degree of blood
pressure reduction. In these patients the use of ACE inhibitors and/or losartan not
only block the molecular messenger, in part responsible for the increased cardiac
mass, but also treat the underlying cause (i.e. the hypertension). In HCM, however,
although the molecular messenger is perturbed, the underlying cause (sarcomeric
dysfunction) remains.
Future studies should focus on whether further regression of LV hypertrophy
can be achieved with newer agents and/or more prolonged therapy, and to determine
the long-term consequences of LV mass regression in patients with HCM.
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8. Discussion
HCM remains a complex clinical condition. Despite its relatively high
prevalence, its genetic diversity and variability of clinical expression limit our ability
to risk stratify patients satisfactorily and identify those at greatest risk of SCD and
hence those that would benefit most from ICD therapy. Underlying this is our poor
understanding of which factors are responsible for the observed phenotypic
variability in the first place. An increased understanding of the mechanisms
responsible for the LV hypertrophy and other clinical features would at least allow us
to identify targets for disease modification.
Potential modifiers must be considered in relation to other factors that cannot
be altered such as gender and age. Modifiers of phenotypic expression need not be
pathophysiologic however. IGF-1 at physiologic levels may modify the expression of
HCM favourably and therefore caution should be applied when considering
antagonising certain systems that logically should result in favourable ventricular
remodelling. Although regression of LV hypertrophy has been demonstrated using
the growth hormone release-inhibiting somatostatin analogue, octreotide, in a very
small number of patients, it is unclear what long-term clinical implications the use of
this treatment will have beyond regression of LV mass.
BNP, although not a modifier of LV hypertrophy, is a modifier of the
physiologic response to the increased LV mass. Its level, however, correlates with
the disease causing mutation rather than the degree of LV hypertrophy, with higher
levels observed in patients with mutations associated with a high risk of ventricular
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arrhythmias. Therefore BNP may be included in the armamentarium of risk factors
for SCD in HCM.
Conversely other modifiers are clearly pathophysiologic, such as the ACE
gene I/D polymorphism, which has been shown to have many adverse affects in a
variety of clinical scenarios and exaggerates the maladaptive process in HCM. In this
instance we have been able to demonstrate that modification of the RAS system can
result in significant regression of LV hypertrophy. However, further work is needed
to ensure that this favourably modifies the other pathophysiologic features of the
disease, such as diastolic dysfunction, and in particular the propensity to arrhythmias
and SCD. In addition, an alternative strategy would be to prevent progression of LV
hypertrophy by introducing ACE inhibition or angiotensin blockade at a stage before
development of the LV hypertrophy.
Fibrosis and fibre disarray also contribute significantly to pathophysiologic
processes in HCM. Therefore LV regression alone may be insufficient to alter
clinical outcomes in HCM without modification of these processes also. However it
is possible that ACE inhibition and/or angiotensin receptor blockade does have an
effect in modifying these processes as well. However these studies were unable to
assess this.
8.1. Conclusions
Identification of modifying factors in the phenotypic expression of HCM
helps in our understanding of the mechanisms which explain the marked variation
observed. This may provide avenues for therapeutic intervention either in the
regression or prevention of development of LV hypertrophy in HCM with potentially
subsequent improvement in symptoms and prognosis.
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BEGLEY, D.A., et al.: Efficacy of Implantable Cardioverter Defibrillator Therapy for Primary and
Secondary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Risk stratification
and effectiveness of implantable cardioverter-defibrillator (ICD) therapy are unresolved issues in hyper¬
trophic cardiomyopathy (HCM), a cardiac disease that is associated with arrhythmias and sudden death.
We assessed ICD therapy in 132 patients with HCM: age at implantation was 34 ± 17years, and 44 (33%)
patients were aged < 20years. Indications were sustained ventricular tachycardia (VT) or cardiac arrest
(secondary prevention) in 47 (36%) patients, and clinical features associated with increased risk for sud¬
den death (primaryprevention) in 85 (64%) patients. There were 6 deaths and 55 appropriate interventions
in 27 (20%)patients during a mean follow-up period of 4.8 ± 4.2 years: 5-year survival and event-free rates
were 96% ± 2% and 75% ± 5%, respectively. ICD intervention-free rates were significantly less for sec¬
ondary than for primary prevention: 64% ± 7% versus 84% ± 6% at 5 years, P = 0.02. Notably, 59 of 67
events (cardiac arrest and therapeutic ICD interventions), or 88%, occurred during sedentary or noncom¬
petitive activity. Incidence of therapeutic shocks was related to age but not to other reported risk factors,
including severityofcardiac hypertrophy, nonsustained VT duringHoltermonitoring, and abnormal blood
pressure response to exercise. ICD related complications occurred in 38 (29%) patients, including 60 in¬
appropriate ICD interventions in 30 (23%) patients. However, 8 (27%) of the patients with inappropriate
shocks also had therapeutic interventions. ICD is effective for secondary prevention of sudden death in
HCM. However, selection of patients for primary prevention of sudden death, and prevention of device
related complications require further refinement. (PACE 2003; 26:1887-1896)
cardiomyopathy, genetics, sudden death, prognosis
Introduction
Hypertrophic Cardiomyopathy (HCM) is a ge¬
netic disease with a prevalence of 1 to 2 per 1000
in the general population. The predominant car¬
diac phenotype is left ventricular (LV) hypertro¬
phy often with associated diastolic and systolic
dysfunction.1 Patients with HCM frequently have
disabling symptoms and are prone to atrial and
ventricular arrhythmias and sudden death.1"2
The cumulative annual incidence of sudden
death in a general HCM population is l%-2%.
However, prognosis depends critically on the refer¬
ral patient population. The calculated incidence of
sudden death is also higher for most family-based
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studies in which the genetic status of the subjects
has been determined.3 Genetic, clinical, morpho¬
logical, and hemodynamic heterogeneity add to
the complexity of risk evaluation in an individual
patient.1"8
Design advances have encouraged the use of
implantable cardrovcrte defibralator (ICD) in re¬
cent years and several clinical trials have indi¬
cated that therapy prevents sudden death in pa¬
tients with certain cardiac problems, such as is¬
chemic heart disease. However, these devices have
not been evaluated in HCM as part of prophylactic
trials for several reasons, including relative rarity
of the disease and difficulties in identifying pa¬
tients who are at risk of sudden death. There are
therefore few data about the efficacy of ICD therapy
in HCM, and this aspect of management strategy
for prevention of sudden death in HCM remains
very much in research domain.9"18
Ventricular arrhythmia is probably the most
common cause of sudden death in HCM.19 ICD
therapy therefore presents a reasonable prospect
PACE, Vol. 26 September 2003 1887
BEGLEY, ET AL.
of improving prognosis in selected patients with
HCM. The present study explores efficacy of this
therapy in a relatively large number of patients
with HCM who received ICD for primary and sec¬
ondary prevention of sudden death.
Methods
The study population consisted of 132 con¬
secutive patients with HCM who were followed at
the National Institutes ofHealth (NIH), and who re¬
ceived ICD devices between May 1987 and March
2001, Table I. Indications for ICD therapy were sec¬
ondary prevention of sudden death in 47 (36%) pa¬
tients; cardiac arrest in 39 patients; and sustained
VT in 11 patients (3 patients had both); clinical
features associated with increased risk for sud¬
den death (primary prevention: young age, non-
Table I.





Age at diagnosis (years) 25 ± 17
range 1-68
Age at implantation (years) 34 ±17
< 20 44 (33)
< 40 88 (67)
range 10-72
Clinical presentations
cardiac arrest 39 (29)




chest pain 52 (39)
dyspnea 67 (51)
fatigue 34 (26)
Coronary artery disease 3 (2)
Obstructive HCM 50 (38)
Prior procedures
LV myotomy and myomectomy 29 (22)
septal myectomy plus apical aneurysectomy 1 (0.8)
mitral valve replacement 3 (2)
dual chamber pacing 24 (18)
alcohol septal ablation 3 (2)
Echocardiographic findings
interventricular septum (mm) 23 ± 8
posterior LV wall thickness (mm) 11 ±3
diastolic LV internal dimension (mm) 44 ± 8
systolic LV internal dimension (mm) 26 ± 10
left atrial dimension (mm) 44 ± 9
() = per cent; LV = left ventricle.
sustained VT on Holter, atrial fibrillation, brady¬
cardia, induced VT, severe LV hypertrophy, my¬
ocardial ischemia, cardiac arrest/syncope, abnor¬
mal blood pressure [BP] response to exercise, ma¬
lignant family history of sudden death, mutation
associated with poor prognosis, and/or LV ejection
fraction < 45%.) in 85 (64%) patients. Risk factors
included syncope or presyncope, young age, fam¬
ily history of sudden death, molecular defect asso¬
ciated with a poor prognosis, nonsustained VT, LV
dysfunction, outflow obstruction, myocardial is¬
chemia, marked left atrial enlargement, and atrial
fibrillation. Thirteen patients received their initial
device at the NIH, 74 patients were recommended
to have an ICD by the NIH, and in 45 patients the
decision was made by the referring center.
Evaluations
Studies included echocardiography (n = 131),
treadmill exercise tests (n = 112), ambulatory elec¬
trocardiographic (ECG) monitoring (n = 130), ge¬
netic screening (n = 83), exercise thallium scintig¬
raphy (n = 115), cardiac catheterization (n = 124),
and electrophysiological study (n = 97).
Definitions
HCM: HCM was defined as LV wall thickness >13
mm in the absence of another cause for the in¬
creased cardiac mass, presence of LV outflow
obstruction, and/or genetic information.
Obstructive HCM: LV outflow gradient > 30
mmHg at rest or > 50 mmHg following provo¬
cation maneuvers.
Severe LVhypertrophy: maximum LV wall thick¬
ness > 30 mm.
Marked left atrial enlargement: diastolic left
atrial dimension > 50 mm.
VT: sustained VT was defined as VT of > 30 sec¬
onds duration or requiring rapid termination
due to hemodynamic compromise.
Therapeutic ICD intervention: ICD discharge that
was preceded by syncope, presyncope, and/or
other cardiac symptoms, or sustained ventric¬
ular arrhythmia determined by interrogation
of ICD. (ICD interventions were spurious if in
the absence of stored electrograms, the event
was not associated with cardiac symptoms, or
if they were related to device/lead malfunc¬
tion, sinus tachycardia or atrial arrhythmia.)
Abnormal blood pressure response to exercise:
a decrease or less than 10 mmHg increase
in systolic blood pressure at peak treadmill
exercise.
ICD Devices
One-hundred-forty-eight devices were im¬
planted in 132 subjects. Twenty-six devices were
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epicardial systems. Approximately 40% had defib¬
rillator capability only, and 60% were cardioverter
defibrillator devices.
Statistics
Patient data are presented as mean ± 1 SD. Dif¬
ferences from mean values were compared by Stu¬
dent's f-test. Cumulative survival and therapeu¬
tic ICD intervention-free rates were determined
by product-limit survival analysis using sudden
death and appropriate ICD shocks, respectively, as
time variables. Cumulative event-free rates were
calculated using the Log rank test. A P value of




Six deaths occurred during a mean follow-
up period of 4.8 ± 4.2 years (maximum, 0.1 to
16.3 years): 5-year survival rate for all patients
was 96% ± 2% (Fig. 1A) Four deaths were car¬
diac and occurred in young patients. Two children,
aged 10 (epicardial leads) and 14 years (endocar¬
dial leads) died in the immediate postoperative
period, from low cardiac output and cardiac tam¬
ponade, respectively; a child aged 14 underwent
cardiac transplantation for severe drug-refractory
symptoms 15 months after receiving an ICD and
died in the immediate postoperative period; and a
24-year-old patient died suddenly while riding a
motor cycle 34 months following device implan¬
tation (cause not established). Two patients, aged
53 years and 74 years, died from noncardiac causes
8.3 years and 9.4 years following ICD therapy,
respectively.
Therapeutic ICD Interventions
Fifty five appropriate ICD shocks occurred in
27 (20%) patients, 5-year intervention-free rate,
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Figurel. Panel A. Survival rates and therapeutic ICD intervention-free rates for all of the patients; Panel B. Survival
rates in patients in whom ICDs were implanted for primary and secondary prevention of sudden death; Panel C.
Comparison of appropriate ICD intervention-free rates in patients in whom ICDs were implanted for primary and
secondary prevention of sudden death; and Panel D. Comparison of ICD intervention-free rates in patients who
presented with cardiac arrest, syncope, cardiac arrest and syncope, and patients who had neither presentations.
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Table II. Table III.
Results and Complications of ICD Therapy Determined Circumstances Surrounding Cardiac Arrest
Events* and Therapeutic ICD Interventions
Follow-up duration (years) 4.8 ±4.2
range 0.1-16.3 Total Events 67
Appropriate discharges Sedentary 27 (40)
patients 27 (20) - sleeping/sitting/resting 23
events 55 - standing/talking 4
age at first event (years) 39 ±21 Noncompetitive activity 32 (48)
range (years) 22-71 - running on the flat/jogging 8
Patients with device related complications 37 (28) - walking/running upstairs 7
Inappropriate ICD interventions - walking 4
patients 30 (23) - playing indoors 3
events 60 - school gymnastic activity 3
etiology-sinus tachycardia 15 - fishing 2
- atrial tachycardia, atrial flutter, or 5 - sexual intercourse 1
atrial fibrillation - surfing 1
- lead malfunction/T wave oversensing 6 - driving 1
- nonsustained VT 2 - yard work 1
- undetermined 2 - postpartum 1
Patients with inappropriate ICD 8/30 (27) Competitive sport 8(12)
shocks who also had - basketball 2
therapeutic interventions - soccer 2
Miscellaneous associated problems - baseball 1
high cardioversion defibrillation threshold 1 - frisbee 1
infection 4
- pick up football 1
anxiety/depression 5 - tennis 1
direct ICD impact by baseball 1
cardiac transplantation 2 Events prior, to, and events during follow-up; () = percent.
deaths 6
- operative 2




- unknown Survival rate in the two groups were similar:
() = percent.
Circumstances Surrounding Cardiac Events
Table III details the circumstances surround¬
ing cardiac arrest and appropriate ICD discharges.
Notably, 59 of 67 (88%) of the events, occurred dur¬
ing sedentary or mild to moderate activity (unde¬
termined in two cases). Only 8 (12%) events were
related to strenuous competitive activity.
Primary Versus Secondary Prevention
of Sudden Death
The duration of follow-up of patients who
received ICD for primary prevention was signifi¬
cantly shorter than in patients who received de¬
vices for secondary prevention of sudden death
(Table IV). The clinical characteristics of the two
groups were similar—secondary prevention was
associated with significantly higher number of risk
factors per patient but the difference became in-
94% ± 3% for primary prevention versus 98% ±
2% for secondary prevention of sudden death, P =
0.8 (Fig. IB). However, the cumulative therapeutic
ICD intervention-free rate was significantly higher
in patients in whom ICD therapy was for primary
versus secondary prevention of sudden death:
the 5-year event-free rates were 84% ± 6% and
64% ± 7% respectively, P < 0.02 (Fig. 1C).
Cardiac Arrest Survivors
The ICD intervention-free rate was also sig¬
nificantly higher in the 94 patients who did not
present with aborted sudden death compared to
that in the 38 cardiac arrest survivors: 87% ± 5%
and 60% ± 9%, respectively at 5 years, P = 0.026.
Risk Factors for Therapeutic ICD Intervention
Young patients (<21 years) and older patients
(>40 years) had higher rates of therapeutic ICD
intervention compared to patients aged 21-40.
(Fig. 2A). However, other risk factors such as
severity of LV hypertrophy, LV outflow obstruc¬
tion, nonsustained VT during ambulatory ECG
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Table IV.
Comparison of Clinical Findings and Prevalence of Risk Factors in Patients who received
ICD Therapy for Primary and Secondary Preventions of Sudden Death
Prevention of Sudden Death
Primary Secondary P value
Number 85 (65) 47 (35)
Follow-up duration (years) 3.4 ± 3.2 7.5 ±4.2 < 0.0001
Gender (males) 52 (61) 28 (60) NS
Symptoms of impaired consciousness
syncope 38 (45) 14(30) NS
presyncope 48 (56) 25 (53) NS
syncope and/or presyncope 66 (78) 29 (62) NS
cardiac arrest, syncope, and/or presyncope 66 (78) 47 (100) < 0.0001
Age (years) 34 ± 16 34 ±20 NS
< 20 24 (28) 20 (43) 0.12
< 40 58 (68) 30 (64) NS
Family history of sudden death 39 (46) 15 (32) NS
>1 sudden death in first degree relatives 5(6) 1 (2) NS
Arrhythmia
atrial tachycardia, flutter, or fibrillation 19 (22) 9(19) NS
spontaneous nonsustained VT 51 (60) 32/46 (70) NS
exercise induced VT 2(2) 3(6) NS
spontaneous sustained VT 0(0) 11 (23) < 0.0001
spontaneous nonsustained or sustained VT 51 (60) 36/46 (78) NS
sustained VT induced at electrophysiological study 46/60 (77) 32/37 (86) NS
Abnormal blood pressure response to exercise 21/83 (25) 13/37 (35) NS
Severe LV wall hypertrophy 19 (22) 11/45 (24) NS
Marked left atrial enlargement 20/84 (24) 10/43 (23) NS
LV outflow obstruction 31/84 (37) 19/46 (41) NS
Myocardial ischemia* 38/74 (51) 15/40 (38) NS
LV dysfunction** 6(7) 5(11) NS
Genetic defect associated with poor prognosis 8(9) 1 (2) NS
Number of risk factors per patient* 3.9 ± 1.6 4.6 ± 1.7 0.025
() = percent; * = positive thallium scintigraphy or ischemic ECG changes during exercise or atrial pacing associated with
chest pain/hypotension; £ = young age, nonsustained VT on Holter, atrial fibrillation, bradycardia, induced VT, severe LV
hypertrophy, myocardial ischemia, cardiac arrest/syncope, abnormal BP response to exercise, malignant family history of
sudden death, mutation associated with poor prognosis, and/or * *ejection fraction < 45%.
monitoring, abnormal blood pressure response
to exercise, and induced sustained ventricu¬
lar arrhythmia were not associated with signifi¬
cantly higher rates of therapeutic ICD intervention
(Fig. 2B-2F). ICD intervention rates were not
higher in the patients who underwent LV my¬
otomy and myectomy or alcohol septal ablation for
obstructive HCM.
Genetic Tests
To date, molecular causes of HCM have been
identified in 24 of the 85 patients who were tested:
/i-myosin heavy chain gene (MYH7) mutations in
19 patients; a-tropomyosingene [TPMl) mutations
in 1 patient; and cardiac actin gene (ACTC) muta¬
tions in 4 patients.
Complications
Serious complications were recorded in 38
(29%) patients, including 60 inappropriate shocks
in 30 (23%) patients, (Table II). Notably, 8 (27%)
of the 30 patients with inappropriate shocks also
received therapeutic interventions. The complica¬
tion rates were similar for primary and for sec¬
ondary prevention of sudden death. Recurrences
were prevented in most cases by reprogramming
the devices.






<21 years vs. 21-40 years, p=0.02
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Figure 2. The relation of therapeutic ICD intervention-free rates to 'risk factors' of sudden death: Panel A. Age;
Panel B. Severity ofLV wall thickness; Panel C. LV outflow obstruction; Panel D. Nonsustained VT during ambulatory
electrocardiographic (ECG) monitoring; Panel E. Abnormal blood pressure (BP) response during treadmill exercise
test (BP did not predict outcome also in the subset of subjects aged < 40 years); and Panel F. Induced sustained
ventricular arrhythmia.
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Discussion
Significant advances in the design of ICD sys¬
tems, with improved ease of insertion, longevity,
programmability, and reduction in size, have lead
to a more liberal use of the devices in HCM. How¬
ever, there is still an important need to exam¬
ine ICD therapy in HCM, as the decision repre¬
sents a lifelong commitment to repeated proce¬
dures and significant exposure to potentially catas¬
trophic complications.
There are scanty reports of ICD therapy in
HCM involving mostly small numbers of highly
selected patients.9-18 Several of these describe its
efficacy in aborted sudden death and in patients
with sustained ventricular arrhythmia, indications
that correspond to recommendations by NASPE
and the ACC/AHA (Class 1 indication, general con¬
sensus that ICD indicated) guidelines.20-21 Few re¬
ports describe ICD therapy for primary prevention
of sudden death (AHA Class lib indication, con¬
sensus that "usefulness/efficacy is less well estab¬
lished by evidence/opinion"). Some studies have
noted a high incidence of therapeutic interven¬
tions in patients selected on the basis of sustained
ventricular arrhythmia induced by programmed
ventricular stimulation.11-13 A recent study re¬
ported outcomes in 128 patients collected from
19 United States and European centers.22 During a
mean follow-up period of 3.1 years, 23% of pa¬
tients received therapeutic interventions or an-
titachycardia pacing for ventricular arrhythmias.
The event rate for 43 patients who were treated
with ICD for cardiac arrest or sustained VT was
11% per year, and for the 85 patients who received
devices for primary prevention the event rate was
4.5% per year.
Risk Stratification in HCM
In the past two decades several indicators of
increased risk have also been identified. Unfortu¬
nately, most are controversial and have poor posi¬
tive or negative predictive values.23
Young Age
The evolving cardiac disease state in the
young is associated with an estimated 2% to 6%
cumulative annual sudden death rate.24-29 A third
of the patients in the present study were <21 years
of age. Young age was frequently associated with
several additional risk factors. The present study
suggests that the efficacy of ICD is most apparent in
two age groups: patients aged <21 years and those
>40 years.
Family History
Sudden death may occur even in family mem¬
bers in whom HCM is reportedly caused by "be¬
nign mutations." Further, a 'malignant' family
history of sudden death originally referred to
the occurrence of premature sudden death (aged
<55 years) in two or more first-degree relatives.30
Although a family history of sudden death was
common in our patients, a 'malignant' family his¬
tory was infrequent. Notably, it was also uncom¬
mon in the cardiac arrest survivors and in the pa¬
tients who had therapeutic ICD interventions.
Genetic Causes ofHCM
The severity of the clinical disease often varies
significantly even in family members in who HCM
is caused by the identical mutation.3-8 For exam¬
ple, the mutation may be associated with no de¬
tectable disease in some family members but cause
severe LV hypertrophy and disabling symptoms in
other family members. The differences in pheno-
typic expression indicate the importance of mod¬
ifying genes and genetic background. These find¬
ings further emphasize the need to individualize
risk stratification even in patients in whom the ge¬
netic cause of the HCM has been determined. Ad¬
ditional problems relate to failure to identify the
genetic cause in halfof the cases ofHCM, and avail¬
ability of the prognostic significance of only a few
of the described mutations.
Arrhythmias
Arrhythmias are common in HCM. Progres¬
sive left atrial enlargement associated with atrial
fibrillation in about 10% of the patients, and may
precipitate hemodynamic collapse. Nonsustained
VT occurs in about 25% of patients, and has
been considered an important marker of sudden
death.31-32 However, its prognostic significance,
particularly in asymptomatic patients, has been
questioned.11-33
Magnitude ofLV Hypertrophy
A recent study reported that the magnitude of
LV hypertrophy is directly related to the risk of
sudden death.34 It has also been noted that sev¬
eral malignant mutations are associated with se¬
vere LV hypertrophy and high disease penetrance,
and conversely, HCM caused by some benign mu¬
tations is associated with mild cardiac phenotype
and reduced disease penetrance.7 However, other
studies have demonstrated that LV thickness in pa¬
tients who die suddenly is similar to survivors,
with a great deal of overlap of LV wall thickness
between the two groups.35-36 Sinisterly, some ge¬
netic causes of HCM are associated with mild LV
hypertrophy low disease penetrance but a high in¬
cidence of sudden death.8 The present study did
not find a higher prevalance of severe LV hypertro¬
phy in cardiac arrest survivors. Severe cardiac hy¬
pertrophy was also not associated with increased
rate of therapeutic ICD interventions.
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Myocardial Ischemia
Myocardial ischemia may occasionally in¬
duce syncope or sudden death in the young.37
In the present study, myocardial ischemia was
not significantly associated with aborted sudden
death, ventricular arrhythmias or sudden death.
Abnormal Blood Pressure Response to Exercise
We noted an abnormal blood pressure re¬
sponse to exercise in about one third of the pa¬
tients.38-39 This 'risk factor' was not associated
with increased rate of therapeutic ICD interven¬
tion, and was not more prevalent in cardiac arrest
survivors.
LV Dysfunction
Patients with impaired systolic function are
prone to arrhythmias and sudden death. LV dys¬
function was present in 11 (8%) patients, in
the current series and 3 had appropriate ICD
interventions.
Clinical Presentation
Aborted sudden death and syncope have been
associated with 8% and 4% annual mortality, re¬
spectively.1-40 Cardiac arrest and syncope were
associated with increased frequency of ICD dis¬
charge but this finding did not reach statistical
significance. A possible explanation may be that
many factors that cause symptoms of impaired
consciousness, notably outflow obstruction and ar¬
rhythmias, were addressed in these patiens.
Physical Activity
Competitive athletic activity has been associ¬
ated with increased risk for sudden death.41 Most
of the cardiac arrests and appropriate ICD events
in our study occurred during sedentary or mild to
moderate activity. However, although only a mi¬
nority of ICD interventions and sudden deaths oc¬
curred during strenuous activity, the percentage
of time spent in strenuous activity is low, so the
risk of an event during strenuous activity is cer¬
tainly higher than during rest or moderate activity.
Whether the advice traditionally given to patients
with HCM not to take part in strenuous activity
improves prognosis remains uncertain.
Primary Versus Secondary Prevention
of Sudden Death
Patients who received ICD had a better prog¬
nosis and lower annual cumulative therapeu¬
tic interventions (primary prevention, 3% and
secondary prevention, 7%) than reported previ¬
ously.22 The low rate of therapeutic ICD interven¬
tions occurred despite the fact that most patients
who received the devices for primary prevention
had a mean of about four risk factors for sud¬
den death, and therefore, most likely represented
a more severely affected patient population than
would normally attend a primary center.
With the exclusion of cardiac arrest, the risk
profile of patients who received an ICD for sec¬
ondary prevention was similar to patients who re¬
ceived the devices for primary prevention of sud¬
den death. The incidence of events in the latter
group was, however, significantly less than that in
patients who received the former group. This in¬
dicates that there are as yet other important risk
factors that have not been identified.
Special Considerations Related
to ICD Therapy in HCM
Current ICD devices have several capabilities
that are potentially useful in HCM: (1) Treatment
of sinus node disease and atrioventricular con¬
duction abnormalities that are common and of¬
ten aggravated by commonly prescribed drugs (p-
blockers, verapamil, and antiarrhythmic drugs).
Indeed, heart block is occasionally the cause of
sudden death.19 As patients with HCM often have
diminished stroke volumes they can only aug¬
ment their cardiac output in response to increased
physiological demand by increasing their heart
rate. Hence, provision of dual chamber pacemaker
function allows management of bradyarrhythmias
and chronotropic incompetence; (2) Short pro¬
grammed atrioventricular intervals reduces LV
outflow obstruction in some affected patients,42
and (3) Certain ICD devices are capable of termi¬
nating atrial fibrillation.
Difficulties with ICD therapy in HCM include:
(1) inability to precisely identify patients who are
at high and low risk, hence, its redundancy—most
patients who receive the devices never have a life-
threatening arrhythmic event; and (2) high inci¬
dence of serious side effects, the most common
being inappropriate ICD interventions. Some of
the problems are in part related to the young age
of the patients in HCM43-48—infections and lead
related problems tend to be higher in the young
compared to adults, possibly because children are
more active and may be less vigilant with wound
care. Young patients also tend to achieve high si¬
nus rates with activity that may be misinterpreted
by the ICD. Other contributing factors and events
are: the frequency of atrial arrhythmias and non-
sustained VT in HCM, high electrical voltages re¬
sulting in T wave sensing, and small cardiac cham¬
ber cavities predisposing to cross-talk.
Study Limitations
Use of symptoms preceding shock as surrogate
for ventricular arrhythmia is unreliable, especially
in this patient population. Stored electrograms
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for verification rhythm prior to shock, available
in newer devices, address this issue. Delivery of
"appropriate" therapy does not equate with resus¬
citation from death.49 The selection of patients for
primary prevention as with previous studies was
not controlled. The significance of the risk factors
for sudden death in this highly selected patient
group may be different from that in a general HCM-
population. It is also likely that the risk of sudden
death is less in the HCM populations that are seen
by cardiac centers that do not specialize in this dis¬
ease. Hence, the findings of studies that describe
the effectiveness of ICD therapy in patients largely
referred to tertiary centers should be interpreted
with caution and may not apply to patients with
HCM managed at primary centers. Further, the ex¬
perience with ICD therapy in HCM remains lim-
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Dual Chamber Pacemaker Therapy for
Mid-Cavity Obstructive Hypertrophic
Cardiomyopathy
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BEGLEY, D., et al.: Dual Chamber Pacemaker Therapy for Mid-Cavity Obstructive Hypertrophic Car¬
diomyopathy. Intracavitary LV obstruction is an important determinant of clinical outcome in hyper¬
trophic cardiomyopathy (HCM). In a minority of patients the obstruction is at the level of the papillary
muscles. Mid-cavity obstructive HCM may be associated with a distal LV aneurysm and a worse progno¬
sis. It is often not amenable to standard cardiac surgery for LV outflow obstruction. The long-term effects
(mean follow-up 4.8 ± 2.9 years) of dual chamber (DDD) pacemaker therapy in 14 patients with mid-cav¬
ity obstructive HCM (mean age 34 ± 16 years, range 15-65 years) were studied. Patients were evaluated
by cardiac catheterization at baseline and 6 months to 1 year after receiving DDD pacemakers off all drug
therapy. Symptoms were improved in all patients and NYHA functional class reduced from 2.8 ± 0.1 to
1.9 ± 0.4 (P < 0.0005). Intracavitary LV pressure gradients was reduced significantly (43 ± 36 vs 84 ± 31
mmHg at baseline, P < 0.0005). There was a significant associated reduction in apical LV systolic pres¬
sure (152 ± 37 vs 188 ± 34 mmHg, P < 0.001). In addition, there was a trend towards increased exercise
tolerance (445 ± 123 vs 396 ± 165). Cardiac output and LV filling pressures were unchanged. In conclu¬
sion, chronic DDD pacing results in significant symptomatic and hemodynamic improvement in this un¬
common but important subset ofpatients with obstructive HCM in whom the role ofcardiac surgery is less
well defined compared with the more typical outflow tract location of LV obstruction. (PACE 2001;
24:1639-1644)
pacing, hypertrophic cardiomyopathy, mid-cavity obstruction
Introduction
Hypertrophic cardiomyopathy (HCM) is a ge¬
netic disease with an autosomal dominant pattern
of inheritance characterized by left ventricular
(LV) hypertrophy in the absence of another cause
for the increased cardiac mass. The cardiac hyper¬
trophy is associated with LV outflow obstruction
in about 30% of the patients.1 In the typical LV
outflow obstruction the pressure gradients are
generated by systolic anterior motion (SAM) of a
mitral valve leaflet and its coaptation with the in¬
ward moving hypertrophied anterior interventric¬
ular septum. The LV outflow tract obstruction is
an important determinant of clinical course and is
often associated with disabling cardiac symptoms;
chest pain, dyspnea, presyncope, syncope, palpi¬
tations, and excessive fatigue.1,2 Cardiac surgery,
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including myotomy and myectomy (Morrow pro¬
cedure), mitral valve plication, and mitral valve
replacement of been performed in patients with
obstructive HCM for many years.3-11 More re¬
cently, dual chamber (DDD) pacemaker therapy
and alcohol septal ablation have been investigated
for relief of drug refractory symptoms in obstruc¬
tive HCM.12-20
In some patients with obstructive HCM the
maximum LV hypertrophy and pressure gradient
are at the level of the papillary muscles. The mid-
cavity obstruction may be associated with a distal
LV aneurysm. This unusual variety of obstructive
HCM is more commonly associated with certain
molecular genetic defects.21,22 In its pure form
there is no SAM, but occasionally, there is ob¬
struction at the LV outflow tract associated with
SAM and at the mid-cavity level.23,24 Patients
with mid-cavity obstructive HCM are often symp¬
tomatic, are prone to ventricular arrhythmias aris¬
ing from the distal LV aneurysm, and may have a
worse clinical outcome.24 Therapeutic options are
unfortunately often limited.25,26
The present study investigates the ability of
DDD pacemaker therapy to relieve symptoms and
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to reduce the intracavitary pressure gradients in
patients with mid-cavity obstructive HCM.
Methods
Patients
The study population consisted of 14 patients
diagnosed with mid-cavity obstructive HCM and
severe symptoms refractory to standard medical
therapy who were referred to the National Heart,
Lung, and Blood Institute between June 1991 and
Oct 1998. Their clinical characteristics are de¬
tailed in Table I. Informed consent was obtained
in accordance with study protocols approved by
the Institute Review Board. All patients had failed
to respond to standard medical therapy with ade¬
quate doses of verapamil and a [3-blocker.
Table I.
Clinical Characteristics of the 14 Patients with
Mid-Cavity Obstructive HCM
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Proximal septum (mm) 20 ± 5.0
Maximum LV wall thickness (mm) 24 ± 5.9
LV internal dimension in diastole (mm) 39 ± 5.0
LV internal dimension in systole (mm) 20 ± 5.0
Left atrium (mm) 47 ± 7.4
Estimated intra-cavitary gradient (mm Hg) 80 ± 34
'recurrent syncope. HCM = hypertrophic cardiomyopathy; LV
= left ventricular.
At baseline, patients underwent the following in¬
vestigations: 12-lead electrocardiograph (ECG), symp¬
tom-limited Bruce protocol exercise test, M-mode,
two-dimensional and Doppler echocardiography,
and right and left heart catheterization as described
previously.14 Patients underwent repeat investiga¬
tions 6-12 months following pacemaker implanta¬
tion. Baseline and follow-up investigations were per¬
formed 5 half-lives off any cardiac medications.
A significant gradient was defined as a gradient
> 30 mmHg across the LVmid-cavity, measured un¬
der basal conditions at cardiac catheterization.
Implantation of Permanent DDD Pacing Systems
DDD permanent pacemakers were implanted
in all patients using standard techniques with the
ventricular lead positioned at the right ventricular
apex. At the baseline study, optimal AV delay was
determined by observing maximal ventricular pre¬
excitation from the 12-lead ECG. After measure¬
ment of right and left heart pressures, the hemo¬
dynamic indices were remeasured during DDD
pacing with short AV delays.14
Statistical Analysis
Data are expressed as mean ± 1 SD. Paired
data were compared by Student's paired f-test. A
value of P < 0.05 was considered significant.
Results
At baseline, eight patients had no evidence of
associated LV outflow obstruction, but five patients
had, in addition to mid-LV obstruction, significant
LV outflow tract obstruction (SAM with brief to
prolonged interventricular septal contact). Figure 1
illustrates echocardiographic findings in a patient
with mid-cavity HCM without LV outflow obstruc¬
tion. Figure 2 illustrates LV angiographic findings
in patients with mid-cavity obstructive HCM.
Functional Improvement
All patients were alive during a mean follow-
up period of 4.75 ± 2.9 years (range 7 months to 8
years). The New York Heart Association (NYHA)
functional class was reduced from 2.8 ± 0.1 to 1.9
± 0.4, P < 0.0005 (Fig. 3). No patient had syncope
during follow-up. Exercise time increased from
396 ± 165 to 445 ± 123 seconds (P = 0.14).
Five patients currently require no medica¬
tion. The remaining patients have been treated
with atenolol, disopyramide, sotalol, diltiazem,
verapamil, enalapril and/or diuretics for residual
symptoms and paroxysmal arrhythmias.
Hemodynamic Changes
The hemodynamic changes following pace¬
maker therapy are summarized in Figures 4 and 5.
At the baseline cardiac catheterization, the mean
apical systolic pressure was 188 ± 34 mmHg which
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A
B
Figure 2. Left ventricular (LV) angiographic
appearance in a patient with mid-cavity obstructive
hypertrophic cardiomyopathy (systolic frame). The
end-hole pigtail catheter traversing the mid-cavity
obstruction is seen. Themarked hypertrophy divides the
LV cavity into a proximal and a distal aneurysmal
segment.
Figure 1. (Panel A) Absence of left ventricular outflow
tract obstruction (no systolic anterior motion [SAM]) in
a patient with mid-cavity obstructive hypertrophic
cardiomyopathy. (Panel B) Continuous wave Doppler
interrogation of mid-cavity left ventricle demonstrating
a velocity of4.7m/s indicating an intracavitary pressure
gradient of about 87 mmHg.
decreased to 152 ± 37 mmHg at the follow-up eval¬
uation, P < 0.001 ZOiy> ±11 The mean intracavi¬
tary gradient decreased from 84 ± 31 to 43 ±36
mmHg (P < 0.0001). The reductions in intracavitary
pressure gradients in patients with pure mid-cavity ob¬
structive HCM and in patients with obstruction at two
LV sites are shown in Figure 5. Figure 6 illustrates the
reduction in LV pressure gradients in a patient with
mid-cavity obstruction only. Right heart pressures, LV
filling pressures (pulmonary artery wedge pressure
and LV end-diastolic pressure), and cardiac output did
not change significantly.
Discussion
Mid-cavity obstruction is an uncommon phe-



















Figure 3. Changes in New York Heart Association
(NYILA) functional class status before pacemaker
therapy (baseline) and at follow-up evaluation. Baseline
characteristics are the central boxes. Follow-up
functional class of patients with pure mid-cavity
obstruction aregiven in the right-sided boxes and follow-
up functional class of the remainder are given in the left-
sided boxes.
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Figure 4. Figure summarizing the hemodynamic findings before (baseline) and following (follow-
up) DDD pacemaker therapy.
age and is often associated with disabling symp¬
toms, heart failure, and arrhythmias. Symptoms
may respond to (B-blockers and/or verapamil and
judicious doses of diuretics.27-31 Patients with
drug-refractory symptoms present a difficult ther¬
apeutic challenge, particularly as the role of car¬
diac surgery for mid-cavity obstructive HCM is
uncertain.
Numerous studies have demonstrated that
DDD pacing relieves symptoms and reduces the
more typical subaortic LV outflow gradients.12-20
The present study suggests that DDD pacing may
Figure 5. Changes in intracavitary pressure gradients in
individual patients. * = patients with mid-cavity
obstruction but without significant left ventricular
outflow obstruction.
1642 November
be also beneficial in mid-cavity obstructive HCM
if symptoms continue to be disabling despite ade¬
quate pharmacotherapy. In this way, major
surgery with uncertain outcomes or cardiac trans¬
plantation may be avoided.
In the present study, mid-cavity obstruction
was complicated by LV outflow tract obstruction
in 5 of 14 patients. However, relief of symptoms
and reduction in LV intracavitary pressure gradi¬
ents were similar in the patients with mid-cavity
obstruction alone and in patients with two LV
sites of obstruction.32
The mechanism by which DDD pacing re¬
duces the intracavitary pressure gradient is uncer¬
tain. Due to markedly distorted LV morphology
Figure 6. Reduction in the intracavitary pressure
gradient in a patient with mid-cavity hypertrophic
cardiomyopathy.
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and limitations of echocardiography the authors
could not ascertain that DDD pacing consistently
widened the narrowed mid-cavity site. However,
correct placement of the ventricular lead appears
to be important for the success of the DDD pace¬
maker therapy. Initially, in two patients, screw-in
leads were used to position the ventricular lead at
the mid-septum (i.e., site of the obstruction). How¬
ever, it became clear that maximum results are ob¬
tained when the ventricular lead is positioned at
right ventricular apex as distal to the site of ob¬
struction as possible.
A common presentation of mid-cavity HCM
are symptoms of impaired consciousness caused
by monomorphic ventricular tachycardia arising
from the LV aneurysm (right bundle morphology
with superior QRS axis).33-36 The availability of
defibrillators with DDD pacemaker capability has
facilitated management of these patients, although
the indication(s) for primary implantation of de¬
fibrillators in this patient population remains to
be clarified.37
A second critical aspect of DDD pacemaker
therapy is the programmed atrioventricular (AV)
delay.38,39 The AV delay should be short enough to
allow for maximum ventricular preexcitation but
sufficiently long not to interfere with left atrial emp¬
tying. Hence, the paced QRS duration should re¬
main maximum during exercise tests, and Doppler
interrogation of mitral inflow velocities at echocar¬
diography should confirm adequate left atrial emp¬
tying during DDD pacing. Patients with delayed in¬
teratrial conduction delay (prolonged P wave) and
rapid AV conduction present the greatest challenge.
The addition of verapamil and/or a (3-blocker drug
in these patients may prolong AV node conduction
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Utility of Genetic Screening in Hypertrophic Cardiomyopathy:
Prevalence and Significance of Novel and Double
(Homozygous and Heterozygous) (3-Myosin Mutations
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ABSTRACT
Genetic screening of the /3-myosin heavy chain gene (MYH7) was evaluated in 100 consecutive unrelated pa¬
tients with hypertrophic cardiomyopathy (HCM) and 200 normal unrelated subjects. Seventeen /3-myosin mu¬
tations were identified in 19 patients. Notably, 13, or 76%, were novel. Mutations were detected in both al¬
leles in two patients: homozygous for Lys207Gln in one, and heterozygous for Pro211 Leu and Arg663His in
another. No mutation was detected in the controls. MF//7-associated HCM was associated with more marked
left atrial enlargement and syncope than non-M!7/7-re!ated HCM. Our findings indicate that: (1) screening
methods should allow identification of novel mutations; and (2) more than one sarcomeric mutation may be
present in a patient more commonly than is appreciated. Further studies are necessary to ascertain the clin¬
ical consequences of the novel and compound gene abnormalities, and to determine whether correlating func¬
tional domain to phenotype provides more useful information about the clinical significance of the molecular
defects.
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a cardiac dis¬ase with an autosomal dominant pattern of inheritance, a
variable phenotypic expression characterized by maladaptive
left ventricular(LV) hypertrophy,and abnormalitiesof diastolic
and systolic function (Wigle et al., 1995). Affected subjects of¬
ten have disabling symptoms and are prone to arrhythmias and
sudden death (Chang et a!., 1995). HCM demonstrates nonal¬
lelic and allelic heterogeneity, and thus far, nine genes encod¬
ing sarcomeric components are known to cause HCM (Fanana-
pazir, 1999; Towbin et al., 2000; Mohiddin and Fananapazir,
2001). The most extensively studied gene is MYH7, coding for
/3-myosin heavy chain (Geisterfer-Lowrance et al., 1990; Ep¬
stein et al., 1992; Fananapazir and Epstein, 1994; Lankford et
al., 1995; Rayment et al., 1995; Palmiter et al., 2000). The fa¬
milial HCM database lists 72 mutations in this gene that, by
September 2001, were associated with HCM (FHC Mutation
Database). Almost invariably, these are missense mutations af¬
fecting the motor or head-lever region of the molecule.
Determination of the molecular causes of HCM has enabled
description of mutation-specific natural histories. For example,
some /3-myosin mutations are associated with high disease pen¬
etrance and a high incidence of sudden death; others with low
penetrance and a relatively benign prognosis (Fananapazir and
Epstein, 1994; Enjuto et al., 2000; Richard et al., 2000). Im¬
portantly, some sarcomeric mutations are associated with mild
LV hypertrophy but a poor prognosis (Varnava et al., 2001;
Karibe et al., 2001). It also allows for preclinical diagnosis in
children and establishes the diagnosis in adults with mild dis¬
ease. Hence, increasingly, a genetic diagnosis is considered an
important component of the management of HCM. However,
despite recent advances, the utility of genetic screening in in¬
dividual patients is unclear.
It is also uncertain which screening method should be uti¬
lized. Mutations may be detected by: (1) specifically testing for
each of more than 100 identified mutations; for example, by re¬
striction fragment length polymorphism (RFLP); (2) sequenc¬
ing the several hundred exons of these nine genes, with or
without preliminary screening such as with single-strand con-
'Inherited Heart Diseases Section, Cardiology Branch, and laboratory of Molecular Cardiology, National Heart, Lung, and Blood Institute,
National Institutes of Health. Bethesda. MD 20892.
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formation polymorphism (SSCP) analysis; or (3) by studying
suitably large kindreds using genetic linkage analysis. Follow¬
ing detection of novel mutations, it is then desirable to prove
causality (even in genes known to cause HCM), and to deter¬
mine the natural history of the associated HCM.
We determined the prevalence and diversity of MYH7 mu¬
tations in a consecutive cohort of unrelated HCM patients and
in normal controlsto: (1) evaluate a sequencing-based strategy
for routine mutation detection in unselected patients: (2) deter¬
mine the degree of MYH7 heterogeneity in normal individuals;
and (3) evaluate the feasibility of describing the natural histo¬
ries of the associated HCM.
METHODS
Patients
A total of 100 consecutive unrelated patients with HCM re¬
ferred to the National Institutes of Health were studied. In¬
formed consent was obtained under protocols approved by the
Institutional Review Board of the National Heart, Lung, and
Blood Institute.
Clinical studies
Studies included 2-D echocardiography, 12-lead electrocar¬
diography, and in selected cases, a treadmill exercise test. HCM
was defined as LV wall thickness >13 mm in the absence of
another cause for cardiac hypertrophy. A family history ofHCM
was defined as present if obtained at the initial clinic interview
and does not include results of subsequent family screening. A
family history of sudden death (SD) was defined as the sudden
death of 1 or more first-degree family members under the age
of 45 years.
Genetic analysis
Genetic analysis was performed on genomic DNA extracted
from whole blood (Gentra). Using previously described primer
pairs and methods (Fananapazirand Epstein, 1994), each of the
first 23 exons of MYH7 was amplified by PCR. SSCP was per¬
formed for each exon for every patient to identify anomalous
conformers. Anomalous conformers were sequenced (BigDye
Terminator. ABI Prism 310) to detect sequence abnormalities
(SeqMan, DNAStar). RFLPs were predicted from mutant and
wild-type sequences (MapDraw, DNAStar) and mutations con¬
firmed by digestion when possible. Genomic DNA from 200
unrelated control individuals was also screened. For each novel
mutation, 100 control DNAs were screened by RFLP. To de¬
termine the degree of MYH7 heterogeneity in a normal popu¬
lation, a further 100 unrelated controls were screened by SSCP
for each exon in which a mutation had been detected in HCM
patients.
Statistics
Data are expressed as mean ± SD. Continuous variables
were analyzed using Student's ?-test for unpaired data. Non-
continuous variables were analyzed using Fisher's exact test. A
p value of <0.05 was considered significant.
RESULTS
Prevalence of known and novel fi-myosin
mutations in the HCM population, and
genotype-phenotvpe correlations
Results of the genetic analysis in the 100 patients with HCM
and their clinical findings are presented in Tables 1 and 2, re-
Table 1. /3-Myosin (MYH7) Mutations Identified in 100 Unrelated Patients with HCM
Patient Mutation Exon Charge change Morphology Clinical findings
1 Arg143Gly 5 Positive-neutral ASH No FH
2 Ser148Ile 5 No ASH FH
3 Lys35lGlu 12 Positive-negative Mid-cavity No FH
4 Arg403Gln 13 Positive-neutral ASH SD, HCM and DCM in family
5 Asn479Ser 15 No ASH No FH
6 Glu500Ala 15 Negative-neutral ASH FH with much SD
7 Gly571 Arg 16 Neutral-positive ASH AF, No FH
8 Arg663His 18 Positive-neutral Mid-cavity No FH, 'arrhythmia' in family
9 Arg663His 18 Positive-neutral Mid-cavity PAF. SD and HCM in family
10 Arg67lCis 18 Positive-neutral ASH PAF, no FH
1 1 Ile736Thr 20 No ASH FH
12 Ser782Asn 21 No Mid-cavity PAF, FH
13 Val763Gly 21 No ASH DCM in family
14 Met822Leu 22 No ASH PAF. FH and much AF in family
15 Gln882Glu 22 No ASH FH
16 Leu908Val 23 No Mid-cavity PAF, No FH
17 Leu908Val 23 No Mid-cavity AF, SD in family
18 Pro21'Leu* + Arg663His 7 & 18 No* ASH AF, AF in family
19 Lys207Gln homozygote 7 Positive-neutral Apical AF, heterozygotes bradycardic
ASH, Asymmetrical septal hypertrophy; SD, sudden cardiac death; AF, chronic atrial fibrillation; PAF, paroxysmal AF; FH,
family history of HCM; DCM, dilated cardiomyopathy. The "No" refers to Pro21 lLeu.
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(n = SI) p value
Age at diagnosis 00+1>T) 31 ± 17 36 ± 18 ns
Symptoms
Asymptomatic 8 1 (5) 7 (9) ns
Cardiac arrest 3 0 3 (4) ns
Presyncope 66 15 (79) 51 (63) ns
Syncope 33 11 (58) 22 (27) 0.01
Chest pain 72 14 (74) 58 (72) ns
Dyspnea 86 16 (84) 70 (86) ns
Palpitations 68 16 (84) 52 (64) ns
CHF 13 5 (26) 8 (10) 0.07
Therapy
Beta-blocker 51 7 (37) 44 (54) ns
Calcium antagonist 42 8 (42) 32 (42) ns
Pacemaker 37 5 (26) 32 (40) ns
LVMM/PTSA 20 4(21) 16 (20) ns
Implantable defibrillator 8 3 (16) 5 (6) ns
Atrial Fibrillation 32 9 (47) 23 (28) 0.17
Echocardiogram
Septum (mm) 21 ± 7 21 ± 7 21 ± 7 ns
Posterior wall (mm) 11 ± 2 11 ± 2 10 ± 2 ns
LVIDd (mm) 45 ± 6 44 ± 7 46 ± 6 ns
LVIDs (mm) 26 ± 6 24 ± 5 27 ± 6 0.06
Fractional shortening (%) 42 ± 7 46 ± 7 41 ± 7 0.01
Left atrium (mm) 44 ± 10 52 ± 1 1 43 ± 9 <0.001
HCM Morphology
ASH (± obstruction) 72 13 (68%) 69 (85%) 0.1
Apical 5 1 (5%) 4 (5%) ns
Mid-ventricular 13 5 (28%) 8 (10%) 0.07
Exercise Test
Duration (sec) 450 ± 199 438 ± 236 453 ± 194 ns
Abnormal BP response 23 5/11 (45%) 18/58 (31%) ns
(), per cent; ns, not significant; LVMM, LV myotomy and myectomy; PTSA, percutaneous transluminal coronary septal
ablation; LVIDd and LVIDs, LV internal dimension in diastole and systole; and BP, blood pressure.
spectively. The functinal domains of ^-myosin's motor region
affected by these mutations are shown in Figure 1.
Seventeen missense mutations were detected in 19 patients
in 1 1 of the first 23 exons of the MYH7 gene. Of these. 13 mu¬
tations, or 79%, are novel. Of the four previously described mu¬
tations, one (Arg403Gln) is associated with a poor prognosis,
one (Leu908Val) is associated with a benign prognosis, and two
(Ser782 Asn and Arg663His) are associated with atrial fibrilla¬
tion. Mutant alleles with the Leu908Val and Arg663His substi¬
tutions were found most commonly present in 2 and 3 patients,
respectively. RFLP confirmed the presence of all novel muta¬
tions, except for Asn479Ser for which no enzyme was available.
Double heterozygosityand homozygosity. Both MYH7 alleles
were abnormal in two patients who have had severe forms of
HCM. Patient 18 has double heterozygosity for the Arg663His
and novel mutation Pro2"Leu (Fig. 2A). He presented at the
age of 56 years with fatigue and hypertension. An echocardio¬
gram at the age of 63 years showed a markedly enlarged left
atrium (61 mm), cardiac hypertrophy (septum 20 mm and pos¬
terior LV wall 10 mm), normal LV dimensions and systolic
function (LV end-diastolicdimension, 36 mm; LV end-systolic
dimension, 22 mm, fractional shortening, 39%), and LV out¬
flow obstruction (estimated gradient, 55 mmHg). A further
echocardiogram at the age of 76 years showed progression of
the disease to LV wall thinning (septum 16 mm), impaired LV
systolic function, and loss of outflow obstruction, associated
with development of congestive cardiac failure and atrial fib¬
rillation. He has been treated with diuretics, atrioventricular
node ablation and pacemaker therapy. Of 3 siblings, one has
both mutations, one has the Arg663His mutation only, and the
third has neither (Fig. 2A). Both siblings with mutations were
subsequently diagnosed with HCM complicated by atrial fib¬
rillation, and the sibling with normal MYH7 alleles has normal
clinical findings, ECG, and echocardiogram.
Patient 19 is homozygous for a novel mutation Lys207Gln
(Fig. 2B). HCM was diagnosed at the age of 47 years follow¬
ing an abnormal electrocardiogram. At the age of 64 years, an
echocardiogram showed a markedly dilated left atrium (62
mm), apical HCM with basal septum measuring 15 mm in¬
creasing to 21 mm toward the apex, posterior LV wall 10 mm,
LV end-diastolicdimension 52 mm, LV end-systolicdimension
30 mm, and no LV outflow gradient. The most recent echocar¬
diogram, at the age of 74 years, shows increased left atrial (66
mm) and LV (56 mm in diastole) dimensions. He was treated
with an implantable cardioverter-defibrillator following several
episodes of syncope, and has had several therapeutic interven-
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FIG. 1. The functional domain of (3-myosin affected by each mutation was predicted from the crystalline structure of the highly
homologous chicken fast skeletal myosin (PDB Id: 2MYS). This structure encompasses the motor region of myosin, which re¬
cent studies suggest comprises four major subdomains connected by three single-stranded joints; the amino-terminal subdomain
(black); Ihe upper 50-kDa subdomain (blue); the lower 50-kDa subdomain (gray), and the converter subdomain (green). Fol¬
lowing the converter, a long helical segment of the heavy chain binds the essential light chain (ELC) and the regulatory light
chain (RLC) together, forming the lever arm (Houdusse et al., 2000). The motor region is shown with the positions of residues
affected by each mutant marked; novel mutations are labeled in red. Approximate positions of residues Lys207, Pro2", and Gly571
are shown; residues Lys207 and Pro2" are contained in loopl overlying the nucleotide pocket which is not resolved on the crys¬
tal structure. The region around Gly571 is also missing, and is in a part of the lower 50K subdomain thought to make contact
with actin. Finally Gin882 and Leu908 are distal within the lever arm and are not seen on this model.
tions. He has also been admitted with congestive cardiac fail¬
ure and is currently in functional class III and has chronic atrial
fibrillation. His single surviving sibling, all 4 children, and three
grandchildren are heterozygous for Lys207Gln (Fig. 2D). This
sibling, aged 80 years, was subsequently diagnosed with mid-
ventricular obstructive HCM and an interventricularseptal wall
thickness of 35 mm. The echocardiograms of a son (43 years),
two daughters (46 and 40 years), and three grandchildren (3, 9,
and 15 years) with the Lys207Gln allele are normal. Several of
the family members, including all three grandchildren with the
Lys207Gln allele but without cardiac hypertrophy, have a
marked resting sinus bradycardia.
Comparison of clinical findings t>/MYH7 and non-MYH7-
associcited HCM: The two groups of HCM patients were sim¬
ilar with regard to age, gender, family history of HCM or sud¬
den death, exercise performance, and need for pharmacological
FIG. 2. (A) Pherogram in patient 18 demonstrating double heterozygosity for Arg663His and Pro21 'Leu. In the pedigree, ages
are in parentheses. One sibling has both MYH7 mutations, another has Arg663His only, and a third has neither. The siblings with
mutations were subsequently diagnosed with HCM and atrial fibrillation. The sibling with normal MYH7 alleles has a normal
ECG and echocardiogram. (B) Pherogram demonstrating homozygosity for Lys207Gln in patient 19. A sibling heterozygous for
Lys207Gln was diagnosed with midcavity HCM, but all other family members with a single mutant allele were normal.
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and/or other therapies. However, patients with MYH7-associ¬
ated HCM were more likely to present with syncope and had
greater left atrial dimensions, despite a similar severity of LV
hypertrophy and higher LV fractional shortening (Table 2). Dif¬
ferences remain significantafter exclusionof the 2 patients with
double mutations. Patients with MT//7-associated HCM also
had a greater tendency to develop atrial fibrillation, but this did
not reach statistical significance.
Genetic analysis of normal controls
All novel mutations (except when a digest was unavailable)
were absent in the RFLP analysis from the DNAs of 100 unre¬
lated normal subjects (200 alleles). SSCP and direct sequencing
of anomalous conformers for exons 5, 7, 12, 13, 15, 16, 18. 20,
21, 22, and 23 in 100 other unrelated normal individuals (200 al¬
leles) identified several single-nucleotide polymorphisms that do
not affect the amino acid encoded. (SSCP for exon 15 was per¬
formed on DNA of all 200 subjects, as RFLP was unavailable for
Asn479Ser). Thus, in 200 control alleles, no MYH7 missense mu¬
tations were present in the 11 exons affected, and each novel mu¬
tation was absent from 400 control alleles.
DISCUSSION
Yield and utility of genetic screening methods
Our study demonstrates that MYH7 mutations are detected
in about 20% of patients with HCM. Most of these have not
been described, indicating that mutations identified to date ac¬
count for a fraction of all MYH7-associated HCM. Only 7 of
19 patients (4 of 17 mutations) had mutations that had been re¬
ported previously. Three of these (Arg403Gln, Arg663His and
Leu9(l8Val) are amongst a relatively few mutations with well-
described natural histories that were similar to those of the un¬
related patients in the present study (Epstein, 1992; Gruver et
at., 1999; Palmiter, 2000).
This degree of MYH7 heterogeneity in HCM patients indi¬
cates that genetic screening must be able to identify novel mu¬
tations. As most mutations are rare, and may even be unique to
certain families, genetic screening strategies relying on identifi¬
cation of previously determined mutations (such as RFLP) will
have limited yields; clinically applicable techniques will most
likely rely on sequencing-basedstrategies. Until automated high-
throughput technologies, such as those based on chip arrays, be¬
come reliable, considerable time and expense are required for
reliable mutation detection in HCM (Mohiddin et al., 2001).
The validity of ascribing causative roles to MYH7 mutations
detected in individual HCM patients can be questioned. Pedi¬
gree expansion with linkage analysis, mutant protein functional
assays, and transgenic models contribute to greater proof of
causal relationships. In practice, definitive proof of causality
will not be available for most detected mutations. The absence
of a mutation from a number of control DNAs, identified by
RFLP, is often cited as proof of cause. This study has shown
that MYH7 heterogeneity in HCM patients is such that most
mutations will also be absent in a large population of unrelated
HCM patients, just as in normal controls.
Although it has been assumed that MYH7 sequence abnor¬
malities are rare in the normal population, there has been little
proof of this. We did not detect any missense sequence abnor¬
malities by SSCP in 100 normal subjects in each of the exons
identified as having mutations in this series of HCM patients,
and did not find the specific abnormalitiesby RFLP in 100 other
controls. Thus, MYH7 is extremely conserved, and coding ab¬
normalities are rare in the absence of cardiomyopathy. For fu¬
ture novel mutations found in the exons of this gene, it should
not now be necessary to demonstrate their absence from con¬
trol DNA as a routine element of the genetic diagnosis. For
other genes, particularly myosin-binding protein C, this deter¬
mination is yet to be made. Thus, these novel mutations are
likely to cause HCM because (1) they involve highly conserved
amino acids; (2) the mutations were absent in 400 alleles from
normal subjects; (3) MYH7 shows no sequence variation in 200
normal alleles and; and (4) HCM was present only in family
members with the mutation.
A further complicating factor is that several sarcomeric gene
mutations may be present in the same patient. Homozygosity
and double heterozygosity for sarcomeric gene mutations have
been described previously, but are assumed to be rare (Nishi et
al., 1994; Jeschke et al., 1998; Richard et al., 1999, 2000). In
this series of consecutive patients, abnormalities in both alleles
of MYH7 were noted in 2% of the patients, or in 10% of those
with MYH7 mutations. If sufficiently frequent, occurrence of
multiple mutations would confound linkage studies, particularly
if heterozygosity involves other genes. It would also diminish
our ability to attribute the disease to a particular mutation and
may, in part, explain the phenotypic diversity characteristic of
HCM. The likelihood of heterozygosity should also be consid¬
ered in genetic counseling of at-risk family members.
Screening for molecular causes of HCM is only valuable for
management of patients if the natural histories of the identified
mutations are known and shared by families in which HCM is
caused by the identical genetic defect. Unfortunately, the ge¬
netic diversity, the rarity of most mutations, and limited num¬
ber of affected subjects, render phenotype-genotype correla¬
tions difficult. Therefore, this aspect of management for
improving risk stratification in HCM is still very much in the
clinical research domain.
Clinical differences between HCM caused by MYH7 and
non-MYHl -associatedHCM: Our findings suggest that MYH7-
associated HCM differs from non-MfW-associated HCM in
certain important clinical respects. Despite better systolic func¬
tion and similar LV wall hypertrophy and frequency of LV out¬
flow obstruction, patients with A/K//7-associated HCM had
greater left atrial enlargement. This implies that MLT/7-associ-
ated HCM is complicated by a greater degree of LV diastolic
dysfunction. Affected patients were also more likely to present
with syncope, perhaps related to an increased incidence of ar¬
rhythmias such as atrial fibrillation.
Implications/ormutation-phenotype correlations'. Our find¬
ings indicate that most HCM patients have an uncharacterized
mutation whose rarity may disallow adequate description of the
associated natural history in unrelated kindreds. Furthermore,
once obtained, application of this information may be limited
to few patients. The large number of MYH7 mutations now de¬
scribed will permit testing of the hypothesis that the site and
nature of mutations within the distinct functional domains of
/3-myosin determine clinical outcomes. A recent study linked a
Phe764Leu mutation in MYH7 to dilated cardiomyopathy. In our
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study, a patient with obstructive HCM (septum of 32 mm) had
a mutation in the preceding residue (Val76;lGly). However, a
sibling with this mutation presented with cardiac failure and di¬
lated cardiomyopathy as a teenager. In the two individuals with
double-mutant alleles, one or both mutations occurred in a loop
(loop 1) overlying the nucleotide-bindingpocket. Thus, muta¬
tions in this region may, in isolation, result in only mild and
poorly penetrant disease.
CONCLUSIONS
MYH7 mutations are found in one-fifth of HCM patients and
are rare in normal subjects. Most HCM patients have mutations
with undescribed natural histories. Mutation detection methods
will have to rely on sequence-based methods. Compound het¬
erozygosity occurs more frequently than has been appreciated
and may be responsible for some of the phenotypic diversity
and incomplete disease penetrance and for sporadic cases of
HCM. Further work on genotype-functional consequence-phe-
notype correlations is needed and may be facilitated by group¬
ing mutant proteins by functional domain affected.
A major advantage of a candidate gene-based screening
method of consecutive unselected patients, such as in this study,
is that patient selection is not biased toward those with a well-
defined family history where the causative mutation is likelier
to have a more penetrant and severe phenotype.
STUDY LIMITATIONS
Results of mutational analysis clearly depend on the referral
patient population and the sensitivity of SSCP (about 85%). For
simplicity, we analyzed only one gene. Analysis of other sar-
comeric genes was beyond the scope of this investigation, but
may demonstrate that multiple heterozygosity may be even
more frequent and further complicate the phenotypic expres¬
sion of HCM.
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Abstract
Background The Wolff-Parkinson-White syn¬
drome, with a prevalence in Western countries of 1.5
to 3.1 per 1000 persons, causes considerable morbidity
and may cause sudden death. We identified two fam¬
ilies in which the Wolff-Parkinson-White syndrome
segregated as an autosomal dominant disorder.
Methods We studied 70 members of the two fam¬
ilies (57 in Family 1 and 13 in Family 2). The subjects
underwent 12-lead electrocardiography and two-
dimensional echocardiography. Genotyping mapped
the gene responsible to 7q34-q36, a locus previously
identified to be responsible for an inherited form of
Wolff-Parkinson-White syndrome. Candidate genes
were identified, sequenced, and analyzed in normal
and affected family members to identify the disease-
causing gene.
Results A total of 31 members (23 from Family 1
and 8 from Family 2) had the Wolff-Parkinson-White
syndrome. Affected members of both families had
ventricular preexcitation with conduction abnormal¬
ities and cardiac hypertrophy. The maximal combined
two-point lod score was 9.82 at a distance of 5 cM
from marker D7S636, which confirmed the linkage of
the gene in both families to 7q34-q36. Haplotype
analysis indicated that there were no alleles in com¬
mon in the two families at this locus, suggesting that
the two families do not have a common founder. We
identified a missense mutation in the gene that en¬
codes the y2 regulatory subunit of AMP-activated pro¬
tein kinase (PRKAG2). The mutation results in the sub¬
stitution of glutamine for arginine at residue 302 in
the protein.
Conclusions The identification of this genetic de¬
fect has important implications for elucidating the
pathogenesis of ventricular preexcitation. Further un¬
derstanding of how this molecular defect leads to su¬
praventricular arrhythmias could influence the de¬
velopment of specific therapies for other forms of
supraventricular arrhythmia. (N Engl J Med 2001;344:
1823-31.)
Copyright © 2001 Massachusetts Medical Society.
THE Wolff-Parkinson-White syndrome isthe second most common cause of parox¬ysmal supraventricular tachycardia in mostparts of the world and is the most co mon
cause in China, being responsible for more than 70
percent of cases.1 In Western countries, the preva¬
lence of the Wolff-Parkinson-White syndrome is 1.5
to 3.1 per 1000 persons.2 4 Tachycardias associated
with the syndrome are usually paroxysmal and may
produce symptoms of prcsyncopc, syncope, and short¬
ness of breath and cause sudden death. Conduction
through an accessory pathway and the association of
the Wolff-Parkinson -White syndrome with supraven¬
tricular tachycardia have led to the creation of an in
vivo reentry model for arrhythmias.5 Research on the
Wolff-Parkinson-White syndrome has appropriately
focused on the atrioventricular pathways, which led
to ablation as an effective therapy.6 We evaluated two
families with familial Wolff-Parkinson-White syn¬
drome in which the probands presented with synco
pe and the electrocardiographic features of the syn¬
drome. A clinical evaluation of members of both
families was followed by linkage analysis to identify
the chromosomal location of the causative gene.
METHODS
Clinical Evaluation
Written informed consent was obtained from all participants ac¬
cording to the guidelines of Baylor College of Medicine; the Na¬
tional Heart, Lung, and Blood Institute of the National Institutes
of Health; and the University ofOttawa Heart Institute. Subjects
were evaluated by means of a detailed analysis of their medical
history, a physical examination, 12-lead electrocardiography, and
two-dimensional echocardiography. A total of 57 members of
Family I and 13 members ofFamily 2 were examined. Two subjects
in Family 1 and six subjects in Family 2 underwent invasive elec¬
trophysiologic study.
Ventricular preexcitation was diagnosed on the basis of the pres¬
ence of a short PR interval (<120 msec) with a widened QRS
complex (>110 msec) or an abnormal initial QRS vector (a delta
wave). In the case of subjects who had a pacemaker, base-line 12-
lead electrocardiograms were obtained from their medical records,
when possible. Sinoatrial abnormalities and conduction disease were
diagnosed if chronotropic incompetence or high-grade sinoatrial
or atrioventricular block was present on the electrocardiogram.
Left ventricular hypertrophy was diagnosed if the thickness of the
septal wall or the left ventricular free wall was at least 13 mm.
Chromosomal Mapping and Identification of Candidate
Genes
Peripheral blood was obtained from each family member we
evaluated. DNA was extracted from white cells, and lymphocytes
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were isolated for the development of transformed cell lines.7 Gcno-
typing was carried out with short tandem-repeat polymorphisms
from the 7q34-q36 region. We examined a total of 12 markers
from the Genethon linkage map, and 2 additional polymorphic
repeats were identified from the published sequence of Pi-derived
artificial chromosomes in the region. An autosomal dominant pat¬
tern of inheritance was assumed, and penetrance was estimated to
be 99 percent on the basis of the observed pattern of inheritance.
The frequencies of the disease allele and the normal allele were
assumed to be 0.0001 and 0.9999, respectively. The allele frequen¬
cies in the case of markers were calculated to be 1/n, where n is
the number of alleles observed in the two pedigrees. Two-point
linkage analysis was performed with version 5.2 of the linkage pro¬
gram.8 Once the disease-causing locus was identified, we used a
candidate-gene approach to identify the responsible gene.
We identified sequences of IM-derived artificial chromosomes
from the Human Genome Project by searching draft sequences
containing Genethon markers mapped to the region. We identi¬
fied two additional informative polymorphic markers from these
sequences to narrow the critical region. We then entered each se¬
quence into the National Center for Biotechnology Information
BLAST search program (http://www.ncbi.nlm.nih.gov/BLAST/)
to identify candidate genes, one ofwhich was the gene that encodes
the y2 subunit of AMP-activated protein kinase (PRKAG2).
Identification of the Mutation in the PRKAG2 Gene
Exon-intron boundaries for protein-encoding sequences of
PRKAG2 (GenBank accession number, AJ249976) complementary
DNA (cDNA) were identified in the GenBank data base with use of
the BLAST search program within the following Pl-derived artifi¬
cial chromosome clones: RP11-79612 (cDNA bp 1 to 205; Gen¬
Bank accession number, AC074257), RP5-1127D14 (bp 557 to
843; GenBank accession number, AC006358), and RP4-563H24
(bp 844 to 1800; GenBank accession number, AC006966). Intron-
ic primers were derived on the basis of these sequences. Primer
sequences are available with the full text of this article at http://
www.nejm.org and at http://www.bcmcardiofellows.org. Frag¬
ments of genomic DNA were amplified by the polymerase chain
reaction (PCR), and the products were purified with use of the
QIAquik PCR purification kit (Qiagen, Valencia, Calif.). In the case
ofprotein-encoding sequences (bp 206 to 556) that were not iden¬
tified in the GenBank data base, RNA was isolated from lympho-
blastoid cells with a random primer and reverse-transcribed with
use of the Prostar system (Stratagene, Cedar Creek, Tex.). Direct
sequencing reactions were performed in both the sense and anti-
sense directions on an automated sequencer (Prism 377, Perkin-
Elmer Applied Biosystems, Foster City, Calif.) with use of a tech¬
nique involving dye-labeled terminators."
RESULTS
Clinical Evaluation
Analysis of Families 1 and 2 (Fig. 1) showed that
the mode of transmission of the WolfF—Parkinson—
White syndrome was consistent with an autosomal
dominant pattern of inheritance. Transmission oc¬
curred with high penetrance but with a variable de¬
gree of expression. Initial clinical presentations includ¬
ed reports of palpitations, presyncope, and syncope.
The onset of clinical symptoms typically occurred in
late adolescence or the third decade of life. All 24 sub¬
jects (16 from Family 1 and 8 from Family 2) for
whom base-line 12-lcad electrocardiograms were avail¬
able had evidence ofventricular preexcitation. Parox¬
ysmal atrial fibrillation or flutter occurred in associ¬
ation with the Wolff-Parkinson-White syndrome in
44 percent of the subjects in Family 1 and 38 per¬
cent of the subjects in Family 2. Twelve members of
Family 1 had had recurrent syncope. A total of eight
subjects underwent invasive electrophysiologic stud¬
ies, and a total of 10 anomalous conduction path¬
ways were identified. Two of the eight (Subjects IIT-5
and IV-1 in Family 2) had two accessory connections,
or tracts. Typical accessory pathways, including two
right-sided pathways and one posterolateral pathway,
were identified. Five of the eight family members who
were studied had evidence ofpreexcitation with dcc-
remental conduction properties.
In addition to preexcitation, other forms of con¬
duction disease were seen. Three young women (Sub¬
jects V-3 and V-4 in Family 1 and Subject V-l in
Family 2) had resting heart rates of less than 50 beats
per minute and an inadequate heart-rate response to
exercise. Progression to high-grade sinoatrial or atri¬
oventricular block requiring the implantation of a
pacemaker occurred in 76 percent of the affected
members of both families who were older than 30
years of age. Cardiac hypertrophy was identified in
8 of 31 affected subjects (26 percent) who were eval¬
uated. In two members of Family 1 (Subjects TV-1
and IV-16) hypertrophy progressed to left ventricu¬
lar dysfunction (ejection fraction, <40 percent). In
one member ofFamily 2 who had left ventricular hy¬
pertrophy (Subject IV-4) severe left ventricular dys¬
function developed that required cardiac transplanta¬
tion at the age of 42 years. Six patients died before
the age of 40 years, but whether they had the Wolff-
Parkinson-White syndrome or other features of the
phenotype is unknown, since neither medical rec¬
ords nor postmortem findings were available.
Chromosomal Location and Haplotype Analysis
In determining the chromosomal location of the
gene responsible for familial Wolff-Parkinson-White
syndrome in Family 1, we first assessed whether there
was linkage to 7q34-q36, a locus previously identi¬
fied as the site of a gene responsible for a familial form
of hypertrophic cardiomyopathy and the Wolff-Par¬
kinson-White syndrome.10 The maximal two-point
lod score was 9.82 for marker D7S636 at a distance
of 0 cM. The maximal two-point lod score was 1.64
Figure 1 (facing page). Pedigrees of Two Families with Familial Wolff-Parkinson-White Syndrome.
The members of each family who died suddenly of an undetermined cause (SD) or from cardiac causes (SCD) and the age at death
are shown. Solid symbols denote affected family members, circles female family members, squares male family members, and
symbols with a slash deceased family members.
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for marker D7S2439 in the analysis involving Family
2. The maximal combined lod score for both fami¬
lies was 9.82 at a distance of 5 cM from marker
D7S636. Combined haplotype analysis indicated a
shared region among affected members flanked by
markers D7S2461 and D7S483 corresponding to a
genetic distance of less than 2.6 cM. Haplotypc analy¬
sis with the use of a total of 10 polymorphic-repeat
markers and 1 single-nucleotide polymorphism for
Family 1 and Family 2 indicated that there were no
alleles in common segregating at this locus, suggest
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D7S505 5 1 5 1 5 1 5 1
D7S636 9 11 9 11 9 12 9 12
D7S642 1 1 1 1 1 2 1 2
D7S2461 4 5 4 3 4 4 4 4
MG7 1 2 1 2 1 3 1 3
MG1 2 3 2 3 3 4 3 4
D7S2439 1 3 1 1 1 2 1 2
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Figure 2. Haplotypes, Recombination, and Genetic Map of the PRKAG2 Genomic Region in Family 1 and Family 2.
Panel A shows the results of haplotype analysis of nine members of Family 1 involving numerous polymorphic-repeat markers and
one single-nucleotide polymorphism in the 3' untranslated region (3' SNP) of PRKAG2. MG7 and MG1 are novel markers identified
on the basis of the sequence of P1-derived artificial chromosomes. In Subject IV-29, a crossover occurred between D7S2439 and
D7S483, marking the distal limit of the shared region in this family. In Panel B, the results of haplotype analysis of six members of
Family 2 involving the same polymorphic markers indicate that a crossover occurred between D7S2439 and MG1 in Subject III-3,
marking the proximal limit of the shared region in this family. All affected members of both families had the R302Q mutation in
PRKAG2. All affected members of Family 2 had a mutation (the substitution of adenine for guanine) at bp 1912 in the 3' untranslated
region of PRKAG2, whereas none of the affected members of Family 1 had this mutation. Panel C shows the distance (in centimor-
gans) of each marker shown in Panels A and B from the region of interest. Black bars in Panels A and B show the region shared by
all the affected members of both families. In Panel C, an integrated map of the PRKAG2 genomic region shows the genetic distances
in centimorgans derived from the Genethon linkage map and the approximate positions of the crossovers (arrows). The drawing is
not to scale. The accession numbers of the sequenced P1-derived artificial chromosomes are shown above the bold lines.
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founder. The distinct haplotype of affected members
in each family is shown in Figure 2.
Identification of the Mutation in the PRKAG2 Gene
After we determined that PRKAG2 was in the crit¬
ical genomic region, we amplified and sequenced from
genomic DNA affected and unaffected family mem¬
bers. A sequence variation (the substitution of ade¬
nine for guanine) was identified that corresponded
to bp 995 of the PRKAG2 cDNA sequence in all af¬
fected members in Family 1. This change results in
a change in the amino acid at residue 302 from ar-
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gininc to glutaminc (R302Q). The identical sequence
variation was subsequently found in all affected mem¬
bers ofFamily 2. Unaffected relatives in both families
had no evidence of this sequence variation. The same
PGR product from genomic DNA was sequenced in
300 chromosomes from control subjects selected from
the general population, which showed no evidence of
sequence variation. The existence of the R302Q mu¬
tation was independently confirmed by analysis of the
results of restriction-enzyme digestion (Fig. 3). Tak¬
en together, the findings indicate that this mutation
in PRKAG2 is likely to cause familial Wolff-Parkin¬
son—White syndrome. An additional sequence vari¬
ation (the substitution of adenine for guanine) was
identified at bp 1912 in the 3' untranslated region of
PRKAG2 that was present in all affected members of
Family 2, but not Family 1. This finding further con¬
firms that these two families are unrelated. We have
analyzed the protein-encoding sequence of PRKAG2
in genomic DNA from five patients with sporadic
cases of the Wolff-Parkinson-White syndrome and
did not detect any mutations.
DISCUSSION
We studied two families in which the probands
presented with the Wolff-Parkinson-Whitc syn¬
drome. Of the total of 70 family members whom we
examined, 31 were affected in five generations. The
trait is inherited in an autosomal dominant pattern
with complete penetrance and variable degrees of ex¬
pression. All affected subjects had electrocardiograph¬
ic evidence ofpreexcitation. Certain features occurred
more commonly in our subjects than in those with
sporadic Wolff-Parkinson-White syndrome. Parox¬
ysmal atrial fibrillation and flutter were present in 44
percent of the subjects in Family 1 and 38 percent
of the subjects in Family 2, an incidence that is sig¬
nificantly higher than the incidence of 15 to 20 per¬
cent that has been reported for sporadic Wolff-Par-
kinson-Whitc syndrome.11-'2 In addition, conduction
abnormalities and cardiac hypertrophy are uncont
monly associated with sporadic Wolff-Parkinson-
White syndrome but were commonly seen in the two
families that we studied.13 Elcctrophvsiological studies
showed a higher than expected incidence of preexci¬
tation with dccrcmcntal conduction properties.1415
Six subjects died suddenly from cardiac causes before
the age of 40 years. Although definitive diagnoses
could not be confirmed in these obligate gene car¬
riers, this finding suggests that the risk of sudden
death is higher in patients with familial Wolff-Par-
kinson-White syndrome than in patients with spo¬
radic cases. Nevertheless, the Wolff-Parkinson-Whitc









Figure 3. Sequence Analysis and Secondary Confirmation of the PRKAG2 Mutation.
Sequence analysis of the sense strand of genomic DNA from an affected member of Family 1 indicates the substitution of adenine (A)
for guanine (G) at bp 995 of PRKAG2 complementary DNA. This results in the substitution of glutamine for arginine (R302Q) in the
PRKAG2 protein (arrow in Panel A). The mutation contained within a 190-bp amplicon abolishes an Hpy188l restriction-enzyme site,
resulting in the persistence of this fragment in affected members after restriction-enzyme digestion (Panel B).
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and in studies of young survivors of sudden cardiac
arrest who did not have gross structural heart disease,
the syndrome was present in up to 33 percent of pa¬
tients.16-17
In both families the gene responsible mapped to
7q34-q36, which had been previously documented
to be the locus responsible for disease in a family
with combined hypertrophic cardiomyopathy and the
Wolff-Parkinson-White syndrome.10 Using the candi-
date-gene approach, we identified the gene PRKAG2,
which encodes the y2 regulatory subunit of AMP-
activated protein kinase. The genetic defect is a point
mutation resulting in the substitution of glutamine
for argininc (R302Q). That the mutation was re¬
sponsible for the phenotype in these families was
confirmed by the following findings: the mutation
was present in all affected members of two unrelated
families, the mutation was absent in all unaffected
members of both families as well as in 300 chromo¬





























Figure 4. Regulation and Function of AMP-Activated Protein Kinase.
In response to an elevated ratio of AMP to ATP, AMP-activated protein kinase is activated by both direct AMP binding and phos¬
phorylation by AMP-activated protein kinase kinase (AMPKK). AMP-activated protein kinase may also be activated in response to
the increase in cyclic AMP (cAMP) and resultant increase in the AMP:ATP ratio induced by ^-adrenergic stimulation. The diverse
functions of AMP-activated protein kinase include the inactivation of nonessential ATP-consuming pathways, the regulation of the
activity of creatine kinase, and the restoration of ATP levels through increased fatty-acid oxidation to meet vital cellular needs such
as ion-channel activity and sarcomeric contraction. In addition, AMP-activated protein kinase may migrate to the nucleus and reg¬
ulate gene transcription.
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ginine is highly conserved across several species, re-
fleeting the functional biologic importance of this
amino acid.
The same mutation occurred in the two families
despite the absence of a common founder. The ab
scncc of a common founder is based on the following
evidence: the two families were not known to be re¬
lated, they did not share alleles segregating in the vi¬
cinity of the PRKAG2 gene, and the single-nucleotide
polymorphism identified at bp 1912 of PRKAG2
was present in all affected members of Family 2, but
not Family 1. Nucleotide substitutions tend not to oc¬
cur at random. Substitutions of adenine for guanine,
as occurred in the mutation identified in the two fam
ilics we studied, arc 10 to 40 times as frequent as oth¬
er base substitutions.18 The substitution in PRKAG2
occurred at a CG doublet, and these doublets arc of¬
ten referred to as "hot spots" for mutation.19
The PRKAG2 gene consists of 569 amino acids
with a calculated molecular mass of 63 kd.20 The
y subunit of the AMP-activated protein kinase hct-
crotrimer functions as the AMP-binding site, thus
regulating the activity of the protein. However, it is
not possible to determine whether the R302Q mu¬
tation directly affects AMP binding, since the se¬
quence of the AMP-binding site is not known.21
AMP-activated protein kinase functions as a met¬
abolic sensor in cells, responding to cellular energy
demands by regulating diverse ATP-using pathways
and ATP-generating pathways.22 In the presence of
an elevated ratio of AMP to ATP, AMP-activated
protein kinase is activated by the direct binding of
AMP, which exposes a threonine of the catalytic unit.
The threonine is then phosphorylated by an upstream
kinase (AMP-activatcd protein kinase kinase).20 Ac¬
tivation decreases the use of ATP for nonessential
functions and stimulates ATP-generating pathways,
conserving ATP for more vital cellular requirements
(Fig. 4). The PRKAG2 isoform has a high level of
expression in cardiac tissue, and it is also present in
skeletal muscle, the brain, the placenta, the liver, the
kidneys, and the pancreas.20
The Wolff-Parkinson-White syndrome is thought
to be due to accessory pathways derived from mus¬
cle fibers that provided direct continuity between
atrial and ventricular myocardium during cardiogcn-
esis.23 The molecular defect that we found may in
some way inhibit the normal regression ofmuscle fi¬
bers during atrioventricular scptation. Although the
propensity for arrhythmias in patients with familial
Wolff-Parkinson-White svndromc is well known, the
mechanism that triggers these episodes at the mo¬
lecular level is not understood. The activation of
AMP-activated protein kinase in response to /3-adre¬
nergic stimulation could account for the develop¬
ment of tachyarrhythmias during exercise or meta¬
bolic stress.24-25
It is unclear whether the R302Q mutation acts as
an activating or inactivating mutation. However, the
mutation probably leads to an alteration in the phos¬
phorylation ofdownstream substrates within the heart.
Potential targets arc likely to include enzymes involved
in energy metabolism and ion channel proteins. An
important task will be to identify the proteins whose
phosphorylation is affected by this mutation. Although
AMP-activatcd protein kinase affects gene expres¬
sion,26'27 its role during cardiac development is un¬
known. The identification of this genetic defect has
important implications for the diagnosis and treat¬
ment of the Wolff-Parkinson-Whitc syndrome. The
relation between the role of AMP-activated protein
kinase in cardiac electrophysiology and the manage¬
ment of supraventricular arrhythmias and conduc¬
tion disease remains to be elucidated.
Supported in part by a grant (86-2216) from the American Heart Asso¬
ciation and by a grant from the El lie and Wollard Cain Foundation.
Presented in part at the 22nd Annual Meeting of the North American
Society of Pacing and Electrophysiology, Boston, May 3, 2001.
Wc arc indebted to the families who participated in the study; to
Donna Orchard, R.N., for technical assistance; and to Debbie
Graustein and Moira Lonjj for assistance in the preparation of the
manuscript.
REFERENCES
1. Wan Q, Wu N, Fan W, Tang YV, Jin L, Fang Q. Clinical manifestations
and prevalence of different tvpes of supraventricular tachvcardia among
Chinese. Chin Med T (Engl) 1992;105:284-8.
2. Packard JM, Graertingcr JS, Graybiel A. Analysis of the electrocardio¬
grams obtained from 1000 young healthy aviators: ten year follow up. Cir
dilation 1954;10:384 400.
3. Hejtmancik MR, Hermann GR. The electrocardiographic syndrome of
short P R interval and broad QRS complexes: a clinical study of 80 cases.
Am Heart I 1957;54:708-21.
4. Guize L, Soria R, Chaouat JC, Chretien JM, Iloue D, Le Heuzey JY.
Prevalence et evolution du syndrome de Wolff-Parkinson-White dans une
population de 138 048 sujets. Ann Med Interne 1985;136:474-8.
5. Kastor JA, Goldreyer BN, Moore EN, Spear JF. Re-entry — an impor¬
tant mechanism of cardiac arrhythmias. Cardiovasc Clin 1974;6: 111 35.
6. Jackman WM, Wang X, Friday KJ, et al. Catheter ablation of accessor)'
atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofre-
quency current. N Engl J Med 1991;324:1605-11.
7. Neitzel TT. A routine method lor the establishment ofpermanent grow¬
ing lvmphoblastoid cell lines. Hum Genet 1986;73:320 6.
8. Ott J. Analysis of human genetic linkage. Rev. ed. Baltimore: Johns
Hopkins University Press, 1991.
9. Rosenblum BB, Tee TG, Spurgeon ST, er al. New dye-labeled termina¬
tors for improved DNA sequencing patterns. Nucleic Acids Res 1997;25:
4500-4.
10. MacRae CA, Ghaisas N, Kass S, et al. Familial hypertrophic cardiomy¬
opathy with Wolff-Parkinson-White syndrome maps to a locus on chromo¬
some 7q3. J Clin Invest 1995;96:1216-20.
11. Campbell RW, Smith RA, Gallagher JJ, Pritchett ET, Wallace AG.
Atrial fibrillation in the preexcitation syndrome. Am J Cardiol 1977;40:
514-20.
12. Bauernfeind RA, Wyndham CR, Swiryn SP, et al. Paroxysmal atrial fi¬
brillation in the Wolff Parkinson White syndrome. Am J Cardiol I98l;47:
562-9.
13. Al -Khatib SM, Pritchett ET. Clinical features of Wolff- Parkinson
White syndrome. Am Heart J 1999;138:403-13.
14. Kl ein GJ, Guiraudon GM, Kerr CR, et al. "Nodoventricular" accesso
ry pathway: evidence for a distinct accessor)* atrioventricular pathway with
atrioventricular node-like properties. J Am Coll Cardiol 1988;11:1035 40.
15. Aliot E, de Chillou C, Revault d'AUoncs G, Mabo P, Sadoul N. Ma
haim tachycardias. Eur Heart J 1998;19:Suppl E:E25-E31, E52-E53.
16. Benson DW Jr, Benditt DG, Anderson RW, et al. Cardiac arrest in
young, ostensibly healthy patients: clinical, hemodynamic, and electrophys¬
iologic findings. Am I Cardiol 1983;52:65 9.
1830 • N F.ngl J Med, Vol. 344, No. 24 • June 14, 2001 • wwwv.nejm.org
IDFNTIFICATION OF A GENE RESPONSIBLE FOR FAMILIAL WOLFF-PARKINSON-WHITE SYNDROME
17. Topaz O, Perin E, Cox M, Mallon SM, Casccllanos A, Myerburg RJ.
Young adult survivors of sudden cardiac arrest: analysis of invasive evalua¬
tion of 22 subjects. Am Heart J 1989;118:281-7.
18. Cooper DN, Krawczak M. The mutational spectrum of single base-
pair substitutions causing human genetic disease: patterns and predictions.
Hum Genet 1990;85:55-74.
19. Thompson MW, Mclnnes RR, Willard HF. Thompson & Thompson
generics in medicine. 5th ed. Philadelphia: VV.B. Saunders, 1991.
20. Cheung PC, Salt IP, Davies SP, Ilardie DG, Carling D. Characteriza
tion of AMP-activated protein kinase gamma-subunit isoforms and their
role in AMP binding. Biochem T 2000;346:659-69.
21. Woods A, Cheung PCF, Smith FC, et al. Characterization of AMP
activated protein kinase beta and gamma subunits: assembly of the hetero-
trimeric complex in vitro. J Biol Chem 1996;271:10282-90.
22. Crute BE, Seefeld K, Gamble J, Kemp BE, Witters LA. Functional do¬
mains of the alphal catalytic subunit of the AMP-activated protein kinase.
I Biol Chem 1998;273:35347-54.
23. Dunnigan A. Developmental aspects and natural history of preexcita
tion syndromes. In: Benditt DG, Benson DW Tr, eds. Cardiac preexcitation
syndromes: origins, evaluation, and treatment. Boston: Martinus Nijhoff
Publishing, 1986:21 9.
24. Furlanello F, Bertoldi A, Bettini R, Dallago M, Vergara G. Life threat
ening tachyarrhythmias in athletes. Pacing Clin Electrophysiol 1992;15:
1403-11.
25. Moule SK, Denton RM. The activation of p38 MAPK by the beta-
adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Leu
1998;438:287-90.
26. I.eclerc I, Kahn A, Doiron B. The 5'-AMP-activated protein kinase in¬
hibits the transcriptional stimulation by glucose in liver cells, acting
through the glucose response complex. FEBS Lett 1998;431:180-4.
27. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy
JO. Activation ofAMP-activated protein kinase increases mitochondrial en¬
zymes in skeletal muscle. J Appl Physiol 2000;88:2219 26.
Copyright © 2001 Massachusetts Medical Society.
ELECTRONIC ACCESS TO THE JOURNAL'S CUMULATIVE INDEX
At the Journal's site on the World Wide Web (http://www.nejm.org) you can search an
index of all articles published since January 1990. You can search by author, subject, title,
type of article, or date. The results will include the citations for the articles plus links to the
abstracts of articles published since 1993. Single articles and past issues of the Journal can
also be ordered for a fee through the Internet (http://www.nejm.org/customer/).
N F.ngl J Med, Vol. 344, No. 24 • June 14, 2001 • www.nejm.org • 1831
Journal of the American College of Cardiology
© 2000 by the American College of Cardiology
Published by Elsevier Science Inc.




Myocardial Bridging Does Not Predict Sudden Death
in Children With Hypertrophic Cardiomyopathy
but Is Associated With More Severe Cardiac Disease
Saidi A. Mohiddin,* MB, ChB, MRCP,* David Begley, MB, ChB, MRCP,* Joanna Shih, PhD,+
Lameh Fananapazir, MD, FRCP*
Bethesda, Maryland
OBJECTIVES We sought to examine the association between systolic compression of sections of epicardial
coronary vessels (myocardial bridging) with myocardial perfusion abnormalities and clinical
outcome in children with hypertrophic cardiomyopathy (HCM).
BACKGROUND It has recently been suggested that myocardial bridging is an important cause of myocardial
ischemia and sudden death in children with HCM.
METHODS Angiograms from 57 children with HCM were reviewed for the presence ot bridging (50%
or more maximum systolic arterial compression). QT interval indices, echocardiographic and
cardiac catheterization findings, treadmill exercise tests, exercise thallium scintigraphy, Holter
monitoring and electrophysiologic study findings were compared in children with and
without bridging. The findings were also related to the presence or absence of compression
of septal branches of the left anterior descending artery (LAD).
RESULTS Bridging was present in 23 (40%) of the children. Multiple coronary arteries were involved in
four children. Bridging involved the LAD in 16 of 28 (57%) affected vessels. Myocardial
perfusion abnormalities were present in 14 of 30 (47%) children without bridging and in 17
of 22 (94%) children with bridging, p = 0.002. However, bridging was associated with more
severe septal hypertrophy (19 ± 8 mm vs. 28 ± 8 mm, p < 0.001), a higher septurmposterior
wall thickness ratio (2.7 ± 1.2 vs. 1.8 ± 0.9, p < 0.001), and higher left ventricle (LV)
outflow gradient (45 ± 37 mm Hg vs. 16 ± 28 mm Hg, p = 0.002). Compression of septal
LAD branches was present in 37 (65%) of the children and was significantly associated with
bridging, severity of LV hypertrophy and outflow obstruction. Multivariate analysis demon¬
strated that LV septal thickness and septal branch compression, and not bridging, were
independent predictors of thallium perfusion abnormalities. There was a 90% power at 5%
significance to detect an effect of bridging on thallium abnormalities at an odds ratio of 3.
Bridging was also not associated with significantly greater symptoms, increased QT and QTc
intervals and QTc dispersion, ventricular tachycardia on Holter or induced at EP study, or a
worse prognosis.
CONCLUSIONS Bridging and compression of septal branches of the LAD are common in HCM children and
are related to magnitude of LV hypertrophy. Left ventricular hypertrophy and compression
of intramyocardial branches of the epicardial coronary arteries may contribute to myocardial
perfusion abnormalities. Our findings suggest that bridging does not result in myocardial
ischemia and may not cause arrhythmias or sudden death in HCM children. (J Am Coll
Cardiol 2000;36:2270-8) © 2000 by the American College of Cardiology
Chest pain and myocardial ischemia are common in hyper¬
trophic cardiomyopathy (HCM). About two-thirds of adult
patients have regional myocardial perfusion abnormalities as
demonstrated by exercise thallium-201 scintigraphy and
positron emission tomography studies (1,2). Further evi¬
dence for myocardial ischemia has been provided by stress-
induced anaerobic metabolism with reduced myocardial
lactate consumption or lactate production in patients with a
history of chest pain (1). Children with I ICM are at higher
risk for sudden death than adult patients, and exercise
thallium myocardial perfusion abnormalities occur more
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frequently in children who present with syncope or cardiac
arrest (3).
Several mechanisms have been proposed to explain myo¬
cardial ischemia in HCM. These include increased meta¬
bolic demand (4,5), dysfunction and paucity of the coronary
microvasculature (5-8), elevated left ventricle (LV) diastolic
pressure reduced vasodilator reserve (9,10), bridging of
epicardial coronary arteries (1,11-13) and compression of
septal branches of the left anterior descending artery (LAD)
(4,14-17).
The significance of compression of sections of epicardial
coronary vessels has been controversial. In a recent communi¬
cation, Yetman et al. (13) report that bridging is an important
cause of angina and myocardial ischemia, is associated with
greater dispersion of the QT interval and is a significant risk
factor for ventricular arrhythmias and sudden death in children
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Abbreviations and Acronyms
ECG = electrocardiogram
EP = electrophysiologic study
HCM = hypertrophic cardiomyopathy
LAD = left anterior descending artery
LV = left ventricle
QT = QT interval
QTc = corrected QT interval
VT = ventricular tachycardia
with IICM. Given the potential therapeutic implications of
these observations, we have reviewed the prevalence and
clinical correlates of bridging in HCM children evaluated at
the National Institutes of Health.
METHODS
Patients. The study comprised children with HCM who
underwent coronary angiography at the National Institutes
of Health between January 1989 and April 1999 and
included children whose records were assessed retrospec¬
tively. All children underwent M-mode and 2D echocardi¬
ography and HCM was defined as a hypertrophied, nondi-
lated LV in the absence of another cause for the increased
cardiac mass. Studies were performed after >5 half-lives off
all cardiac medications.
Measurements. HEMODYNAMIC STUDIES. Cardiac cathe¬
terization was performed using intravenous sedation.
Right heart pressures and cardiac output were measured
with a thermodilution Swan-Ganz catheter. Left ventri¬
cle outflow pressure gradient was recorded from the
side-arm of a femoral artery sheath, a 5F or 6F end-hole
pigtail catheter placed in the LV and also by careful
withdrawal of the catheter from LV apex to ascending
aorta. Significant obstruction was defined as a subvalvular
gradient of >30 mm Idg at rest or >50 mm Hg following
provocation.
ANGIOGRAPHIC ASSESSMENT OF BRIDGING. Selective cor¬
onary angiography was performed using standard Judkins
catheter technique. Cineangiographic films were reviewed
independently by two observers, one of whom was blinded
to clinical histories. All coronary segments showing evi¬
dence of bridging were assessed quantitatively. A 35 mm
cineprojector incorporating a digital video camera was used
to capture images of each bridged artery. Angiographic
boundaries were detected automatically by the analysis
software and manual corrections made when necessary.
Absolute arterial dimensions (mm) were measured using the
coronary artery catheter as reference. The following were
estimated: length of bridged segment and severity of bridg¬
ing [(systolic diameter of the artery just distal to bridging
minus systolic diameter of the bridged segment) > systolic
diameter of the artery just distal to bridging X 100].
Coronary bridging was defined as a maximum systolic
compression ^50% (13).
SYSTOLIC COMPRESSION OF SEPTAL BRANCHES OF THE
LAD. Septal perforator compression was defined as the
transient occlusion of septal branches of the LAD during
systole and was determined to be either present or absent by
two independent observers.
EXERCISE DURATION, HEART RATE AND BLOOD PRESSURE
RESPONSES TO EXERCISE. Treadmill exercise tests were
performed using the Bruce protocol. Exercise duration,
heart rate and blood pressure responses were recorded. An
abnormal exercise blood pressure was defined as
<20 mm Hg increase in peak sphygmomanometer systolic
pressure compared with resting value (18).
MYOCARDIAL ISCHEMIA. Exercise thallium scintigraphy was
performed following an overnight fast by previously described
methods (3). At peak exercise, up to 2 mCi of thallium (dose
determined by patient weight) was administered intravenously
and the patient exercised for an additional 45 to 60 s, with
thallium images obtained within 10 min after exercise. Repeat
images were acquired approximately 3 to 4 h later following
administration of up to 1 mCi of thallium. Horizontal long
axis, vertical long axis, and short axis tomograms were recon¬
structed and analyzed qualitatively in the anterior, apical,
inferior, septal and lateral regions. Stress and reinjection images
were normalized to the region with the maximum myocardial
activity on the stress images and each region was assigned as
abnormal or normal. A region of reduced thallium uptake was
determined to be abnormal but reversible if it normalized on
reinjection images, and to be abnormal and irreversible if it
persisted. The presence or absence of apparent cavity dilation
was also determined.
ARRHYTHMIAS. Ilolter recordings obtained nearest the
time of angiography were analyzed for the presence or
absence ofventricular tachycardia (VT), defined as >3 beats
duration. The QT and QTc intervals were measured from
the 12-lead electrocardiogram (ECG) by a physician
blinded to the clinical findings. QTc dispersion was defined
as the difference between the longest and shortest QTc
intervals measured on all 12-lead ECG leads. Electrophysi¬
ologic (EP) studies were performed at the time of the
cardiac catheterization in 36 of the children using previously
described methods (19).
Statistical analysis. Patient data are presented as mean ± 1
SD. Two-sample data were compared by Student t test.
Cardiac survival rates for patients with and without bridging
were determined by the Kaplan-Meier estimates and com¬
pared with the logrank test. Cardiac events were defined as
sudden death or resuscitated cardiac arrest. Multivariate logis¬
tic regression analysis was used to determine the independent
contributions of LV wall thickness, LV outflow obstruction,
septal compression and bridging to presence of thallium
perfusion abnormalities. The power of the study to detect a
contribution of bridging to thallium abnormalities was calcu¬
lated on the binomial model with the logit link with and
without adjustment for confounding effects of the other vari-
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Table 1. Clinical Findings in the HCM Children: Prevalence of
Risk Factors
Cardiorespiratory arrest, syncope and/or presyncope 35 (61%)
Family history of —2 premature sudden death 12 (21%)
Myocardial ischemia 31 (54%)
VT during ambulatory Holter monitoring 14 (25%)
Genetic abnormality associated with a poor prognosis 4 (6%)
Severe LV hypertrophy (LV wall thickness &30 mm) 12 (21%)
Flat* or hypotensive BP response to baseline exercise 26 (46%)
al clinical features associated with sudden death 53 (93%)
*<20 mm Hg increase in systolic arterial blood pressure (BP).
ables (20). A p value < 0.05 was considered statistically
significant.
RESULTS
Characteristics of the study population. From a total of
163 children admitted for assessment during this 10-year
period, 57 (35%) had selective coronary angiograms of
sufficient quality for quantitative analysis. Of these, 35
(61%) were catheterized before the identification of coro¬
nary bridging as a potential determinant of outcome and
their angiograms and case histories were reviewed retrospec¬
tively. Indications for catheterization included the charac¬
terization of LV outflow gradient, the assessment of chil¬
dren considered to be at high risk for sudden death, and for
symptoms such as chest pain, dyspnea and syncope. The 22
children assessed after this time were a consecutive series
and had similar clinical features. Henceforth, no distinction
is made between these groups. There was a high prevalence
of risk factors associated with sudden death (Table 1).
Prevalence, severity, and distribution of bridging. Myo¬
cardial bridging is illustrated in Figure 1. A total of 28
bridges were present in 23 (40%) of the children. Multiple
bridging sites were identified in 4 (7%) of the 57 children:
2 coronary segments in 3 patients, and 3 segments in 1
patient. Bridging was located at mid-LAD in 13 (46%),
proximal LAD in 1 (4%), distal LAD in 2 (7%), a diagonal
branch in 5 (18%), an obtuse marginal branch in 4 (14%),
and the posterior descending branch of the right coronary
artery in 3 (11%) of all 28 bridges. The mean length of the
compressed coronary segment was 15 ± 7 mm, range 6 to
39 mm, with a mean systolic narrowing of 76 ± 18%. The
severity of maximum compression was between 50% and
75% in 15 (54%) and 75% and 100% in 13 (46%) of the
bridges. Complete systolic occlusion of the coronary lumen
was seen in 8 (29%) of the bridges.
The relation of bridging to clinical findings. The clinical
correlates ofbridging are shown in Tables 2 and 3. The ages
at diagnosis of HCM and cardiac catheterization were
similar in the children with and without bridging. Clinical
presentation (chest pain and symptoms of impaired con¬
sciousness, including cardiac arrest) was similar in the two
groups.
ECHOCARDIOGRAPHY. LV wall thickness at proximal in¬
terventricular septum was significantly greater in the chil¬




Figure 1. Figure illustrating coronary angiograms in three children with
hypertrophic cardiomyopathy. Diastolic frames are on the left and systolic
frames on the right. Panel A = 6-year-old male with mid-left anterior
descending artery (LAD) bridging and compression of its intramyocardial
branches. Panel B = 13-year-old female with bridging of proximal
posterior descending branch of the right coronary artery with complete
compression of its septal branches. Panel C = Complete compression of
septal branches of the LAD. This child had bridging of an obtuse marginal
branch. Large arrows indicate sites of bridging of epicardial arteries and
small arrows indicate compression of septal branches.
with bridging was 28 ± 8 mm compared with 19 ± 8 mm
in children without bridging, p < 0.001. Furthermore,
children with bridging had a greater degree of asymmetrical
septal hypertrophy and higher LV outflow gradients (Table
2, Fig. 2). The diastolic LV cavity in children with bridging
was 39 ± 7 mm in contrast to 43 ± 6 mm in children
without bridging; p < 0.05.
HEMODYNAMIC VARIABLES. At cardiac catheterization, 15
(65%) of the 23 children with bridging had LV outflow
obstruction at rest or following provocation compared with
13 (38%) of the 34 children without bridging, p = 0.08.
Mean resting LV outflow gradient was greater in patients
with bridging than without (37 ± 34 mm I Ig vs. 14 ±
24 mm Hg, p = 0.005). The association between LV
outflow obstruction and bridging was further demonstrated
by significantly higher LV systolic pressure in affected
children (Table 2, Fig. 2).
EXERCISE THALLIUM SCINTIGRAPHY. Reversible myocar¬
dial abnormalities were present in 31 (65%) of 48 children
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Table 2. Clinical Findings in HCM Children With or Without Myocardial Bridging
(>50% Max. Systolic Compression)
All
Children Absent Present
n = 57 n = 34 n = 23 p Value
Age (yrs)
At diagnosis (range) 10 ± 6 11 ± 6 (0.03-18) 10 ± 6 (0.1-17) 0.23
At angiography (range) 15 ± 4 15+4 (6-20) 14 ± 4 (4-20) 0.35
Follow-up (yrs)
From diagnosis 8 ± 6 9 + 6 8 ± 6 0.7
From catheterization 4 ± 4 5 ± 4 3 + 3 0.08
Gender
Males 43 (75%) 28 (82%) 15 (65%) 0.25
Family history of HCM 25 (44%) 13 (38%) 12 (52%) 0.44
Family history of sudden death 12 (21%) 8 (24%) 4 (17%) 0.74
Clinical presentation
Asymptomatic 10 (18%) 6 (18%) 4 (17%) 0.99
Chest pain 33 (58%) 20 (59%) 13 (57%) 0.92
Dyspnea 31 (54%) 18 (53%) 13 (57%) 0.99
Presyncope 29 (51%) 16 (47%) 13 (57%) 0.67
Syncope 23 (40%) 15 (44%) 8 (35%) 0.67
Cardiac arrest 4 (7%) 3 (9%) 1 (4%) 0.64
Echocardiographic indices
Aorta (mm) 29 + 4 29 ± 4 29 + 4 0.87
Left atrium (mm) 39 ± 7 38 ± 7 39 ± 8 0.63
LVIDd (mm) 42 ± 7 43 ± 7 39 ± 6 0.02
LVIDs (mm) 23 ± 6 24 ± 6 21+6 0.06
Interventricular septum (mm) 23 ± 9 19 ± 8 28 ± 8 0.0004
Posterior LV wall (mm) 11 ± 3 12 ± 4 11 ± 3 0.43
Septum to posterior LV wall ratio 2.2 ± 1.1 1.8 ± 0.9 2.7 ± 1.2 0.001
LV outflow gradient (mm Hg) 28 ± 35 16 ± 28 45 ± 37 0.002
Cardiac catheterization
Right atrium (mm Hg) 6 ± 3 6 + 3 5 ± 3 0.88
Systolic right ventricle (mm Hg) 34 ± 10 33 ± 9 36 ± 11 0.23
Mean pulmonary artery (mm Hg) 18 ± 7 18 + 7 18 ± 6 0.99
Cardiac index (1/min/m2) 3.1 ± 0.7 3.0 ± 0.6 3.2 + 0.8 0.30
PCWP (mm Hg) 12 ± 5 12 ± 5 12 + 5 0.67
Systolic LV (mm Hg) 123 ± 28 116 ± 21 133 ± 34 0.03
LV end-diastolic pressure (mm Hg) 16 ± 8 16 ± 9 17 ± 8 0.77
Mean aortic pressure (mm Hg) 72 ± 12 75 ± 13 68 ± 10 0.04
LV outflow gradient (mm Hg) 23 ± 31 14 + 24 37 + 34 0.005
Number with septal compression (%) 37 (65%) 14 (41%) 23 (100%) < 0.0001
LVIDd = diastolic LV internal dimension; LVlDs = systolic LV internal dimension; PCWP = pulmonary arterial capillary
wedge pressure.
who underwent thallium studies (Table 3, Fig. 2). Abnor¬
malities in myocardial thallium uptake were also signifi¬
cantly associated with increased LV wall thickness (septum,
26 ± 9 mm vs. 16 ± 3 mm, p = 0.0001; higher ratio of
septum:posterior LV wall thickness, 2.4 ± 1.1 mm vs. 1.4 ±
0.5 mm, p < 0.005), and greater LV outflow gradients at
cardiac catheterization (26 ± .33 mm Hg vs. 7 ±
12 mm Hg, p < 0.05). Multivariate analysis demonstrated
that LV septal thickness and septal perforator compression,
and not LV obstruction or bridging, were independent
predictors of reversible myocardial thallium uptake abnor¬
malities (Table 4). After adjustment for confounding fac¬
tors, the study has a power of 90% at 5% significance level
to detect an odds ratio of 3 for a bridging effect on thallium
abnormalities.
Thallium myocardial abnormalities most frequently af¬
fected the septum and anterior segments, the LV wall
segments supplied by the most frequently bridged vessel.
However, segmental defects in thallium uptake are often
unrelated to the coronary artery compressed. The pattern of
abnormalities on thallium scintigraphy is no different be¬
tween the 16 children with LAD compression and the 7
with bridging of another coronary. Furthermore, stress-
induced apparent LV cavity dilation, suggesting subendo¬
cardial ischemia, is a finding that cannot easily be attributed
to bridging and was present in more than a third of the
children. Thus, the distribution of myocardial thallium
defects indicates the importance of factors other than
bridging in etiology of the myocardial ischemia.
EXERCISE TESTS. There were no significant differences in
mean exercise durations, resting and peak systolic blood
pressure in children with and without bridging (Table 3).
ELECTROCARDIOGRAPHIC VARIABLES. The mean QJ and
QTc intervals and QTc dispersion were not significantly
different in children with and without bridging (Tabic 3).
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Table 3. Clinical Findings in HCM Children With or Without Myocardial Bridging
(s50% Max. Systolic Compression)
Intramyocardial Bridging
All Children Absent Present p Value
Treadmill exercise test (n = 52) (n = 32) (n = 20)
Exercise duration (s) 511 ± 228 534 ± 254 474 ± 178 0.36
Baseline heart rate (beats/min) 83 ± 14 82 ± 15 84 ± 12 0.48
Peak heart rate (beats/min) 167 ± 35 167 ± 39 166 ± 28 0.93
Baseline systolic BP (mm Hg) 123 ± 20 129 ± 19 114 ± 19 0.007
Peak systolic BP (mm Hg) 149 ± 43 154 ± 45 142 ± 38 0.32
Abnormal exercise BP response 26 (50%) 16 (50%) 10 (50%) 0.77
Exercise thallium scintigraphy (n = 48) (n = 30) (n = 22)
Abnormal study 31 (65%) 14 (47%) 17 (94%) 0.002
Number of abnormal segments 86/288 (30%) 34/180 (19%) 52/108 (48%) < 0.0001
Perfusion abnormality
Anterior 25 11 14 0.01
Septum 21 6 15 0.003
Subendocardium* 18 7 11 0.01
Inferior 11 4 7 0.17
Apex 9 4 5 0.47
Lateral 2 2 0 0.50
12-lead ECG (n = 53) (n = 32) (n = 21)
QT interval (ms) 433 ± 59 438 ± 52 425 ± 67 0.26
QTc interval (ms) 475 ± 50 471 ± 56 482 ± 40 0.31
QTc dispersion (ms) 40 ± 27 38 ± 25 42 ± 30 0.59
Ventricular tachycardia
On Holter 7/42 (17%) 3/23 (13%) 4/19 (21%) 0.68
Induced at EP study 5/36 (14%) 3/24 (13%) 2/12 (17%) 0.99
'Reversible apparent LV cavity dilation.
BP = sphygmomanometer cuff blood pressure; EP study = electrophysiologic study.
AMBULATORY HOLTER MONITORING AND ELECTROPHYSI-
OLOGIC STUDIES. Nonsustained VT was recorded in 17%
of the children during ambulatory ECG monitoring. Sus¬
tained VT was also induced in 17% of the children.
Differences in VT on I loiter and VT induced at EP study
in children with or without bridging were not statistically
significant (Table 3).
Clinical outcomes. Cardiac events (sudden death [n = 2],
cardiac arrest [n = 4]) occurred in two children with
bridging and in four without. The cumulative survival rate at
20 years ofage in both children with bridging was 85 ± 10%
and without bridging 82 ± 8%, p = 0.9 (Fig. 3). In
addition, LV systolic dysfunction occurred in three children
without bridging and in one child following transmural
myocardial infarction (none in children with bridging). One
child in each group underwent cardiac transplantation for
severe symptoms and exercise limitation.
Compression of septal branches of the LAD. Children
with partial or complete compression of septal branches of
the LAD had significantly greater LV wall thickness,
asymmetrical septal hypertrophy, thallium perfusion defects
and LV obstruction compared with children without com¬
pression (Table 5). Septal compression occurred in all of the
23 children with bridging but in only 14 of the 34 children
without bridging, p < 0.001. QT intervals, VT on Holter or
induced at EP study, and prognosis were not significantly
different in children with or without compression of the
septal branches.
DISCUSSION
Several mechanisms have been postulated to explain an
increased incidence of sudden death in IICM. These
include ventricular arrhythmias, an atrial arrhythmia causing
severe hypotension because of associated LV dysfunction,
bradyarrhythmias, LV outflow obstruction and myocardial
ischemia (1,4).
MYOCARDIAL ISCHEMIA. More than half of patients with
HCM have reversible myocardial perfusion abnormalities as
demonstrated by exercise thallium or sestamibi studies,
despite having large normal epicardial vessels with high flow
velocity (1,3,4). The perfusion abnormalities are believed to
represent regions of myocardial ischemia caused by one or
more mechanisms (1-17).
PREVALENCE AND CLINICAL SIGNIFICANCE OF BRIDGING.
Bridging is a common finding, seen in up to 10% ofpatients
who undergo coronary angiography (21-24). It is observed
in up to 40% of patients with chest pain and normal
coronary arteries after administration of drugs such as
nitroglycerin and isoproterenol (22). Muscle bridges are
identified at autopsy or aortocoronary bypass surgery in 5%
to 86% of cases (24-27). Bridging is more common in
cardiac diseases that are associated with LV hypertrophy
(23,27,28). Its angiographic prevalence in adult patients
with HCM is about 30% to 80% (11,22). Compression of
the intramyocardial septal arteries also occurs more fre-
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Figure 2. Figure showing interventricular septal wall thickness (panel A), ratio of septum:posterior wall thickness (panel B), and left ventricle outflow
gradient at cardiac catheterization (panel C) in children with and without bridging of epicardial coronary arteries or compression of septal branches, and
in children with and without myocardial perfusion abnormalities. Thallium (—ve), normal myocardial perfusion; thallium (+ve), abnormal myocardial
perfusion.
quently in patients with LV hypertrophy. It is present in
>70% of patients with aortic stenosis or HCM and may be
related to severity of the LV hypertrophy (1,29).
Several reports have indicated that bridging may cause
myocardial ischemia (13,24,25,28,30-32). Bridging has also
been reported to cause myocardial infarction, abnormalities
of the QT interval, VT and sudden death (13,33-37).
Surgery to unroof or bypass the bridge and coronary artery
stenting have also been described to improve symptoms in
isolated cases and in small series of patients (13,38-41).
There is, however, as yet no convincing evidence that
surgery improves morbidity or mortality in patients with
bridging (24,27). Bridging may be an incidental finding in
patients without another cardiac explanation for chest pain.
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Table 4. Relation of Thallium Perfusion Abnormalities to
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SD = Standard deviation.
In several case reports myocardial hypertrophy was also
present, and some of the patients in these reports may have
had HCM. As only 15% of coronary flow occurs during
systole, the physiologic relevance of bridging is question¬
able. Bridging may be postulated to cause myocardial
ischemia if there is increased myocardial demand and/or
diastolic compression of the coronary vessel. However,
several studies have not demonstrated that bridging causes
critical stenosis during diastole (17,22,30,31).
Yetman et al. (13) described a strong relation between
bridging, chest pain, history of cardiac arrest, reduced
exercise capacity, hypotensive responses to exercise, in¬
creased QTc dispersion, VT and poor prognosis in 36
children with HCM diagnosed and evaluated over about 40
years. They found no association between bridging and
degree of LV hypertrophy or LV outflow obstruction.
Following diagnosis with HCM, the five-year survival rate
in children with bridging was 67% and 94% in the children
without bridging. They concluded that bridging was an
important cause of myocardial ischemia in their HCM





























Figure 3. Figure showing survival rates in children with and without bridging.
Cardiac death was defined as death or cardiac arrest. The number of children
at different age intervals is indicated at the bottom of each panel.
Table 5. Clinical Findings in HCM Children With or Without
Compression of Septal Branches of the LAD Artery
Compression of Septal Branches
Absent Present p Value
Echocardiographic indices (n = 20) (n = 37)
Interventricular septum 17 ± 5 26 ± 9 0.0004
(mm)
Posterior LV wall (mm) 12 ± 4 11 ± 3 0.30
Septumiposterior wall 1.5 ± 0.5 2.5 ± 1.2 0.001
thickness ratio
LV outflow gradient 13 ± 29 35 ± 36 0.02
(mm Hg)
Cardiac catheterization (n = 20) (n = 37)
Systolic aortic pressure 108 ± 18 97 ± 12 0.01
(mm Hg)
Mean aortic pressure CO
+
100 69 ± 7 0.01
(mm Hg)
LV outflow gradient 10 ± 15 30 ± 31 0.01
(mm Hg)
Coronary bridging 0/20 23/37 (76%) < 0.0001
Exercise thallium scintigraphy (n = 17) (n = 31)
Abnormal study 4 (24%) 27 (87%) < 0.0001
Number of abnormal 9 (9%) 77 (41%) < 0.0001
segments
authors performed surgical unroofing of the myocardial
bridge in three of the children and suggest that this
procedure reduces myocardial ischemia. As thallium myo¬
cardial scintigraphy was available in less than a third of the
children, the contribution of bridging to myocardial perfu¬
sion abnormalities was not adequately assessed.
The authors found coronary compression persisting
through 50% of diastole, providing a credible mechanism
for limitation of flow. Diastolic compression was calculated
from the number of angiographic frames showing diastole
and the proportion of these showing bridging (13). To allow
this calculation, both the start and duration of diastole need
to be accurately measured; this is difficult to do from
angiographic records without simultaneous echocardio¬
graphy, electrocardiographic or phonocardiographic re¬
cordings. Coincidental quantitative coronary and diastolic
information can be obtained from LV or aortic angiograms
from the "nonselective" coronary runoff. This, however, may
dramatically reduce sensitivity for the detection ofmoderate
degrees of bridging. Using LV angiography may also result
in detection sensitivities favoring detection of mid LAD
compression, as this artery is seen more clearly than other
epicardial arteries in right anterior oblique views and is seen
at an orientation most likely to reveal eccentric compression.
Bridging is phasic, with transition from maximum to
minimum compression. Identifying the end of the period of
compression is therefore difficult and requires strict defini¬
tion. Compression deforms the coronary lumen in an
eccentric manner. The maximum compression is a measure
of the short axis of an ellipse; lumen area is reduced
according to elliptical and not circular geometry. For exam¬
ple, a concentric stenosis of 60% but an elliptical compres¬
sion of 84% will reduce lumen area by 75% (27). Therefore,
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regardless of the fraction of diastole during which compres¬
sion persists, significant effects on flow will result only if
compression remains severe.
Coronary compression increases with catecholamine ad¬
ministration (22). Therefore, coronary compression may be
increased in frequency and severity during exercise when
diastole is abbreviated. We assessed compression at rest and
it is possible that during exercise the severity of compression
may be flow limiting. Coronaries compressed at rest are
likely to be those most severely affected during exercise. As
the presence of bridging at rest does not predict myocardial
perfusion abnormalities, it seems unlikely that the more
frequently occurring bridging during exercise will do so.
Furthermore, patterns of perfusion abnormality and artery
affected were poorly matched.
Comparisons with similar studies. The present study was
undertaken to investigate the prevalence of bridging and
clinical significance of bridging and systolic compression of
the septal branches of the LAD in children with IICM. Wc
were unable to reproduce the findings ofYetman et al. (13).
Bridging, despite identical definitions, was present more
frequently, involved most epicardial arteries, and was occa¬
sionally at several coronary sites in the same child.
Exercise-induced reversible thallium myocardial perfu¬
sion abnormalities were more common in children with
bridging and compression of septal branches. Iffowever, in
contrast to the findings of Yetman et al. (13), bridging was
associated with significantly greater LV hypertrophy, asym¬
metrical septal hypertrophy and LV outflow obstruction.
Multiple regression analysis supported the hypothesis that
the thallium abnormalities were related to severity of hy¬
pertrophy and presence of septal compression rather than
caused by bridging. Symptoms, diminished exercise capac¬
ity, and abnormal blood pressure responses to exercise were
not more common in children with bridging.
Yetman et al. (13) found that a QTc difference of>60 ms
in any of the 12 ECG leads differentiated children with and
without bridging with a sensitivity of 92% and a specificity
of 77%. In our study, the QT, QTc, and dispersion of QTc
intervals were not longer in the children with bridging. We
were also unable to demonstrate a relation between bridg¬
ing, spontaneous VT and VT induced at EP study, or
cardiac events (sudden death, cardiac arrest, and myocardial
infarction).
The differences between the findings of two studies may
be explained in part by the fact that Yetman et al. (13) relied
on echocardiographic and angiographic records extending
over a period of 41 years from 1956 to 1997. Patient
selection may have significantly influenced their findings; on
average, in their group without bridging, HCM was diag¬
nosed eight years earlier than in the group with bridging.
The most rapid period of disease progression (LV hyper¬
trophy and development of LV outflow obstruction) and
highest incidence of sudden death is during the second
decade of life. Calculation of survival rates from the time of
diagnosis of HCM perpetuates the confounding effect of
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selection on the results. Indeed, symptoms, ventricular
arrhythmias, cardiac arrest and sudden death are uncommon
under 10 years of age. Hence, if the time interval from
diagnosis of LICM is used to calculate survival, children
aged 3.3 (median) years would be expected to have a better
prognosis than those diagnosed at 11.2 years, irrespective of
the presence or absence of factors such as bridging. In our
study, children with and children without bridging were
diagnosed and evaluated at similar ages, and we calculated
age-related outcomes.
An important consequence of the long duration of the
Yetman et al. (13) study is that the management of some of
the children in that series predated the advent of beta-
blocker and verapamil therapies, which are now used rou¬
tinely to manage symptoms and myocardial ischemia in
children with I ICM. These children were severely affected
with a high prevalence of risk factors for sudden death
(Table 1). The better survival rates in our series may reflect
more current methods of management.
Conclusions. Bridging was present in about half of our
children with I ICM. Mid-LAD was the most commonly
affected vessel but other coronary arteries were also involved.
Compression of septal branches of the LAD was present in
65% of the children. Both bridging of epicardial arteries and
systolic compression of the septal branches were related to
LV hypertrophy and LV outflow obstruction. Thallium
myocardial perfusion abnormalities were related to LV
hypertrophy, LV outflow obstruction, bridging and systolic
compression of the septal perforators. Multivariate analysis
identifies only LV hypertrophy and septal compression as
independent predictors of thallium abnormalities. No sig¬
nificant association was found between bridging and symp¬
toms, ventricular arrhythmias and incidence of sudden
death. These findings suggest that cardiac surgery (or
stenting) for bridged arteries in children with HCM is not
indicated. Verapamil and beta-adrenergic receptor blockade
therapy and relief of LV outflow obstruction may provide
adequate anti-ischemic therapy.
Study limitations. The present study consists of a selected
subset of children with HCM who were evaluated by
cardiac catheterization and, in many cases, by EP studies in
part because of severity of their clinical presentation. Our
standard practice has been to assess the coronary circulation
in all children undergoing catheterization to determine the
gross coronary anatomy; in many children LV or aortic root
angiography was considered to sufficiently visualize the
proximal coronaries. A smaller proportion required selective
coronary angiography for adequate characterization. Only
this latter group has been considered for the current study,
as nonselective studies do not have the coronary resolution
required for evaluating the distal coronaries and for quan¬
titative analysis. Nonetheless, the children studied are a
subset of a population referred for tertiary evaluation and
thus are not considered representative of the larger popula¬
tion of HCM children. It is likely, however, that our
population of children more accurately reflects current
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patterns of diagnosis and referral than that in the study of
Yetman et al. (13). The prevalence of bridging in an
unselected population of HCM children is expected to be
lower in keeping with less severe cardiac hypertrophy.
However, it is likely that the relation of bridging to severity
of LV hypertrophy and myocardial perfusion abnormalities,
and the finding that bridging does not significantly deter¬
mine clinical outcome, may also apply to HCM children
who attend nontertiary cardiac centers.
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